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ABSTRACT 
 
Development of various therapeutic approaches for the treatment of breast cancer is 
on the rise. Among them, chemotherapy has been widely practised for the treatment 
of breast cancer. However, the approach exposes the patient to various kinds of side 
effects caused by the drugs. Although gene therapy finds a decent approach but it is 
expensive and associated with delivery problems. In order to avoid the side effects of 
chemotherapeutic drugs and achieve a cheap and toxicity free therapeutics, the focus 
has been gradually shifting towards biomolecule-based therapeutics like gene, 
peptide and proteins as an alternate therapeutic strategy. 
In our present investigation, we have developed protein-based various therapeutic 
strategies in breast cancer which includes two proteins, bovine α-lactalbumin (BLA) 
and hen egg white lysozyme (LYZ). Both of them are already reported to have 
antitumor and anticancer activity. However no detail investigation was performed in 
breast cancer. Moreover, it was also reported for BLA that the specific structural 
state is responsible for its antitumor or anticancer activity. Here both the proteins 
were transformed into their self-assembled nanostructure state using simple 
desolvation technique through the chemical crosslinking process. Both the 
nanoassembly were characterized in details and their anti-proliferative activity in 
breast cancer cells was evaluated.   
The nanostructures were characterized using FESEM (Field Emission Scanning 
Electron Microscopy), AFM (Atomic Force Microscopy) and DLS (Dynamic Light 
Scattering) analysis for size and shape, FTIR (Fourier Transform Infrared 
2 
 
Spectroscopy for bonds involved in nanoassembly), Circular dichroism and 
Fluorescence spectroscopy and conformational change of proteins. Microscopy and 
DLS analysis confirmed their average size as 300 nm. The stability of both the self-
assembled nanostructures of lysozyme (snLYZ) and α-lactalbumin (snBLA) were 
examined against thermal, pH and protease stress and found to be highly stable. 
Moreover, both of them demonstrated excellent hemocompatibility in human 
erythrocytes as well as cytocompatibility in normal human cells like HaCaT and 
mouse cells like 3T3.  
When the nanoassemblies were applied to breast cancer cells MCF-7 and MDA-
MB231, they demonstrated high ( > 90% ) cell death at 24 h and almost complete 
cell death after 48 h of administration. The microscopic images confirmed that the 
internalization of protein assemblies by MCF-7 cancer cells was the major cause of 
such cell death. Further, the investigation also confirmed that such death was 
mediated by reactive oxygen species (ROS) generation.The microscopic image and 
western blotting results confirmed that apoptosis had no role in cell death 
mechanism. 
The cytotoxic behaviour of snBLA was compared with a well reported anti-cancer 
agent BAMLET (bovine α-lactalbumin made lethal to tumor cells) in four different 
cancer cell lines including two breast cancer cell lines MCF-7 and MDA-MB-231. 
Our synthesized snBLA demonstrated better cell killing potential than BAMLET 
with much higher hemocompatibility. 
Both the nanoassembly demonstrated high Tamoxifen loading (124%) through 
chemical crosslinking process and release of drug efficiently in a pH-responsive 
3 
 
manner. Furthermore the drug release process was completely regulated by 
conformational change of the protein in nanoassembly. 
In our next step we attempted to develop Graphene oxide nanosheets (GOns) and 
Zinc oxide nanoparticle (ZnONP) based therapeutic strategy in breast cancer to 
compare with our protein-based therapeutic approach. 
Graphene oxide nanosheets (GOns) and Zinc oxide nanoparticles (ZnONP) are being 
developed as drug carriers, however, such an approach was plagued with problems 
such as hemotoxicity and cellular biocompatibility. Hence, we made an attempt to 
develop a therapeutic strategy based on ZnONP and GOns by functionalizing them 
with BLA protein. The surface functionalization with BLA improved their 
hemocompatibility in human erythrocytes and cytocompatibility in normal human 
cells. They also demonstrated high anti-proliferative activity in breast cancer cells 
via the ROS-based mechanism of cell death. However, considering the consequence 
like protein degradation in cells and subsequent exposure of GOns and ZnONP to 
cells may lead to their accumulation in normal cells and tissues that might limit their 
use as a rational approach.  
Therefore, in our present study, we concluded that our developed stable self-
assembled nanostructured lysozyme and α-lactalbumin can be used as a rational 
therapeutic strategy in breast cancer. 
 
KEYWORDS: Breast Cancer; lysozyme; bovine α-lactalbumin; self-assembly; 
graphene oxide nanosheet; zinc oxide nanoparticles; drug loading and release; 
reactive oxygen species; cellular uptake; biocompatibility. 
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Chapter 1 
Introduction 
 
According to GLOBOCAN 2008, the second most commonly diagnosed cancers 
worldwide is breast cancer that is associated with 10.9% of the global cancer 
incidences (Ferlay et al., 2010). Recently documented statistics about breast cancer in 
the year 2013, reveal 1.8 million incidences of breast cancer and 4,64,000 deaths. As 
a result of breast cancer, 13.1 million people had disease assisted life years (DALY’s) 
in 2013 with the developing and developed countries contributing 63% and 37% 
respectively (Fitzmaurice et al., 2015). 
 As far as the cancer therapy is concerned there have been ample ways to treat 
breast cancer and chemotherapy is the most common among them. Numerous 
chemotherapeutic drugs such as paclitaxel, tamoxifen, cisplatin, 17-DMAG are 
widely used for the treatment of breast cancer (Andey et al., 2015; Zhou et al., 2002). 
Many new compounds such as 2, 2'-diphenyl-3, 3'-diindolylmethane (DPDIM) are 
being also pursued recently as potential anti-breast cancer agents in breast 
cancertherapy (Bhowmik et al., 2013). These compounds, however, inflict serious 
side effects that sometimes limit their use beyond a certain dose in patients. Gene 
therapy is a promising and expensive approach, but it is plagued with problems with 
site specific delivery. While metal/non-metal nanoparticles such as Fe2O3, Ag, Au, 
TiO2 , ZnO have shown a lot of promise in targeted drug delivery system against 
cancers, their accumulation in body tissues and cells and their subsequent detrimental 
side effects have raised further concerns about their future applications (Baek et al., 
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2012; Balasubramanian et al., 2010; Banerjee, 2011; Chakraborti et al., 2009; Iversen 
et al., 2013; Khandelia et al., 2014; Scown et al., 2009). 
Due to the problems mentioned above, the attention is shifting gradually 
towards protein-based therapeutics. A small protein, lysozyme has already been 
reported for possessing anti-tumorigenic potential (Caseli and Schumacher, 1955; 
Guo et al., 2007; Ye et al., 2008). Another protein bovine α-lactalbumin (BLA)  is 
also reported to possess anti-cancer activity (Lin et al., 2008; Sternhagen and Allen, 
2001; Thompson et al., 1992; Xu et al., 2005) and cancer-preventing potential 
(Parodi, 2007). A suitable cancer drug or vehicle should not only be target specific, 
but it must be biocompatible and biodegradable so that its existence after its desired 
action should not bring harmful effect on healthy cells and tissues. Protein-based 
drugs have been proposed to be a new generation therapeutic agent in many diseases 
including cancer which not only acts as a therapeutic agent without causing any 
cytotoxicity but can also be used as drug carrier with targeted therapy. 
Proteins are normally extremely sensitive to various kinds of external stress 
because of their intimate link between their unique 3-D structure and biological 
function (Hegyi and Gerstein, 1999; Martin et al., 1998; Thornton et al., 1999). They 
can change their secondary as well as tertiary structure depending on the external 
chemical environments and surface properties proteins can be modulated by external 
means (Neklesa et al., 2011). Proteins also possess unique properties to form self-
assembled nanostructures. They form disordered as well as ordered aggregates 
(sometimes known as amyloid) in cells and in many cases that may cause number of 
lethal diseases (Aguzzi and O'Connor, 2010; Ciryam et al., 2013; Jucker and Walker, 
2013; Ross and Poirier, 2004). However, protein and their self-assembled structure 
can be externally driven in-vitro and this has recently been explored towards many 
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applications in biology and medicine (Gangar et al., 2013; Jabbari, 2009; Li et al., 
2008; Liu et al., 2011; Panda et al., 2013; Xu et al., 2014; Zhang, 2003; Zhu et al., 
2013). 
Biological molecules including proteins, peptides, nucleic acids and lipids have 
inherent properties for self-assembling into the fundamental biological unit, known as 
the cell. Cellular events like amyloid ﬁbril formation, antigen-antibody recognition, 
chromatin assembly, and phospholipid membrane self-assembly are excellent 
examples of molecular self-assembly. 
Recently small proteins such as bovine and human α-lactalbumin were also reported 
to be made lethal against number of tumor cells where a specific conformational state 
of the protein was responsible for forming the conjugate known as BAMLET (Bovine 
α-lactalbumin made lethal to tumor cells) or HAMLET (Human α-lactalbumin made 
lethal to tumor cells) with oleic acid to cause tumor cell death (Rammer et al., 2010; 
Zhang et al., 2009).The hydrophobic cores present in HAMLET and BAMLET are 
structurally distinct from their native forms (Mok et al., 2007). 
The idea behind using LYZ to develop its self-assembled nanostructure for cancer 
therapy was originated from its earlier reports of its anti-tumorigenic and anti-cancer 
potential. 
However, besides cancer cells, in most of these cases proteins have been used as 
conjugates with either chemotherapeutic drugs (Ma et al., 2007; Niidome et al., 2014) 
or oleic acid which showed various levels of toxicity to healthy cells as well. 
However, if protein alone acts as a therapeutic agent or can be made lethal against 
cancer cells without conjugating with other molecules like chemotherapeutic drugs, 
the post-administration side effect could be avoided. 
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In our present investigation, we have used hen egg white Lysozyme (LYZ) having a 
molecular mass of 14.4 kDa and bovine α-lactalbumin (BLA) having molecular mass 
of 14.17 kDa for the preparation of self-assembled nanostructured particle and 
applied in breast cancer cells to examine its anticancer effect. 
 The anticancer potential of exogenous native LYZ was reviewed exhaustively 
in 1989 by Sava et al where he reviewed various models and mechanism of action of 
LYZ-mediated cancer cell death (Sava et al., 1989). Lysozyme was used earlier for 
antitumor activity in many in vivo model systems of animal tumors (Fukawa et al., 
1982; Sava, 1989; Sava et al., 1988; Sava et al., 1986). However, after 1989, except 
the report on the anti-proliferative effect of recombinant human lysozyme in gastric 
cancer cells (Guo et al., 2007), no significant progress was made towards LYZ- based 
therapeutic approach in cancer. Recently lysozyme extracted from a marine bacterium 
has been found to inhibit angiogenesis and tumor growth in mice (Ye et al., 2008). 
In our present investigation we have prepared a structurally stable self-assembled 
nanostructured lysozyme (snLYZ) and bovine α-lactalbumin (snBLA) synthesized 
using a simple desolvation technique. Further, we characterized the nanoassemblies 
for their shape and size using Field Emission Scanning Electron microscopy 
(FESEM), Atomic force microscopy (AFM) and Dynamic light scattering (DLS) 
particle size analysis. The conformational state of the protein self-assembly was 
characterized using Circular Dichroism (CD), Tryptophan and ANS fluorescence 
spectroscopy. Using these techniques the stability studies of the protein 
nanoassemblies were performed against varying temperature, pH and protease related 
stress.  
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These protein nanoassemblies were evaluated for their anticancer activity in breast 
cancer cells using the MTT assay and the cellular uptake study was also performed. 
Moreover, we also conjugated the nanoassemblies with activated folic acid to observe 
the enhancement in uptake in breast cancer cells. The drug loading and pH responsive 
drug (Tamoxifen) release potential were also studied. The hemocompatibility assays 
for the above mentioned protein nanoassemblies along with the drug loaded state 
were also performed. We also attempted to develop graphene oxide nanosheet (GOns) 
and zinc oxide nanoparticles (ZnONP)-based therapeutic approach in breast cancer 
for a comparative reason with our protein based approach. 
In addition to the above, we have also synthesized graphene oxide nanosheets (GOns) 
and Zinc oxide nanoparticles (ZnONP’s) by modifying the standard synthesis 
procedures. The anticancer activity of GOns and ZnONP were evaluated in breast 
cancer cells. Both these nanostructures were functionalized with bovine α-
lactalbumin and their anticancer activity were evaluated in breast cancer cells. The 
GOns and ZnONP nanostructures along with their protein functionalized states were 
also evaluated for their hemocompatibility. Overall, the thesis contains a detailed 
study on the development of two small protein based therapeutic option for breast 
cancer and an approach to establish a realistic strategy for future implementation. 
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Chapter 2 
Literature Review 
Cancer is one of the leading causes of death worldwide which figured out to be 7.6 
million deaths (approximately 13% of all deaths) in 2008 and the death projection is 
on the rise. Breast cancer is the most common types of cancer and responsible for 
majority of cancer death among females, accounting for 23% of all cancer cases and 
14% of all cancer-related deaths (Ferlay et al., 2010). 
Breast cancer is still the foremost cause behind cancer death among females in 
economically developing countries, toppling cervical cancer from the top position, 
which was the leading cause of cancer death a decade ago (Jemal et al., 2011). 
Recently documented statistics about breast cancer in the year 2013, reveal 1.8 
million incident cases of breast cancer and 4,64,000 deaths. Breast cancer resulted in 
13.1 million people leading disease assisted life years (DALY’s) in 2013 with the 
contribution from developing and developed countries being 63% and 37%, 
respectively (Fitzmaurice et al., 2015). 
More alarming findings reported are as follows (Fitzmaurice et al., 2015): 
1. Every woman among 18 women developed breast cancer after birth till 79 
years. 
2. Breast cancer had the highest incidence among women in 161 countries and is 
the most common cause for cancer deaths in women in 98 countries. 
3. The ranking for breast cancer moved from sixth in the year 1990 to fifth in the 
year 2013 (see Table 2.1). 
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4. The number of breast cancer incidence rates in the year 2013 increased by 
8,98,000 (99% increase) compared to the year 1990 (see Fig.2.1A). 
Table 2.1 Global Rankings of various Cancers for both sexes based on absolute years 
of life lost (YLLs) between the year 1990 and 2013. 
Rankings 1990 Rankings 2013 
1 Tracheal, bronchus 
and lung cancer 
1 Tracheal, bronchus 
and lung cancer 
2 Stomach Cancer 2 Liver Cancer 
3 Liver Cancer 3 Stomach Cancer 
4 Colon and rectum 
cancer 
4 Colon and rectum 
cancer 
5 Leukemia 5 Breast cancer 
6 Breast cancer 6 Esophageal Cancer 
7 Esophageal Cancer 7 Leukemia 
8 Cervical Cancer 8 Pancreatic Cancer 
9 Brain and Nervous 
system Cancer 
9 Cervical Cancer 
10 Non-Hodgkin 
lymphoma 
10 Brain and Nervous 
system Cancer 
 
5. The breast cancer incidence rates would have increased by 38% with a stable 
population and age. However, with aging population with unchanged 
incidence rates would have pushed the breast cancer incidence rates to 35% 
and 26% respectively (see Fig.2.1B). 
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Figure 2.1 Cancer statistics between the period 1990-2013 (A) Incidences of breast 
cancer is on the rise from 1990 to 2013, (B) Percentage change in incidence rate due 
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to population growth (35%), due to change in age structure (38%) and due to change 
in incidence rates (26%). 
6. Eventhough female breast cancer incidence is lower in developing countries, it 
is increasing rapidly compared to developing countries where rates have been 
stable to declining since the early 2000s.  
7. Between 1990 and 2013, age standardized incidence rates (ASIRs) per 
100,000 have increased by 17% globaly (44.36 to 51.73), 46% in developing 
countries (22.74 to 40.40) and 8% in developed countries (69.75 to 74.98) (see 
Fig.2.2). 
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Figure 2.2 Current statistics for Age-standardized incidence rates (ASIR) of Breast 
cancer (Fitzmaurice et al., 2015). 
8. Age-standardized disability assisted life years (DALY) during the period 
between 1990-2013 have decreased at the global level by 17%, for developed 
countries by 25% and 3% for developing countries see Fig.2.3. 
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Figure 2.3 Current statistics for ASIR of disease assisted life years (DALY) for 
Breast cancer (Fitzmaurice et al., 2015). 
The incidence rates of breast cancer (Ranks first in 37% of the countries among 188 
countries) is a major concern world-wide. Breast cancer (37%) contributes to the 
major chunk of the cancer burden, closely followed by prostate cancer (29%) (see 
Fig.2.4). 
 
Figure 2.4 Prevalence of various forms of cancers among 188 countries based on 
incidence rates of the year 2013 (Fitzmaurice et al., 2015). 
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The factors that result in the international variation in incidence rates of breast cancers 
largely arise from changes in the reproductive and hormonal behavior of females 
world-wide (Jemal et al., 2010). Reproductive factors that contribute to the risk of 
breast cancer include a prolonged menstrual history, obesity, nulliparity, 
postmenopausal hormone therapy, oral contraceptives, and late onset of pregnancy 
(Hulka and Moorman, 2001). Apart from the above mentioned reproductive factors 
increased alcohol consumption, observed in many western countries also increases the 
chances of  breast cancer (Baan et al., 2007; Key et al., 2006). 
 
Figure 2.5 Mortality due to various forms of cancers among 188 countries based on 
mortality rates for the year 2013 (Fitzmaurice et al., 2015). 
Breast cancer is the most common malignancy type diagnosed in women in developed 
countries and developing countries (Fitzmaurice et al., 2015). The incidences of breast 
cancer have reached alarming proportions and is a major health problem in India 
(Yeole et al, 2003). As per the survey carried out by Indian Council of Medical 
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Research (ICMR) in the metropolitan cities such as Delhi, Mumbai, Chennai and 
Bangalore, during the period between 1982 to 2005, the incidences of breast cancer 
have increased two-fold. There has been a steady increase in the  incidences of breast 
cancer in India and approximately 100,000 new patients are being diagnosed with 
breast cancer every year (Yip et al., 2006; Michael et al., 2003). A 12% increase in 
breast cancer incidences have been recorded in cancer registries during the period 
1985 to 2001, which accounts for 57% increase in the cancer burden of India (Yip et 
al., 2006; Hadjiiski et al., 2006). The total cancer cases in India are likely rise from 
979,786 cases in the year 2010 to 1,148,757 cases in 2020. Breast cancer of males and 
females in India, alone is expected to cross the figure of 100,000 by the year 2020 
(Takiar et al., 2010). 
Cancer cells possess self-sufficiency in growth signals, insensitive to antigrowth 
signals, limitless replicative capability, prolonged angiogenesis, apoptosis evading 
potential, tissue invasion and metastasis potential (Hanahan and Weinberg, 2000) and 
due to the above mentioned characteristics of cancer cells, targeting cancer cells has 
been an uphill task. A number of oncogenes and tumor suppressor genes are found 
mutated in cancer (Stehr et al., 2011).  
Estrogen receptor (ER) expression is the key indicator for potential responses to 
endocrine therapy (ET). Around 70% of all breast cancers are hormone responsive 
and ER-positive (Lumachi et al., 2013). The introduction of Tamoxifen therapy led to 
a significant increase in post-surgical survival and a decrease in relapse, particularly 
in women in early stages of breast cancer and those having ER+ve tumors. 
Tamoxifen binds to the estrogen receptors in breast cancer cells and stops estrogen 
from binding to them and prevents estrogen mediated stimulation of growth and cell 
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proliferation. Tamoxifen acts as an anti-estrogenic agent in breast cells, whereas it 
acts as an estrogen mimetic in tissues, such as the uterus and bones. Since, it acts like 
estrogen in some tissues and as an anti-estrogen in others, it is popularly known as 
selective estrogen receptor modulator (SERM).  
For women with ER receptor-positive invasive breast cancer, tamoxifen can be given 
for five years after surgery to avoid relapse (Koberle and Thurlimann, 2005). It also 
reduces the risk of development of a new breast cancer in the contralateral breast. For 
early stage breast cancer, this drug is mainly used for women who have not yet gone 
through menopause. Tamoxifen can also stop the growth and even shrink tumors in 
women with metastatic breast cancer. It can also be used to reduce the risk of 
developing breast cancer in women at high risk (Hu et al., 2015). Tamoxifen has a lot 
of other advantages. It improves the lipid profile and bone mineral density in post-
menopausal patients, however it also suffers from disadvantages such as 
thromboembolic disorders, uterine disorders and other malignancies (Munshi and 
Singh, 2008). 
A lot of other chemotherapeutic agents have been developed after the synthesis of 
Tamoxifen which includes paclitaxel, doxorubicin, gemcitabine, cisplatin and 
Abraxane. Side effects of paclitaxel induces bone marrow suppression, 
hypersensitivity reactions, cardiovascular problems, neurotoxicity, mucositis, hepatic, 
renal and dermatological problems (Cella et al., 2003). Doxorubicin causes 
myelosuppression and cardiac arrhythmias (Tacar et al., 2013). Pulmonary and 
neurological toxicity is associated with Gemcitabine (Gupta et al., 2002). 
Cardiovascular disorders are associated with cisplatin-based therapy (Uner, 1993). 
Conventional treatment such as chemotherapy is plagued with problems related to 
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site-specific drug delivery, drug resistance and recurrence of cancer. Hence, new and 
more evolved forms of treatment procedures are required for the treatment of cancer.  
Due to the above pitfalls associated with chemotherapy, gradually the focus is shifting 
towards protein-based therapeutics. Commercially, for example, albumin-bound 
Paclitaxel (Abraxane) was the first protein-nanoparticle formulation that was 
approved on January 2005, by US-FDA for treating metastatic Breast cancer (Miele et 
al., 2009). Abraxane consists of nanoparticles of paclitaxel, stabilized with the protein 
human albumin through hydrophobic interactions and have a particle size of 130 nm. 
Albumin has a number of advantages that make it an attractive choice for drug vehicle 
in cancer. It is a natural transporter of endogenous molecules such as vitamins and 
hormones having non-covalent interactions (Hawkins et al., 2008; Purcell et al., 
2000). Moreover albumin facilitates endothelial transcytosis through glycoprotein 
(gp60) receptor (albondin) (Miele et al., 2009).  
A small protein, lysozyme has already been reported for possessing anti-tumorigenic 
potential (Caseli and Schumacher, 1955; Guo et al., 2007; Ye et al., 2008). The 
mature hen egg white LYZ is composed of 129 amino acids (Canfield, 1963) and the 
structure of lysozyme is consistent under a variety of conditions, making it an ideal 
choice for crystallography studies. The active site of lysozyme contains a deep 
crevice, which divides the protein into two separate domains linked by an α helix. The 
first domain (residues 40 to 85) consists mostly of β-sheet structure, whereas the 
second domain (residues 89-99) is more helical in nature (Strynadka and James, 
1991). Lysozyme is a basic protein having a molecular weight of 14.4 kDa with its 
isoelectric point in the range of 10.5-11.5 (Carr, 1953). Lysozyme acts as a natural 
bacteriostatic and bactericidal agent by degrading the poly-saccharide (N-acetyl 
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glucosamine (NAG) and N-acetylmuramic acid) that is present in the cell walls of 
many bacteria. The  bacterial  polysaccharide  consists  of  long  chains  of alternating  
amino  sugars:  N-acetylglucosamine  (NAG)  and N-acetylmuramic acid (NAM). It is 
widely distributed in various physiological fluids and such as human colostrum, milk, 
blood, tears, saliva, nasal mucus and in cells of the immune system (Cegielska-
Radziejewska et al., 2008). Lysozyme is stable under a wide range of conditions, and 
hence, used as a food preservative for meat, seafood, fruits, vegetables and dairy 
products (Touch et al., 2009). Lysozyme is used to treat ulcers, infections and 
neoplastic diseases, and as a component in ophthalmologic preparations (Gasior-
Chrzan, 1988; Permanetter and Meister, 1984; Rubio, 2014). Moreover, lysozyme 
plays an important role in the immune system response of organisms in response to 
infections and inflammation (Thompson et al., 1990). Due to the aggregation 
propensity of lysozyme, it can be used for designing protein assemblies for the 
delivery of drugs and nutraceuticals (Diarrassouba et al., 2015; Price et al., 1999). 
The first report on antitumorigenic activity of native lysozyme (nmLYZ) was 
documented by Caselli and Schumacher (Caseli and Schumacher, 1955). During the 
period between 1955 and 1989, several studies on antitumorigenic and anticancer 
effect of nmLYZ on the immunogenic response on various in vivo models were 
reported by few groups. Two remarkable studies performed by Babudieri-Callerio 
and Callerio (Callerio-Babudieri and Callerio, 1963; Callerio, 1959) where they 
demonstrated that the effect of LYZ on H.S 1 (mesenchymal origin), Hep2 (epithelial 
nature) strains and HeLa cells produced irregular granular structures in the cytoplasm. 
Bovine α-lactalbumin (BLA)  is another such protein present in the whey fraction of 
bovine milk and reported to possess anti-cancer activity (Lin et al., 2008; Sternhagen 
and Allen, 2001; Thompson et al., 1992; Xu et al., 2005) and cancer-preventing 
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potential (Parodi, 2007). The structure of α-lactalbumin is well known and is 
composed of 123 amino acids and 4 disulfide bridges. The molecular weight is 14.17 
kDa, and the isoelectric point lies close to 4.2 (Bramaud et al., 1997). The α-
lactalbumin content in human milk and bovine milk is 28 and 3% respectively. Both 
the human and bovine α-lactalbumin variants share a 72% similarity in amino acid 
sequence. Both human and bovine α-lactalbumin contains 6, 5 and 0.9% (wt/wt) of 
tryptophan, cysteine and methionine respectively. Therefore, the only difference in 
the amino acid compositions of bovine and human milks is mainly attributed to 
their α-lactalbumin content (Heine et al., 1991). The protein has a distinct binding site 
for calcium and zinc ions. The binding of calcium increases the stability of the protein 
and known as holo α-lactalbumin. The calcium depleted state of the protein is known 
as apo α-lactalbumin. It mainly functions as a modifier protein in lactose biosynthesis 
(Brodbeck et al., 1967). Moreover due to the aggregation propensity of α-lactalbumin, 
it can be used for the preparation of protein self-assemblies for delivery of bioactive 
substances (Livney, 2010). Incidentally, both the above mentioned proteins are 
monomeric and low molecular weight proteins (14 kDa approx.) having closely 
similar aminoacid sequences and Ca2+ binding pockets. 
Recently small proteins such as bovine and human α-lactalbumin have also been 
reported to be made lethal against number of tumor cells where a specific 
conformational state of the protein was responsible for forming the conjugate known 
as BAMLET (Bovine α-lactalbumin made lethal to tumor cells) or HAMLET (Human 
α-lactalbumin made lethal to tumor cells) with oleic acid to cause cell death (Rammer 
et al., 2010; Zhang et al., 2009). The hydrophobic cores present in HAMLET and 
BAMLET are structurally distinct from their native forms (Mok et al., 2007). 
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However, in most of these cases proteins have been used as conjugates with either 
chemotherapeutic drugs (Ma et al., 2007; Niidome et al., 2014) or oleic acid which 
showed various levels of toxicity to healthy cells as well. However, if protein alone 
acts as a therapeutic agent or can be made lethal against cancer cells without 
conjugating with other molecules, the post-administration side effects could be 
avoided. 
A suitable cancer drug or vehicle should not only be target specific, but it must be 
biocompatible and biodegradable so that its existence after its desired action should 
not bring harmful effect on healthy cells and tissues. Protein-based drugs have been 
proposed to be a new generation therapeutic agent in many diseases including cancer 
which not only acts as a therapeutic agent without causing any cytotoxicity but can 
also be used as drug carrier with targeted therapy. 
Proteins are normally extremely sensitive to various kinds of external stress because 
of their intimate link between their unique 3-D structure and biological function 
(Hegyi and Gerstein, 1999; Martin et al., 1998; Thornton et al., 1999). They can 
change their secondary as well as tertiary structure depending on the external 
chemical environments (Neklesa et al., 2011). Proteins also possess unique properties 
to form self-assembled nanostructures that can be externally driven in-vitro and this 
has recently been explored towards many applications in biology and medicine 
(Gangar et al., 2013; Jabbari, 2009; Li et al., 2008; Liu et al., 2011; Panda et al., 
2013; Xu et al., 2014; Zhang, 2003; Zhu et al., 2013). 
There are certain advantages of using self-assembled protein nanostructures in 
biology and medicines, like 1) They are normally nontoxic, non-immunogenic, 
biocompatible and biodegradable (natural proteins); 2) They are good candidates for 
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conjugation with drug molecules 3) They are structurally and functionally modifiable 
to make them fit for loading various compounds like anti-cancer drugs and hence, can 
be used in targeted drug delivery. Nanoparticles developed from natural proteins are 
usually biodegradable, easy to metabolize, and surface modifications can easily be 
done for efficient attachment of drugs (Weber et al., 2000). Nanoparticles from 
various proteins have been developed including bovine and human serum albumin, 
zein and gliadin (Weber et al., 2000). 
Self-assembly is the inherent property of numerous multimeric biological structures to 
assemble from their respective parts through the random arrangement of molecules 
and due to the weak formation of chemical bonds between the surfaces (Hosseinkhani 
et al., 2013). Molecular self-assembly is a powerful tool for scientists fabricating and 
developing novel supramolecular architectures and spontaneous assembly of 
molecules into structurally well-deﬁned and stable arrangements through noncovalent 
and covalent interactions (Duval-Terri et al., 2003; Grill et al., 2007). 
In most of the cases, molecular self-assembly relies on chemical and structural 
compatibility (Whitesides and Grzybowski, 2002). Electrostatic, hydrogen bond, 
hydrophobic or hydrophilic and van der Waals interactions are involved in such 
chemical processes. Such collective interactions can produce molecules that are 
structurally and chemically stable (Hosseinkhani et al., 2013). Molecular components 
require inherently compatible properties such as speciﬁc surface characteristics, 
surface charge, and polarizability, mass and surface functionalities to self-assemble 
into diﬀerent physiological forms (Whitesides and Grzybowski, 2002). Biological 
molecules including proteins, peptides, nucleic acids and lipids have inherent 
properties that facilitate self-assembling into the cell. Events such as amyloid ﬁbril 
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formation, antigen-antibody recognition, and chromatin as well as phospholipid 
membrane self-assembly are excellent examples of molecular self-assembly. 
Many artificial bio-nanostructures have been developed by programming specific 
molecular self-assemblies based on the combination of multiple hydrogen bonds and 
coordination bonds (Conn and Rebek, 1997; Philp and Stoddart, 1996; Rebek, 1996; 
Sanders, 1995; Sun et al., 2002). 
In biological systems, many types of cellular and sub-cellular structures, such as 
microtubule network, actin filaments, flagella, clathrin lattices, viruses and 
chromatins are generated spontaneously by self-assembly of various biomolecules, 
including nucleicacids, lipids and proteins. Microtubules are naturally occurring 
nanotubes having a diameter of 24 nm formed by self-assembly of α-tubulin and β 
proteins, in the presence of GTP, which actively participates in intracellular transport 
and the development of cytoskeletal components (Mandelkow and Mandelkow, 
1994). The clathrin lattice has a diameter of approximately 100nm and is a polyhedral 
structure developed due to self-assembly of clathrin triskeleton comprising of three 
proteins along with Mg2+ ion, that is involved in receptor-mediated endocytosis (Fotin 
et al., 2004; Kirchhausen and Harrison, 1984). 
The virus is also a good example of a naturally formed supramolecular assembly 
having a discrete size and possess a rod-like or spherical morphology of approximate 
diameter of 18–100 nm (Matsuurua, 2014). Such assemblies comprise of genomic 
nucleic acids encapsulated in an outer protein case known as the capsid. Most 
spherical viruses developed from the self-assembly of proteins, possessing an 
icosahedral symmetry involving C5, C3, and C2-symmetric axes. 
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The satellite tobacco necrosis virus is the smallest virus having a diameter of 18 nm 
and is formed due to the self-assembly of 60 protein subunits. Tomato bushy stunt 
virus (TBSV, the diameter of 33 nm) is another instance where the virus formed from 
180 quasi-equivalent protein subunits (Branden, 1999; Olson et al., 1983). 
Various amphiphilic strategies have been used to develop and design protein/peptide 
assemblies. Self-assembly of peptide nanofibers have been developed from 
amphiphilic peptides (Cui et al., 2010; Palmer and Stupp, 2008). Boerakker et al. 
developed a “giant amphiphile” consisting of an apo-protein of horseradish 
peroxidase (HRP) and heme-modified polystyrene, which self-assembled to form a 
protein vesicle (Boerakker et al., 2002). Although simple, the giant amphiphile 
approach suffers from various disadvantages, such as the broad size distribution of the 
nanocapsules ranging from 100–1000 nm and very low enzyme activity.  
Recently, Kimizuka et al. also reported the development of protein microcapsules by 
cross-linking proteins at water interface (Morikawa et al., 2012). Protein 
microcapsules and nanotubes can also prepared by layer-by-layer adsorption of 
proteins (Komatsu, 2012; Tong et al., 2008) but, such artificial protein assemblies 
created through hydrophobic eﬀects , electrostatic interactions, lack of precision and 
discreteness when compared with natural biomolecular assemblies created through 
specific interactions (Matsuurua, 2014). 
Linear self-assembly of protein 
Hemoproteins, such as hemoglobin, myoglobin, cytochromes, and peroxidases, can 
disassemble into heme (cofactor) and apoprotein, and reconstitution can create 
various artificial hemoproteins (Hayashi and Hisaeda, 2002).Hayashi et al. developed 
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a liner assembly of hemoprotein by successive inter protein heme–heme pocket 
interactions (Kitagishi et al., 2007).  
Barrel / tubeself-assembled structure of proteins 
In 1993, pioneering work on the tubular hollow assembly of peptides was reported by 
Ghadiri (Ghadiri et al., 1993). The peptide nanotubes were formed by self-assembly 
of cyclic D, L-peptides composed of alternating D- and L-amino acids. The internal 
diameter was regulated by the structure of cyclic peptides. Self-assembled nanotubes 
from cyclic peptides containing hydrophobic side chains were applied to 
transmembrane ion channels (Bong and Ghadiri, 2001; Brea et al., 2010). 
Gazit et al. found that the simple dipeptide L-phenylaranyl-L-phenylalanine (FF), 
which is the hydrophobic core motif of ß-amyloid, self-assembled into stiﬀ nanotubes 
(Cherny and Gazit, 2008; Gazit, 2007; Reches and Gazit, 2003). When a concentrated 
solution of FF in hexafluoroisopropanol was diluted by water, ordered semi-
crystalline structures were formed. Transmission electron microscopy (TEM) images 
showed well-ordered tubular assemblies formed having a diameter of 100 nm. The 
authors also suggested that discrete silver nanowires can be synthesized by reduction 
of silver ions within nanotubes used as a template, followed by enzymatic digestion of 
the peptide. The dipeptide FF can form vertically aligned nanotubes by self-assembly 
on siliconized glass plates (Reches and Gazit, 2006). 
Kruif et al. found self-assembled α-lactalbumin into protein nanotubes in the presence 
of Ca2+ ion after partial hydrolysis by a protease (Graveland-Bikker et al., 2009). The 
protein nanotubes were proposed to consist of dimeric building blocks, which self-
assemble through β-sheet stacking. 
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Ring shaped self-assembly of protein 
Closed ring-shaped self-assemblies of proteins can be developed by specific 
interactions between the ligand dimer and the receptor protein dimer under proper 
conditions. Wagner et al. reported that two dihydrofolate reductase (DHFR) proteins 
can be linked by a suitable peptide linker in the presence of  bis-methotrexate 
spontaneously forming cyclic structures with diameters ranging from 8 to 20 nm 
(Carlson et al., 2006). The authors are also developed enzyme nano-rings (10–70 nm) 
by self-assembly of DHFR–human histidine triad nucleotide binding 1 (hHint1) 
protein with bis-methotrexate. The size of the nanoring regulated the enzymatic 
activity of hHint1 (Chou et al., 2008). Therefore, such enzyme activity can be 
regulated by designing similar kind of ring-shaped assemblies. 
Sphere, cage and polyhedral assemblies 
An artificial C3-symmetric peptide conjugatecontaining three β-sheet forming 
peptides (trigonal-(FKFE)2) self-assembled to form spherical assemblies having a 
diameter of 19 ± 4nm (Matsuura et al., 2005). Similarly C3-symmetric peptide 
conjugates having three tryptophan zipper-forming peptides (CKTWTWTE) 
demonstrated pH-responsive changes in the secondary structure of nanoassembly in 
the presence of water as a solvent.  
The conjugate self-assembled nanospheres are having a diameter of 30 nm by forming 
a tryptophan zipper at pH 7 and was also converted into a mixture of nanofibers and 
nanospheres through the formation of β-sheets at pH 11. The conjugate was converted 
to irregular aggregates mediated by random coil structure at pH 3 (Matsuura et al., 
2011). 
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The design of artificial protein subunits, which form symmetrically arranged protein 
oligomers, result in the formation of three-dimensional protein cage assemblies that 
may reduce the loss in entropy of the self-assembly process in water. In 2001, Yeates 
et al. designed 16 nm tetrahedral protein cages by the self-assembly of a fusion 
protein of  bromo-peroxidase together along with the M1 matrix protein of the 
influenza virus  linked with a nine-residue helical linker (Lai et al., 2012; Lai et al., 
2013; Padilla et al., 2001). 
Hydrogels based on protein self-assembly 
Wang et al. designed artiﬁcial proteins that could self-assemble to form hydrogels 
(Wang et al., 2005).The group designed artiﬁcial proteins with an ionic self-
complementary peptide group with the polar and nonpolar peptide molecules arranged 
alternately. Stable β-sheet structures were formed from these peptides that self-
assembled to form nanoﬁbers. The interwoven network of these nanofibres that 
provided the scaﬀold hydrogel with high water retaining capacity and responds to 
changes in pH in its environment. These protein hydrogels can be used for facilitating 
wound closure and tissue repair. These protein hydrogels are biodegradable and find 
applications in drug delivery systems, which deliver drug-protein complexes in the 
treatment of cancer.  
Adams et al. designed peptide nanotubes from surfactant-like peptides (Adams et al., 
2007). Such peptide nanotubes can be used as frames for generation of metal 
nanocrystals and fabrication of nanowires. Peptide nanotubes can also perform as ion 
channels when introduced in the phospholipid bilayer present on the cell membrane. 
Recent reports show protein structures and peptides can form complexes with various 
metals and semiconducting elements. Surface-binding peptides can bind covalently 
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with the metal surfaces such as gold (McMillan et al., 2001). These properties can 
find various applications in design and fabricate nanobiosensors. Various applications 
of self-assembly of protein architectures are shown in Table 2.2. 
 
Table 2.2 Few key applications of self-assembled proteins in bio-nanotechnology 
related applications. 
Applications References 
Self-assembly of amphiphilic peptides to nanoscale ﬁbers for 
designing nanostructured ﬁbrous scaﬀold that resembles 
extracellular matrix 
(Hartgerink et al., 2001) 
Formation of various nanostructures like nanoﬁbers, 
nanotubes, vesicles, helical ribbons, and ﬁbrous scaﬀolds for 
biomedical applications. 
(Zhang et al., 2002) 
Artiﬁcial proteins can self-assemble to form hydrogels in 
response to pH and environmental changes. Such protein 
hydrogels can be used for advanced wound closure and 
tissue repair in regenerative medicine and tissue engineering. 
Peptide nanoﬁbers may be used as drug delivery systems 
with better biocompatibility. 
(Niece et al., 2003) 
Nanoengineering of molecular design frames and 
supramolecular structures 
(Chung et al., 2011) 
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A lot of recent progress has been made in the construction of artificial nano-and 
micro-sized protein/peptide architectures. Peptide nanofibers were fabricated by the 
self-assembly of coiled-coil-forming and β-sheet-generating peptides. Interprotein 
heme–hemepocket interactions resulted in the formation of nanotubes. Specific 
interactions between ligands and receptors provided ring-shaped protein assemblies. 
The self-assembly of fusion proteins resulted in the construction of protein cages. The 
generation of artificial nano and micro-structures from protein/peptide conjugates 
allows new avenues for improvisation in bio-nanotechnology. The protein/peptide 
nano-architectures may be explored for their effects in various diseases such as cancer 
since, it has observed that the change in secondary structures may add new properties 
like specific toxicity towards cancer cells. 
Breast cancer is the disease having the greatest presence of nanotechnological 
therapeutic agents in the clinic. The pegylated form of liposomally encapsulated 
doxorubicin is currently used for the treatment of metastatic cancer, and albumin-
paclitaxel nanostructures commercially known as Abraxane is currently under use for 
the treatment of breast cancer. More than 150 clinical trials are currently  using these 
drugs in combination with biological therapeutics. Despite these advancements, breast 
cancer morbidity and mortality is unacceptably high. Nanotechnology offers potential 
solutions to the historical challenge that has rendered breast cancer so difficult to 
contain and eradicate. Apart from these protein self-assemblies, there are other non-
protein materials such as zinc oxide nanoparticles and graphene oxide nanosheets that 
are also being used for studies involving drug delivery and therapy in cancer. 
Zinc oxide (ZnO) is a common nanomaterial and has a wide range of applications 
(Fan and Lu, 2005). ZnO acts as a photocatalyst, and it helps in the degradation of 
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environmental pollutants (Xu et al., 2007; Yeber et al., 2000). ZnO nanoparticles 
(ZnONPs) find use in cosmetics, paints, and medical products. They are also used as 
antibacterial agents and its application on the surface prevents microorganism 
growth(Jones et al., 2008). ZnONPs are also used as ingredients in dietary 
supplements as it stimulates the immune system and acts as an anti-inflammatory 
agent(Prasad, 2008; Rincker et al., 2005).  
Various in-vitro studies demonstrated increased toxicity of ZnO-NPs towards 
mammalian cells (Jeng and Swanson, 2006; Lai et al., 2008). Brunner et al.(Brunner 
et al., 2006) showed increased toxicity of ZnONPs (19 nm) towards human 
mesothelioma and rodent fibroblast cells causing DNA and mitochondrial damages. 
ZnO also shows increased toxicity towards cancer cells (Sahu et al., 2013). ZnO 
mediated toxicity towards HaCaT and A549 cells was found to be inhibited when the 
surface of ZnO was coated with foetal bovine serum (Horie et al., 2009). However the 
specific serum components were not identified which provided the protection against 
ZnO mediated cytotoxicity. Hence, surface functionalization aspects of ZnONP may 
be explored further for cancer therapy. 
Graphene oxide (GO) is a graphene derivative having covalent bonds between carbon 
and oxygen (Dreyer et al., 2010). The continuous increasing interest of researchers for 
graphene oxide (GO) has been primarily attributed due to its excellent material 
characteristics, such as superior optical, electronic, chemical as well as mechanical 
properties (Dong et al., 2012). GO is used as an essential component of biological 
sensors for the detection of  dopamine (DA) (Ponnusamy et al., 2014), glucose 
(Unnikrishnan et al., 2013), sildenafil (Li et al., 2013), folic acid (Ren et al., 2011), 
ATP, GTP (Wang et al., 2014), DNA fluorosensing (Zhang et al., 2014b) and protein 
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detection (Lin et al., 2014).Moreover, the good surface functional properties of GO 
finds applications in targeted hydrophobic drug delivery applications and helps in 
targeting cancer cells by the folic acid functionalization and near infrared 
photothermal therapy (Qin et al., 2013). GO has already been explored in tissue 
engineering (Erika et al., 2014; Kang et al., 2015; Ku and Park, 2013; Lee et al., 
2011), as an antibacterial agent  (Chen et al., 2014; Gurunathan et al., 2012) and 
shown promising results against liver (Corr et al., 2013; Lammel et al., 2013), lung 
(Chang et al., 2010) and breast cancer cells experimentally (Liu et al., 2008). 
Although GO nanosheet (GOns) shows wide applications in various kinds of 
biomedical sciences, its biocompatibility has been a great concern (Liao et al., 2011; 
Singh et al., 2012; Wang et al., 2012). Since most of the biological and medical 
applications expose GOns to cells and tissues, biocompatibility of GOns has become a 
major issue to be considered. Recently, Liao et al. have demonstrated increased 
hemolysis with the decrease in GOns size. However, the GOns had a broad size 
distribution with an extremely irregular shape (Liao et al., 2011). Since the 
cytotoxicity of a nanomaterial depends on its shape and size, it is essential to 
understand the exact mechanism behind such cytotoxicity.  
In an another study, coating of GOns with chitosan led to the elimination of toxicity 
associated with GOns (Liao et al., 2011). Similarly, coating of GOns with 
polyethylene glycol increases its biocompatibility and stability in various biological 
solutions. GOns is also a material suitable for the attachment of hydrophobic drugs 
with a high level of aqueous solubility (Jabbari, 2009; Liang et al., 2013). In a very 
recent finding, Wang et al. demonstrated a dose-dependent GOns toxicity towards 
human ﬁbroblast cells where GOns showed to cause toxicity at a dose higher than 50 
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μg/ml. In contrary, Ryoo et al. reported that GOns was highly biocompatible with 
improved gene transfection eﬃcacy in NIH-3T3 ﬁbroblasts (Ryoo et al., 2010). 
Moreover, GOns in many cases has recently been reported biocompatible and a 
potential candidate for biological applications, such as drug delivery and carriers in 
cancer therapy (Zhang et al., 2014a).  
Therefore, the apparent connection between GOns and the toxicity produced by them 
has yet not been established. GOns with various shape and size have their varying 
effect on the biological system, and hence they differ in biocompatibility. In a recent 
report, Shen and the group have documented the preparation and characterization of 
bovine serum albumin (BSA) functionalized GOns (Shen et al., 2010). However, the 
average size (length) of GOns was close to 1.0 µM, and the BSA protein was 
comparatively large (Molecular mass is 66 kDa). 
Large protein can limit the effective functionalization of GO surface, as they cannot 
bind entire surface homogeneously. In other findings, Mu and the group (Mu et al., 
2012) reported on the preparation of protein-coated GOns and its size-dependent 
cellular uptake. Although, in the same study, the GOns used were heterogeneous in 
shape, the protein, BSA was coated based on the strong protein binding capacity of 
GOns. However, such binding may not be strong enough to withstand the stress 
associated with prolonged circulation in the blood for biomedical applications. Hence, 
conjugating GOns with a protein or protein assembly having therapeutic properties 
will not only increase the biocompatibility but also improve its therapeutic application. 
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Chapter 3 
OBJECTIVES AND SCOPE 
 
The main aim of the current research work was the development of suitable 
therapeutic strategies using self-assembled protein nanostructures in breast cancer. 
The specific objective of the present thesis consists of the following: 
1. Synthesis of self-assembled nanostructures of hen egg-white lysozyme 
(snLYZ) and bovine α lactalbumin  (snBLA)  and their detailed 
characterization in terms of size, shape, function, homogeneity, stability, and 
conformation.  
2. Evaluation of their anti-proliferative potential in breast cancer cells such as 
MCF-7 and MDAMB-231, the mechanism of their cytotoxicity as well as cell 
death by studying Hsp90 and Caspase 3 expression. 
3. Evaluation of hemocompatibility and cytocompatibility of snLYZ and snBLA 
in normal cells.  
4. Synthesize graphene oxide nanosheets (GOns) and Zinc oxide nanoparticles 
(ZnONP) and develop their therapeutic approach in breast cancer using bovine 
α-lactalbumin-mediated surface functionalization and comparison with protein 
nanostructure based approach. 
5. Study of drug loading, pH-responsive drug release in vitro and design of 
suitable formulation using protein nanoassembly and drug to develop the dual 
therapeutic approach in breast cancer.    
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Scope of the work: 
There are numerous ways for the treatment of breast cancer, and chemotherapy is the 
most common among them. For the treatment of breast cancer various 
chemotherapeutic drugs such as paclitaxel, tamoxifen, cisplatin, 17-DMAG are used, 
however, administration of these compounds induce serious side effects. Hence, the 
focus has shifted to protein-based therapeutics that are highly biocompatible and 
efficacious. 
The current research work on the self-assembly of protein nanostructures has wider 
applications for cancer therapy. The previously known applications of protein 
nanostructures have been limited to drug delivery e.g. Abraxane, where the human 
serum albumin protein was used for preparing protein nanoparticles for paclitaxel 
delivery. However, the anti-proliferative activity of the protein was never been 
investigated. In the current investigation, we have developed self-assembled protein 
nanostructures that possess anti-cancer activity apart from their drug carrying 
abilities. The protein nanostructures were found to be highly stable against 
temperature, pH and protease related stress. The synthesized protein nanostructures 
can be used to provide a dual therapeutic approach for the treatment of cancer. The 
acidic environment of cancer cells can be exploited to use these protein nanostructures 
as a therapeutic agent and as a carrier for the drug. These protein nanostructures, 
when loaded with the drug Tamoxifen, have demonstrated excellent drug loading and 
delivery capabilities in response to pH. Hence, these protein nanostructures have a 
wide scope of usage, by loading of various other anti-cancer agents 
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Chapter 4 
Preparation and Characterization of Protein Nanostructures 
 
4.1 Materials and Methods 
 
4.1.1 Materials 
N-acetylcysteine (NAC), Glutaraldehyde (GTD) (25%), Tamoxifen citrate (TAM), N-
hydroxysuccinimide (NHS), and Whatman filter paper were purchased from Sigma-
Aldrich, India. Lysozyme, Bovine α-lactalbumin, Folic acid (FA), MTT assay kit, 
Ethanol, DMEM, Fetal bovine serum (FBS), antibiotics, DAPI, acridine orange, 
Fluorescein diacetate, Phenylmethanesulfonyl fluoride (PMSF), Proteinase K (PK), 
Sodium cacodylate, Sodium phosphate buffer, 1-anilinonapthalene-8-sulfonic acid 
(ANS) and Disodium EDTA were purchased from HiMedia India Pvt. Ltd. Milli-Q 
water was used in all the experiments.  
T-25 flasks, 96 well plates and all other plasticwares were purchased from Tarsons 
Pvt. Ltd., 3T3 (murine fibroblast cell line), HaCaT (human keratinocyte cell line), 
A549 (human lung adenocarcinoma epithelial cell line) MDAMB-231 and MCF-7 
(Breast cancer cell line) cells were procured from NCCS, Pune, India. 
Triton-X was purchased from Calbiochem, India. Human blood (B +ve) was freshly 
obtained from the donor before the experiments. All the glasswares used in the study 
were purchased from Borosil, India. All other reagents were of analytical grade. 
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4.1.2 Methods 
4.1.2.1 Preparation of self-assembled nanostructured bovine α-lactalbumin 
(snBLA) and lysozyme (snLYZ) 
Native protein (10 mg) of LYZ or BLA was taken in a beaker and 2 ml of Milli-Q 
water was added. The contents were stirred at 500 rpm for 5 min. Ethanol was added 
dropwise at the rate of 1ml/min and results in the change of colour into turbid white. 
The cross linker Glutaraldehyde (GTD) was added to achieve a final concentration of 
0.1%.The contents were stirred at 500 rpm, for 8 h followed by five cycles of 
centrifugation (25000g, 30 min, 40C). The pellet was resuspended in 2 ml of Milli-Q 
water and stored for further use at 40C. The frequent washing and five cycles of 
centrifugation were carried out, in order to remove the residual GTD from the 
formulation. 
During the process of optimization, snLYZ was prepared using various concentrations 
of GTD such as 0.1, 0.3, 1 and 3%. The biological activity assay of LYZ (see section 
4.1.2.2.1) (see Supplementary Figure S1), Field emission scanning electron 
microscopy (FESEM) imaging (see section 4.1.2.2.4) (see Supplementary Figure S3), 
Circular dichroism (CD) and tryptophan (Trp) Fluorescence spectroscopy (see section 
3.2.4) (see Supplementary Figure S2) were performed for the optimization of GTD 
concentration. Although, the various concentrations of GTD were used in the 
preparation of snLYZ, the optimized GTD concentration, i.e., 0.1% was used in the 
preparation of snLYZ and subsequent experiments. 
Protein (BLA) amount of 1, 3, 5, 10 and 20 mg were used as the starting material for 
optimizing the synthesis of self-assembly (see Supplementary Figure S4). The rest of 
the procedure remains same as mentioned above. After optimization of protein 
concentration, we also crosschecked the use of GTD concentration along with its 
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effect on the zeta potential of the particles (see Supplementary Figure S5 and S6). 
Moreover, we also optimized the effect of duration of crosslinking on the particle size 
of the self-assembly by increasing the duration of cross-linking from 3-8 h (see 
Supplementary Figure S7). 
4.1.2.2 Folic acid conjugation of snLYZ and snBLA 
 
We prepared the snLYZ/snBLA-folic acid (snLYZ-FA) conjugates with the aim of 
increasing the specificity of snLYZ for cancer cells (Lale et al., 2015). For the 
preparation of snLYZ/snBLA-FA conjugate, the prepared snLYZ/snBLA was 
suspended in 5 ml of Milli-Q water, followed by the addition of 25µl of 2 mg/ml 
stock solution of NHS-activated FA. NHS-activated FA was prepared as reported by 
Kouchakzadeh and colleagues (Kouchakzadeh et al., 2015). The carboxylic functional 
groups of the NHS folate were conjugated with the amino groups of the snBLA and 
snLYZ under alkaline conditions. NHS folate (2.5 mg) was dissolved in 1 mL of 0.1 
M bicarbonate buffer (pH 10), and slowly added to the stirring solution of 
snBLA/snLYZ. The reaction was allowed to continue for 45 min at ambient 
temperature. The contents were centrifuged at 25000 g for 10 min at 40C. The process 
was repeated five times to remove any residual unreacted NHS-FA. 
4.1.2.3 Characterization of snLYZ and snBLA 
4.1.2.3.1 Field emission scanning electron microscopy (FESEM) 
For capturing high-resolution images of various self-assembled nanostructured 
samples, FESEM study was performed. A volume of 10 µl of protein assembly (2 
mg/ml) was spread on a glass slide and allowed to dry in a desiccator. The glass slides 
with the samples were fixedon a carbon tape attached to the aluminium stub. The 
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aluminium stub was placed in a gold sputtering unit for 30 s. The samples were 
subsequently placed in the FESEM (NOVA NANO SEM 450) sample chamber and 
images were captured at a voltage of 5 kV.  
4.1.2.3.2 Atomic force microscopy (AFM) 
AFM imaging and measurements were performed using Bioscope Catalyst AFM 
(Bruker Corporation, Billerica, MA) with silicon probes. A volume of 10 µl of protein 
assembly (2 mg/ml) was placed on a freshly peeled mica surface followed by drying 
under a continuous flow of nitrogen gas. The mica discs were gently washed with 200 
µl of Milli-Q water. 
 The mica discs were allowed to dry in a desiccator overnight. The standard tapping 
mode was used for capturing images of different samples at room temperature in the 
presence of air. The nominal spring constant of the cantilever used was 20-80 N/m. A 
standard scan rate of 0.5 Hz with 512 samples per line was used for imaging the 
samples. AFM image of the snLYZ/snBLA sample was captured the next day. 
4.1.2.3.3 Dynamic light scattering (DLS) particle size analysis and zeta-potential 
analysis 
 The average particle size analysis and ζ-potential measurement of the aqueous 
suspensions of protein assembly were performed on a Malvern Zetasizer Nano-ZS 
DLS analyzer. A sample volume of 10 µl of snLYZ and snBLA (2 mg/ml) was taken 
and diluted with 1990 µl of deionized water and applied to DLS instrument for 
sizeand ζ potential analysis.  
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4.1.2.3.4 FTIR analysis of snLYZ and snBLA 
A sample volume of 100 µl (1 mg/ml) of snLYZ and snBLA was used for analysis. The 
samples were analysed at pH 7.0 in ATR mode. The spectral range was used between 
4000 cm−1and 500 cm−1 with a resolution of 2 cm−1 and 25 scans per spectrum in 
absorbance mode. 
4.1.2.3.5 Circular Dichroism (CD) spectroscopy 
CD  spectra  of  native lysozyme (nmLYZ), native BLA (nmBLA) , snLYZ and 
snBLA (200 µg/ml)  was  recorded  using  a  JASCO  J-815  CD polarimeter. Sodium 
cacodylate (20 mM) at pH 7.4 was used as a buffer for measuring the CD spectra. All 
the measurements were carried out at physiological temperature (37ºC) and a constant 
flow of N2gas.  
Each spectrum represented the average of three accumulations recorded between 
wavelengths of 200-250 nm, with a 0.2 nm resolution, and a bandwidth of 1.0 nm. A 
scan speed of 100 nm/min and a standard sensitivity was set using a cuvette of path 
length of 0.1 cm. Appropriate buffer contribution was subtracted from every 
measurement. The percentage of the secondary structures (α-helix and β-sheet) was 
calculated using the software provided along with the instrument. The CD signal in 
mdeg was converted to molar residue ellipticity (θ) [deg.cm2.dmol-1] using Eqn.4.1 
(Sohl et al., 2008).  
[θ] = 100 x (signal ) / C x n x l ---------------------------(4.1)  
The signal is in mdeg; C represents the protein concentration in mM, ‘n’ represents 
number of amino acid residues in the protein, ‘l’ represents the path length in cm. 
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4.1.2.3.6 Tryptophan (Trp) fluorescence measurement 
For Trp fluorescence measurement, 20 mM sodium phosphate buffer was used at pH 
7.4. The Trp fluorescence spectra were measured with a Perkin-Elmer LS-55 
Luminescence spectrometer. Samples of nmLYZ, snLYZ (28 µg/ml), BLA and 
snBLA (60µg/ml) were incubated, and spectra were measured at 37°C. An excitation 
wavelength of 290 nm was used, and Trp fluorescence emission spectrum (represents 
the average of three accumulations recorded) was recorded in the range of 300 to 400 
nm. The excitation and emission slit widths were set at 5 and 10 nm, respectively. 
Background corrections were made with buffer without protein in all cases. 
4.1.2.4 Stability analysis 
4.1.2.4.1 Stability of snLYZ and snBLA across various temperature and pH 
Both snLYZ and snBLA were exposed to a temperature range of 20-80 ºC using the 
peltier accessory and their CD spectra were generated. The concentration of protein 
used for generating CD spectra of snLYZ and snBLA was 300 µg/ml. The Trp 
fluorescence spectra of snLYZ (28 µg/ml) and snBLA (60 µg/ml) was also measured 
in the temperature range of 20-80 ºC. 
The CD spectrum of snLYZ was also recorded by varying the pH of the buffer in the 
pH range of 5-10.The Trp fluorescence of snLYZ and snBLA was measured in a pH 
range of 3.0 to 7.4 for snLYZ and 5-10 for snBLA respectively. 
For ANS-based fluorescence study, the ANS concentration was optimized by 
incubating the native protein with varying concentrations of ANS ranging from 10 – 
150 µM ANS for 30 min at 25°C. ANS bound fluorescence emission spectra were 
measured at 25°C at an excitation wavelength of 350 nm. The slit width of 5 nm and 10 
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nm were used for excitation and emission band pass, respectively with a scan rate of 
240 nm/min. The optimized ANS concentration was added to snBLA solution in 20 
mM phosphate buffer, pH 7.4. Solutions were incubated at various pH for 30 min at 
25°C. Protein-bound ANS fluorescence was measured at 20-80°C and with varying pH 
(5-10) at an excitation wavelength of 350 nm with a slit width of 5 nm and 10 nm for 
excitation and emission bandpass, respectively. 
 
4.1.2.4.2 Proteinase K (PK) assay 
 The stability of snLYZ and snBLA was evaluated by analyzing the proteolytic 
susceptibilities of both solutions. PK (3 µM) was applied to both the solution (200 
µg/ml) and incubated for 10 min at pH 7.4. The reaction was quenched by the 
addition of 1 mM PMSF (PK inhibitor). The absorbance of both the samples was 
recorded in a wavelength range of 250-305 nm and necessary baseline corrections 
were made. The absorbance of the control sample, i.e., PK solution was also measured 
and deducted. The extent of degradation of the snLYZ, snBLA and their native forms 
were measured from the drop in absorbance. 
 
4.1.2.4.3 Lysozyme activity of snLYZ 
  Cells of Micrococcus lysodekticus (9 mg) were suspended in 30 ml of 100 mM 
sodium phosphate buffer, pH 7.4, shortly before the assay. Each of the microplate 
wells contained 50 µl samples and 200 µl of micrococcus cell suspension. The plate 
was gently shaken for 1.0 min in a microplate reader (iMark, Bio-Rad) followed by 
measurement of absorbance at 450 nm and continued for 10 min at 1 min interval. 
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To observe the effect of pH on the lytic activity of LYZ in snLYZ, the pH of the 
sodium phosphate buffer was varied from 3 to 7.4 with the addition of 1N HCl. 
Lysozyme activity (Ng et al., 2013) was measured by measuring the change in OD 
over a period of 10 min and is represented by the following formula. 
 10 min -----------------initialLys activity (Change in O.D) = O.D  - O.D (4.2)  
4.1.2.4.4 Surface hydrophobicity of snLYZ and snBLA 
An increase in the surface hydrophobic character of a protein has been shown to 
provide stability to proteins from thermal stress (Gromiha et al., 2013; Pace et al., 
2011). Hence, estimation of surface hydrophobic character of the protein surface will 
provide an indirect measurement of thermal stability of the protein.  
8-Anilinonaphthalene-1-sulfonic acid (ANS) is a common extrinsic ﬂuorescence 
probe usually used to determine the hydrophobic character of the protein surface. 
Here, snLYZ/snBLA-bound ANS ﬂuorescence was used to determine the surface 
hydrophobic character of the protein. ANS concentration of 110 µM was added to 6.0 
μM nmLYZ, nmBLA, snLYZ and snBLA solution prepared in 20 mM phosphate 
buffer, pH 7.4.  
Solutions were incubated for 30 min at 25°C. Fluorescence spectra were measured 
with a PerkinElmer LS 55 spectroﬂuorimeter at 25°C. The excitation wavelength was 
fixed at  350 nm with slit width 5 nm, 10 nm for excitation and emission bandpass, 
respectively and at a scan rate of 240 nm/min.The fluorescence emission range was 
kept at 360-650 nm. 
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4.1.2.4.5 Thioflavin T assay for detection of amyloid formation 
Thioflavin-T (ThT) is a benzothiazole salt used as a dye for the visualization and 
quantification of fibrillar and misfolded protein aggregates or amyloid both in-vitro 
and in-vivo (Hawe et al., 2008).  ThT upon binding with the amyloid fibrils causes a 
peak-shift from 450 to 490 nm. Normally when excited at 440 nm, the ThT bound 
amyloid fibrils show an intense peak at 490 nm (Hudson et al., 2009).  
ThT (20µM) bound protein fluorescence was recorded to monitor the presence of 
amyloid fibrils in snLYZ and snBLA. Both snLYZ and snBLA solutions were 
incubated with ThT (20µM) for 20 min at room temperature. After incubation, the 
nmLYZ and snLYZ samples were excited at 440 nm and the emission fluorescence 
was measured within an emission range of 450 nm and 600 nm used for the ThT 
assay. 
4.2 Results and Discussion 
 
4.2.1 Preparation and Characterization of snLYZ and snBLA 
The preparation method for snLYZ/snBLA and its conjugates is given schematically 
in Fig.4.1. The details are provided in the “Materials and Methods Section”. The 
prepared snLYZ was characterized using Field emission scanning electron 
microscopy (FESEM) (see Fig 4.2 A), Atomic force microscopy (AFM) (see Fig 4.2 
B), DLS particle size analyser (see Fig 4.2 C). The synthesized snLYZ demonstrated a 
particle size of 300nm as evidenced from FESEM image, AFM image and DLS 
particle size analysis. 
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Figure 4.1 Schematic representation of preparation of snLYZ/snBLA and its 
conjugates with Tamoxifen (TAM) and activated Folic Acid (FAa). 
 
The prepared snBLA was characterized using Field emission scanning electron 
microscopy (FESEM) (see Fig 4.3 A), Atomic force microscopy (AFM) (see Fig 4.3 
B), DLS particle size analyser (see Fig 4.3 C).  The synthesized snLYZ demonstrated 
a particle size of 300 nm as observed from FESEM image, AFM image and DLS 
particle size analysis. Moreover, one of the most important aspects of our result was 
the shape of snLYZ and snBLA particles, which was clearly observed to be spherical. 
However, both protein nanoassemblies were found remain stable for a period of 3 
months at a pH of 7.4 and a temperature of 40C. 
45 
 
 
(A) (B)
(C)
 
Figure 4.2 Characterization of size and shape of snLYZ. (A) Field emission scanning 
electron microscopy (FESEM) of snLYZ. (B) AFM image of snLYZ (C) 
Hydrodynamic diameter of snLYZ obtained by DLS particle size analysis. The overall 
nanostructure size was found to 300 nm. 
 
Such a spherical shape offers the least resistance against the flow and achieves 
maximum penetration potential across cell membranes.The zeta potential of snLYZ 
and snBLA was found to be -39.1 mV and +40 mV respectively. 
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Figure 4.3 Characterization of size and shape of snBLA. (A) Field emission scanning 
electron microscopy (FESEM) of snBLA. (B) AFM image of snBLA (C) 
Hydrodynamic diameter of snBLA. The overall nanostructure size was found to be 
300 nm. 
 
Zeta potential usually measures the electrostatic potential at the surface of the particle. 
Normally ±30 mV suggests that the particles in suspension are highly stable and less 
susceptible to agglomeration. Hence, the snLYZ and snBLA particles are highly 
stable in suspension without forming aggregates or agglomerated particles. 
FTIR analysis clearly revealed the presence of amide I and amide II for nmBLA and 
nmLYZ respectively(see Fig. 4.4 A and B).  
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Figure 4.4 FTIR spectra analysis of Amide I and Amide II band between 1500cm-1 – 
1725 cm-1. (A) nmLYZ and snLYZ (B). nmBLA and snBLA. In both the protein 
nanostructures a peak shift in Amide I and II peaks was observed. 
 
From Fig. 4.4A, the amide I and amide II peaks and formation of a single peak at 
1605.92 cm-1 for snLYZ is due to the crosslinking of GTD. On the otherhand snBLA 
showed a clear change in both shape of spectra and peak position of amide I and 
amide II, which indicates a change in the secondary structure of the BLA in the 
conjugates (see Fig. 4.4 B). 
The native BLA shows the distinct peak for the amide I and amide II band, however, 
the amide I band shows a slight right shift in snBLA, indicating a structural 
change.Moreover, the amide I band in snBLA is split into two peaks at 1654.87 and 
1695.66 cm-1, which is also a clear indication of structural change due to the 
formation of the crosslink with GTD. The Amide II band in snBLA appears to be 
flattened and broad compared to native BLA, which may be due to interaction with 
GTD. 
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The characterization of the secondary structural state of snLYZ and snBLA was 
carried out using circular dichroism (CD) and fluorescence spectroscopy. The CD and 
Tryptophan (Trp) fluorescence spectroscopy were performed as per the protocol 
mentioned in Materials and Methods section. 
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Figure 4.5 Characterization of nmLYZ and snLYZ with respect to its conformational 
state. (A) Circular dichroism spectra of nmLYZ and snLYZ. (B) Trp fluorescence 
emission spectra of native lysozyme and snLYZ. All data were expressed as the mean 
of three readouts generated from the instrument. 
 
From the change in intensity of CD signal for secondary structural components such 
as α-helix and β-sheet we can estimate the extent of structural change in the protein 
nanostructures. The change in fluorescence intensity of tryptophan (Trp) is also an 
indicative of the structural change associated with the position of the Trp residues 
present in the protein nanostructures. 
We observed a huge drop in the CD signal of snLYZ compared to nmLYZ (see 
Fig.4.5 A). Such a change was inflicted upon snLYZ due to the structural change that 
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occurred while preparing the snLYZ nanoparticles. The percentage of secondary 
structural components were generated by the software associated with the CD 
spectrometer and recorded in Table 4.1. 
Table 4.1 Percentage of secondary structural components of the native protein and the 
protein self-assembly. 
Protein / Protein 
assembly 
α- helix content (%) β- sheet content (%) 
nmLYZ 16.9 20.4 
snLYZ 32.1 37.7 
nmBLA 22.9 21.2 
snBLA 25.5 28.5 
 
We observed a similar kind of drop in the CD signal of snBLA compared to nmBLA. 
Such a change was induced on snBLA due to the structural change that occurred 
while preparing the snBLA nanoparticles. The percentage of secondary structural 
components are shown in Table 4.1. 
The CD spectra of both snLYZ and snBLA showed a prominent change in the 
secondary structure (see Fig.4.4 A and Fig.4.5 A) as reflected from the percentage of 
secondary structural components (see Table 4.1).  
We observed an increase in the α- helix (16.9 - 32.1 %) and β-sheet content (20.4 - 
37.7 %) by almost two folds in the snLYZ nanostructure. However we observed a 
significant increase in the β-sheet content (21.2 - 28.5 %) of snBLA with minimal 
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change in the α- helix (22.9 – 25.5 %). Such, a change in the secondary structural 
components is bound to induce a change in Trp fluorescence intensity. We observed a 
clear drop in the Trp fluorescence intensity of snLYZ and snBLA (see Fig.4.5 B and 
Fig.4.6 B). 
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Figure 4.6 Characterization of snLYZ and snBLA with respect to its conformational 
state. (A) Circular dichroism spectra of native BLA and snBLA (B) Trp fluorescence 
emission spectra of nmBLA and snBLA. All data were expressed as the mean of three 
readouts generated from the instrument 
 
The drop in the Trp fluorescence intensity of snLYZ and snBLA was due to the 
translocation of the Trp residues present on the surface of the nanostructure to the 
more hydrophobic regions of the protein nanostructure. Since, the Trp fluorescence 
recorded is due to the Trp residues present on the surface of the protein , any 
alteration or shift in the location of Trp residues from periphery, to the more 
hydrophobic regions or the inner core of the protein is bound to reduce the overall Trp 
fluorescence. 
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4.2.2 Stability analysis 
Stability of the protein nanostructures was assessed by exposing the protein 
nanostructures to varying temperature, pH and protease mediated stress. Stability 
against increased temperature related stress is a major issue (Kaushik and Bhat, 1999). 
The thermal stability of proteins can be analyzed using CD spectroscopy (Sujak et al., 
2007). The stability of a protein structure under varying conditions of change in pH 
can also be studied using CD spectroscopy (Kwaambwa and Maikokera, 2008). Apart 
from analyzing the stability of protein nanostructures using CD spectroscopy, Trp 
fluorescence spectroscopy and ANS fluorescence spectroscopy also can be used for 
analyzing the stability of protein nanostructures(Kwaambwa and Maikokera, 2007; 
Yamamoto et al., 2006). 
4.2.2.1 Thermal stability of snLYZ and snBLA 
 
The thermal stability analysis of both snLYZ and snBLA across a temperature range 
of 20-800C was performed in a CD spectrometer. The temperature related stress may 
cause a change in the overall structure of the protein nanostructure. Hence, to study 
the secondary structural change in the protein nanostructure due to increased thermal 
stress, CD spectroscopy was performed. 
The CD signal remained stable for both snLYZ (Fig. 4.7A, B and C) and snBLA (Fig. 
4.8A, B and C) in a temperature range of 20-80 0C indicating increased stability 
compared to their native forms where we observed a clear variation in the CD signal 
indicating instability. The native proteins change their structure in response to thermal 
stress so that they can maintain their stability, however beyond a certain level of 
thermal stress the protein suddenly deviates from the natural CD signal as observed in 
nmLYZ (see Fig.4.7 A and C).The overall change in the CD signal at 222 nm is 
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shown in Fig.4.7 C. We have plotted the CD signal at 222 nm for comparison between 
nmLYZ and snLYZ since, it represents the signal from the α- helix region. Moreover, 
the region around the α- helix shows a visible change in signal intensity which can be 
extrapolated to obtain a line graph between Temperature and CD signal. 
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Figure 4.7 Thermal stability analysis of (A) native lysozyme (nmLYZ), (B) self-
assembled nanostructured lysozyme (snLYZ) by CD spectroscopy. (C) Comparison of 
the change in molar ellipticity of nmLYZ and snLYZ at 222nm (α-helix). All data 
were expressed as the mean of three readouts generated from the instrument. 
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The CD signal from nmLYZ showed maximum variation beyond 600C (Fig. 4.7A and 
C)  indicating structural changes in the native lysozyme. This wasbecause at higher 
temperatures the strength of the hydrogen bonds present in the protein decreases.  
The same reason may be ascribed to the constant variation in CD signal with an 
increase in temperature for nmBLA (Fig. 4.8A and C) indicating thermal 
instability.The CD signal from snBLA remains stable indicating the stability of 
snBLA.The CD signal measures the change in secondary structural components in a 
protein structure. A fairly consistent CD signal indicates that no significant structural 
change has occurred.  
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Figure 4.8 Thermal stability analysis of (A) native bovine α-lactalbumin (nmBLA), 
(B) self-assembled nanostructured bovine α-lactalbumin (snBLA) by CD 
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spectroscopy. (C) Comparison of the change in molar ellipticity of nmBLA and 
snBLA at 222nm (α-helix). All data were expressed as the mean of three readouts 
generated from the instrument. 
 
In order to assess the thermal stability of both snLYZ and snBLA, we also measured 
the Trp fluorescence at varying temperature conditions. We found that the drop in Trp 
fluorescence for snLYZ (Fig.4.9A, B and C)and snBLA(Fig.4.10A, B and C)were 
comparatively less compared to their native states.  
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Figure 4.9 Thermal stability analysis of (A) native lysozyme (nmLYZ), (B) self-
assembled nanostructured lysozyme (snLYZ) by Tryptophan (Trp) fluorescence 
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spectroscopy. (C) Comparison of the change in Trp fluorescence of nmLYZ and 
snLYZ. All data were expressed as the mean of three readouts generated from the 
instrument. 
The increased drop in fluorescence of the native proteins due to increase in 
temperature suggests that the Trp residues present on the surface moved from the 
surface of the protein to the core of the protein structure or the Trp residues moved to 
region surrounded by hydrophobic residues. 
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Figure 4.10 Thermal stability analysis of (A) native bovine α-lactalbumin (nmBLA), 
(B) self-assembled nanostructured bovine α-lactalbumin (snBLA) by Tryptophan 
(Trp) fluorescence spectroscopy. (C) Comparison of the change in Trp fluorescence of 
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nmBLA and snBLA. All data were expressed as the mean of three readouts generated 
from the instrument. 
 
Since, the Trp residues directly contribute to the Trp fluorescence, any decrease in the 
number of Trp residues on the surface of the of the protein would cause a reduction in 
the overall fluorescence intensity. Such a change in Trp fluorescence is also an 
indicative of structural change and the environment around the Trp residues present 
on the surface of the protein.  
ANS is a surface hydrophobicity marker for proteins and usually used for the indirect 
measurement of the surface hydrophobicity on the surface of the protein. The increase 
in protein-bound ANS fluorescence is an indicator of an increase in surface 
hydrophobicity of the protein. The protein bound ANS fluorescence for nmLYZ 
showed that with an increase in temperature the surface hydrophobicity of native 
protein increased indicating an increase in surface hydrophobicity (see Fig 4.11A and 
C).  
snLYZ demonstrated no change in ANS fluorescence intensity till 600C, however a 
slight increase in ANS fluorescence intensity indicating a slight increase in surface 
hydrophobicity was observed at 70 and 800C (see Fig 4.11 B and C).  
The results indicate that with the increase in temperature structural changes occurred 
on the surface, of the native protein. Such a change on the surface of the protein may 
be due to the weakening of the hydrogen bonds present in the protein. The increase in 
surface hydrophobicity is also a protective mechanism that protects the protein against 
thermal stress (Gromiha et al., 2013). 
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Figure 4.11 Thermal stability analysis of (A) native Lysozyme (nmLYZ), (B) self-
assembled nanostructured lysozyme (snLYZ) by ANS fluorescence spectroscopy and 
(C) Comparison of the change in ANS fluorescence of nmLYZ and snLYZ. All data 
were expressed as the mean of three readouts generated from the instrument. 
 
The protein bound ANS fluorescence for nmBLA and snBLA also showed that with 
increase in temperature the surface hydrophobicity of native protein decreased 
indicating instability whereas the surface hydrophobicity of snBLA increased slightly 
indicating more stability (Fig.4.12 A, B and C). 
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Since, ANS binds with the hydrophobic residues present on the surface of the protein, 
the increase in the intensity of the ANS bound fluorescence is an indirect measure of 
the surface hydrophobicity of the protein. 
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Figure 4.12 Thermal stability analysis of (A) native bovine α-lactalbumin (nmBLA), 
(B) self-assembled nanostructured bovine α-lactalbumin (snBLA) by ANS 
fluorescence spectroscopy. (C) Comparison of the change in ANS fluorescence of 
nmBLA and snBLA. All data were expressed as the mean of three readouts generated 
from the instrument. 
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The reason for such a change on the surface of the protein may be due to the 
weakening of the hydrogen bonds present in the protein. Moreover, the increase in 
surface hydrophobicity is also a protective mechanism that protects the protein against 
thermal stress. 
4.2.2.2 Stability of snLYZ and snBLA against varying pH 
snLYZ and snBLAwereincubated in buffers at various pH ranging from pH 3-8 for 
nmLYZ and pH 5-10 for snBLA respectively. The CD spectra were recorded along 
with the Trp fluorescence and ANS fluorescence for snLYZ and snBLA. 
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Figure 4.13 pH stability analysis of (A) native lysozyme (nmLYZ), (B) self-
assembled nanostructured lysozyme (snLYZ) by Circular dichroism (CD) 
spectroscopy. (C) Comparison of the change in the structure of nmBLA and snBLA 
60 
 
by measuring the CD signal at 222 nm. All data were expressed as the mean of three 
readouts generated from the instrument. 
 
The results show that the CD signal of snLYZ was fairly constant compared to 
nmLYZ where the CD signal was found to change rapidly (see Fig.4.13A, B and 
C).The CD results of snBLA show that the signal was relatively constant compared to 
nmBLA where the CD signal was found to change rapidly (see Fig.4.14A, B and C). 
The reason for such instability in nmLYZ and nmBLA may be due to the alteration in 
the electrostatic interactions between charged aminoacids present in the protein. Such 
interactions lead to the denaturation of nmLYZ and nmBLA. 
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Figure 4.14 pH stability analysis of (A) native bovine α-lactalbumin (nmBLA), (B) 
self-assembled nanostructured bovine α-lactalbumin (snBLA) by CD spectroscopy. 
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(C) Comparison of the change in the structure of protein nanostructures by CD 
spectroscopy @ 222 nm. All data were expressed as the mean of three readouts 
generated from the instrument. 
 
However, the CD signal remained constant for snLYZ and snBLA with varying pH 
because of no change in the ionization state of the charged amino acids, that cause 
spectral differences (Kwaambwa and Maikokera, 2008).  
We also measured the Trp fluorescence of snLYZ and snBLA under varying pH 
conditions from pH 3 to 7.4. 
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Figure 4.15 pH stability analysis of (A) native lysozyme (nmLYZ), (B) self-
assembled nanostructured lysozyme (snLYZ) by Trp fluorescence spectroscopy. (C) 
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Comparison of the change in protein bound Trp fluorescence of nmBLA and snBLA. 
All data were expressed as the mean of three readouts generated from the instrument. 
 
The Trp fluorescence of nmLYZ showed variation with an increase in pH whereas the 
Trp fluorescence from snLYZ remained fairly constant. The results indicated that 
snLYZ resisted the pH induced structural change whereas nmLYZ underwent 
frequent structural changes as evidenced from the variation in Trp fluorescence 
intensity (Fig.4.15A, B andC). 
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Figure 4.16 pH stability analysis of (A) native bovine α-lactalbumin (nmBLA), (B) 
self-assembled nanostructured bovine α-lactalbumin (snBLA) by Trp fluorescence 
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spectroscopy. (C) Comparison of the change in protein bound Trp fluorescence of 
nmBLA and snBLA. All data were expressed as the mean of three readouts generated 
from the instrument. 
 
Similarly, snBLA was found to be more stable compared to the nmBLA when 
exposed to varying pH environments as evidenced from the Trp fluorescence intensity 
(Fig.4.16 A, B and C).The Trp fluorescence intensity of nmBLA showed the variable 
intensity with increase in pH,however, the Trp fluorescence intensity of snBLA had 
subtle variations but was observedrelatively constant (Fig. 4.16 C). 
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Figure 4.17 pH stability analysis of (A) native lysozyme (nmLYZ), (B) self-
assembled nanostructured lysozyme (snLYZ) by ANS fluorescence spectroscopy. (C) 
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Comparison of the change in protein bound ANS fluorescence of nmLYZ and snLYZ. 
All data were expressed as the mean of three readouts generated from the instrument. 
 
Such a change in nmBLA was due to the change in the ionization state of the charged 
amino acids, which cause spectral differences, (Kwaambwa and Maikokera, 2008). 
We also observed the protein bound ANS fluorescence of snLYZ and snBLA with an 
increase in the environment pH. So that we can obtain the information about the 
surface characteristics of the protein nanostructures.  
The protein bound ANS fluorescence of snLYZ decreased rapidly with increase in pH 
whereas the ANS fluorescence of nmLYZ remained fairly constant.  
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Figure 4.18 pH stability analysis of (A) native bovine α-lactalbumin (nmBLA), (B) 
self-assembled nanostructured bovine α-lactalbumin (snBLA) by ANS fluorescence 
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spectroscopy. (C) Comparison of the change in protein bound ANS fluorescence of 
nmBLA and snBLA. All data were expressed as the mean of three readouts generated 
from the instrument. 
 
These results indicated that nmLYZ resisted the pH induced change in surface 
hydrophobicity whereas snLYZ underwent rapid decrease in surface hydrophobicity 
as evidenced from the drop in ANS fluorescence intensity with increase in pH 
(Fig.4.17 A, B and C). 
The results obtained for snBLA were quite different from the results of snLYZ. The 
protein bound ANS fluorescence for snBLA and native BLA clearly show that the 
surface hydrophobicity of native BLA decreased rapidly with increase in pH (see Fig. 
4.18 A,B and C) indicating instability,whereas snBLA showed no change in its 
snBLA bound ANS fluorescence intensity indicating incresed stability. 
The results clearly indicate that the surface hydrophobic character of snLYZ 
decreases rapidly and for snBLA remains intact with increase in pH.  
Proteinase K (PK) assay was performed to observe the stability of the protein 
nanostructures in the presence of PK. Proteinase K solution is stable over a 
broad range of pH (4.0-12.5) with an optimum pH of 8.0 (Burrell, 1993). Proteinase 
K is a nonspecific serine protease that preferentially digests proteins after 
hydrophobic amino acids (Brar et al., 2013). For globular proteins, the hydrophobic 
residues reside inside the core of the structure while the polar residues reside on the 
surface of the protein. Upon unfolding under stress, the proteins go into non-native 
state with substantial hydrophobic residues exposed to the solvents which make 
Proteinsae K easy to digest the protein. PK normally digests non-native proteins very 
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fast but not the native one, however the high amount of PK can also attack native 
structure as well.  
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Figure 4.19 UV-Vis spectroscopic measurement of nmBLA and snBLA before and 
after treatment with 3 μM Proteinase K (PK). The protein nanostructures resist 
Proteinase K related stress. All data were expressed as the mean of three readouts 
generated from the instrument. 
 
In this case, nmLYZ and BLA were native but snLYZ and snBLA was partially 
denatured as well as partly unfolded but self-assembled by crosslinking with 0.1% 
GTD. After PK digestion, spectroscopic measurement of snLYZ and snBLA showed 
almost no change in the peak of spectra indicating increased stability against PK 
digestion compared to nmLYZ (Fig. 4.19A and  B). Necessary baseline correction 
was done in order to compare the plots. 
The above result also indicates a possibility that both in snLYZ and snBLA, the 
digestion sites were perhaps not well accessible to PK due to the self-assembly 
process of nmLYZ and nmBLA. Moreover, such stability both against pH and PK 
might be due to higher contents of β-sheet (37.7%) in snLYZ (see Table 1) than 
nmLYZ. All of the above results collectively led to the conclusion that snLYZ might 
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be considered to be structurally, functionally and biologically stable, which satisfies 
one of essential requirements for a drug. 
The activity assay of LYZ was performed to observe the lysozyme activity of snLYZ. 
The lytic activity of LYZ in snLYZ with varying pH, was presented in the Fig.4.20 
which revealed a very minimal change in the lytic activity of snLYZ in a range of pH 
from 5.0 to 9.0. The loss in the LYZ activity of snLYZ may be due to the structural 
change that occurred ofLYZ molecule in snLYZ compared to nmLYZ.  
However, some basal lysozyme activity was still present in snLYZ which did not 
change significantly with anthe increase in pH. In contrary the nmLYZ demonstrated 
maximum activity at pH 5, followed by a rapid decrease in its activity till pH 9. 
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Figure 4.20 Plot of the biological activity of LYZ in nmLYZ and snLYZ at various 
pH (5-9) by Micrococcus lysodekticus assay. The protein nanostructure snLYZ retains 
its activity. All data are expressed as Mean ± S.E.M, n = 3. 
 
However, nmLYZ showed a drastic drop in activity towards higher pH starting from 
pH 5.0, with a maximum drop at pH 9.0. 
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The thermal stability of a protein is also positively correlated with its higher surface 
hydrophobic character. Hence, measuring the surface hydrophobicity of snLYZ and 
snBLA can throw light on the stabilizing effect. ANS is an anionic, aliphatic 
fluorescence dye that spontaneously interacts with non-polar surface residues of a 
protein and exhibit strong fluorescence.  
Hence, measuring the ANS bound fluorescence will provide information about the 
surface hydrophobicity of snLYZ and snBLA.  
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Figure 4.21 Surface hydrophobicity assessment of protein nanostructures using ANS 
Fluorescence spectra. (A) snLYZ and (B) snBLA. Surface hydrophobicity of snLYZ 
was found to increase whereas snBLA was found decreased. All data are expressedas 
a mean of three readouts generated from the instrument. 
 
From our results (Fig.4.21 A), it was clear that our prepared snLYZ demonstrated 
higher hydrophobic surface (as reflected by a higher amount of snLYZ bound ANS 
fluorescence) than nmLYZ-bound fluorescence. Hence, we concluded that more non-
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polar residues were relocated on the surface of snLYZ that also support our previous 
data obtained from Trp fluorescence spectroscopy (Fig. 4.5 B).  
However, snBLA demonstrated decreased surface hydrophobicity (see Fig.4.21 B) as 
evidenced from the decrease in the snBLA bound ANS fluorescence intensity.The 
results of the Trp (see Fig. 4.5B) and ANS bound fluorescence emission (see 
Fig.4.21B)  clearly indicates that the self assembly related structural change resulted 
in the movement of the Trp as well as the hydrophobic residues towards the core of 
the protein structure. 
4.2.2.3 Thioflavin T (ThT) assay 
Thioflavin T assay was used for the detection of amyloids in various protein 
nanoassemblies. ThT upon binding with the amyloid fibrils causes a peak-shift from 
450 to 490 nm. ThT (20µM) bound protein fluorescence was recorded to monitor the 
presence of amyloid fibrils in snLYZ and snBLA. However, since snLYZ and 
snBLAare protein nanoassemblies, there could be a chance that such cytotoxicity 
might be due to the toxicity associated with the amyloid formation in cells.  
However, in CD results, we have observed that snLYZ contains 37.7% β-sheet that is 
considered to be quite high compared to nmLYZ. Juarez et al recently demonstrated 
in HSA (human serum albumin) protein that progressive increase of β-sheet content 
up to 26% was required for fibrillar amyloid formation (Juarez et al., 2009). 
Therefore, there was a necessity to monitor the formation of fibril structure like 
amyloid formation both in snLYZ and snBLA. 
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Figure 4.22 Thioflavin T assay for the assessment of the presence of amyloid in the 
protein nanostructures (A) snLYZ and (B) snBLA. The presence of amyloid produces 
a very intense peak at 490 nm. All data are expressed as a mean of three readouts 
generated from the instrument. 
 
Here we observed that both in snLYZ and snBLA a very intense peak at 490 nm was 
not observed clearly indicating the absence of any amyloid content (see Fig.4.22). 
Hence, we concluded that the cellular toxicity of snLYZ was produced by other 
mechanisms such as ROS generation (snLYZ) with no contribution from amyloid 
toxicity. 
However, in our study, we observed that while the surface hydrophobicity of snLYZ 
was increased substantially, for snBLA, it was reduced significantly Increase in 
surface hydrophobicity of nano-assemblies can also facilitate the loading of 
hydrophobic drugs on the surface of protein nano-assemblies and functionalized 
nanoparticles having hydrophobic character.  
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Chapter 5 
Protein Nanoassembly mediated cytotoxicity, mechanisms 
and targeting of cancer cells. 
5.1 Materials and Methods 
 
5.1.1 Materials 
N-acetylcysteine (NAC), Glutaraldehyde (GTD) (25%), Tamoxifen citrate (TAM), N-
hydroxysuccinimide (NHS), Bicinchoninic assay kit, Oleic acid and Whatman filter 
paper were purchased from Sigma-Aldrich, India. Lysozyme, Bovine α-lactalbumin, 
Folic acid (FA), MTT assay kit, Ethanol, DMEM, Fetal bovine serum (FBS), 
antibiotics, DAPI, acridine orange, Fluorescein diacetate, Nitrocellulose membrane 
from HiMedia India Pvt. Ltd. Milli-Q water was used in all the experiments. T-25 
flasks, 96 well plates and all other plasticwares were purchased from Tarsons Pvt. 
Ltd. 
Both primary and secondary antibodies of Hsp 90, Caspase 3 and β-actin were 
obtained from Abcam. 3T3 (murine fibroblast cell line), HaCaT (human keratinocyte 
cell line), A549 (human lung adenocarcinoma epithelial cell line) MDAMB-231 and 
MCF-7 (Breast cancer cell line) cells were procured from NCCS, Pune, India.  
Caspase 3 inhibitor (218750) and Triton-X was purchased from Calbiochem, India. 
Human blood (B +ve) was freshly obtained from the donor before the experiments. 
All the glasswares used in the study were purchased from Borosil, India. All other 
reagents were of analytical grade. 
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5.1.2 Methods 
 
5.1.2.1 Preparation and Characterization of BAMLET (Bovine α-lactalbumin 
made lethal to tumor cells) 
BAMLET was prepared using a protocol described by Kamijima et al. (Kamijima et 
al., 2008). A mixture of protein and fatty acid (1:120 molar equivalents) was 
dissolved in 5 ml of PBS (pH 7.4) and incubated at 50 °C. After incubation for 10 
min, the mixture was cooled down to room temperature and excess oleic acid was 
carefully removed by centrifugation. BAMLET. The characterization of BAMLET 
was carried out using CD spectroscopy as per the protocol mentioned in Chapter 4 
“Materials and Methods Section”.  
5.1.2.2 Cell viability assay  
The cytotoxicity study of snLYZ was evaluated in MCF-7 Breast cancer cells and 
snBLA was examined in four different cell lines; Breast cancer (MCF-7 and 
MDAMB-231), cervical cancer (HeLa ) and lung carcinoma cells (A549) using MTT 
[3-(4, 5-Dimethylthiazol – 2 - yl) - 2, 5 - Diphenyltetrazolium Bromide] assay at 
various concentrations (16.66 - 333.33 µg/ml). 
 Normal cells such as HaCaT (Human keratinocyte cell line) and 3T3 (murine 
fibroblast cells) were used as a control and treated with similar concentrations of 
snBLA and snLYZ. All the cells were cultured in DMEM (Dulbecco’s Minimum 
Essential Medium) containing 10% fetal bovine serum and 0.1 mg/ml penicillin and 
streptomycin.  
Cells were cultured in T-25 flasks and were incubated at 370C in a humidified CO2 
incubator. All the cells were cultured till 80% confluence and the cells were 
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trypsinized followed by seeding at a density of 1x104 cells/ml. The cells were seeded 
in a 96 well plate containing 300 µl of DMEM in each well, and the cells were 
allowed to proliferate for 24 h. snBLA and snLYZwere administered to the cells, and 
the end point effect was monitored by MTT assay at the end of next 24 h. MTT (10 µl 
of 5 mg/ml stock) was added 6 h before the end point. In the end, media was removed, 
and 100 µl of DMSO was added to dissolve the formazan formed and the absorbance 
was measured at 595 nm. The absorbance values were recorded, and percentage cell 
viability was calculated from the absorbance values and the result was plotted.  
5.1.2.3 Folate conjugation for targeting cancer cells 
The presence of folic acid receptor (FR) in cancer cells can be exploited for targeting 
snLYZ/snBLA against cancer cells (Gaspar et al., 2015; Lu et al., 2014). MCF-7 and 
MDAMB-231 are cell lines that express Folic acid (FA) receptors on its surface. We 
prepared activated folic acid (FAa) preparing N-hydroxysuccinimide ester of folate 
i.e. NHS folate was already reported (Leamon and Low, 1991). 
Hence, we conjugated snLYZ and snBLA with FAa using 0.1% glutaraldehyde as a 
cross-linker leading to the formation of snLYZ/snBLA-folic acid conjugate 
(snLYZ/snBLA-FAa). For the preparation of snLYZ/snBLA-FA conjugate, the 
protocol reported by Li et al. was followed (Li et al., 2011).  
To evaluate the uptake effect of snLYZ/snBLA in cells that do not express FR, we 
used A549 cells as control. Various concentrations (13.33-333.33 µg/ml) of snBLA-
FAa conjugate were administered to both MDAMB-231 cells and A549 cells, and 0-
200µg/ml of snLYZ-FAa was administered to MCF-7 cells and A549 cells. MTT 
assay was performed as per the protocol mentioned in section 5.1.1. 
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5.1.2.4 Cellular Uptake of snBLA/snLYZ in MCF-7 cells 
We performed the fluorescence imaging of MCF-7 cancer cells using fluorescence 
and confocal laser scanning microscope. Fluorescent dyes such as DAPI was used to 
stain the nucleus, and acridine orange was used to observe the cellular uptake of 
snBLA. snLYZ/snBLA - acridine orange conjugate were prepared by crosslinking the 
protein nanostructures with acridine orange using 0.1% glutaraldehyde. The cells 
were exposed to snLYZ/snBLA - acridine orange conjugate for 12 h. At the end of 12 
h, we observed the presence of snLYZ/snBLA particles exhibiting orange 
fluorescence inside the cytoplasm of MCF-7 Breast cancer cells.  
5.1.2.5 Reactive oxygen species (ROS) mediated cell death 
To ascertain ROS generation for snBLA-mediated cancer cell death, we applied 
333.33 µg/ml of snBLA in both MCF-7 and MDAMB-231 cells and kept a 
corresponding group pre-treated with 2 mM N-acetylcysteine (NAC), a ROS 
inhibitor. Similarly, for ROS generation from snLYZ we treated MCF-7 cells with 60-
200µg/ml of the same in the presence and absence of NAC. MTT assay was 
performed as per the protocol mentioned in section 5.1.1 
5.1.2.6 Role of Caspase 3 mediated apoptotic cell death 
To find the role of apoptosis in cancer cell death mediated by snBLA, cell viability 
assay of MDAMB-231 cells was performed in the presence of 100 µg/ml gallic acid 
(GA) and Caspase-3 inhibitor. GA induces apoptosis in various cells mediated by 
caspase-3. We also evaluated the Caspase-3 expression to support our cell viability 
results. Further, we also performed the same experiment with BAMLET for 
comparison. We treated MDAMB-231 cancer cells with native BLA, snBLA and 
BAMLET for 12 h.  
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After treatment, cells were collected and lysed in lysis buffer in the presence of 
protease inhibitor cocktail. The supernatant was obtained after centrifugation at 
12,500 g for 10 min at 4°C. The concentration of protein in the supernatants was 
measured by the bicinchoninic acid (BCA) assay. Then equal amounts of protein (60 
μg) were separated by 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred to the nitrocellulose membrane 
(Millipore, Billerica, MA). The blots were incubated with respective primary 
antibodies overnight at 4°C followed by incubation with the secondary antibody for 4 
h at 37°C. Chemiluminescent detection was performed by the chemiluminescent 
documentation system (MF-Chemibis 2.0; DNR Bioimaging, Israel).  
5.1.2.7 Hemocompatibility assay 
To perform the haemocompatibility assay, 5 ml of B+ve human blood was collected by 
an expert Medical practitioner in heparinized centrifuge tubes. The contents were 
gently resuspended and centrifuged at 1000 g for 10 min. The supernatant was 
removed and the erythrocyte collected at the bottom was washed three times by gentle 
suspension with 10 times the volume of pyrogen-free saline (0.9% NaCl).  
 
The erythrocyte pellet was gently resuspended in normal saline and diluted to 0.8% 
(v/v). The solution was placed in a sterile centrifuge tube, and various test samples 
were administered to evaluate their hemolytic potential. Triton-X (1%) was used as a 
positive control and erythrocyte suspension treated with none was used as a negative 
control. The absorbance of the hemoglobin released was measured at 405 nm. The 
percentage hemolysiswas calculated at 1h, and the graph was plotted between percent 
hemolysis and time (h). 
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5.2 Results and Discussion 
 
5.2.1 Preparation and Characterization of BAMLET 
BAMLET was prepared as per the protocol mentioned in the “Materials and Methods 
section”. BAMLET is a formulation comprising of bovine α-lactalbumin and oleic 
acid. The synthesized BAMLET was characterized by CD spectroscopy and the 
spectra was similar to earlier reported results by Kamijima et al. (Kamijima et al., 
2008) (see supplementary figure S8).  
5.2.2 Cytotoxicity study of snLYZ and snBLA 
The cytotoxicity assay of snLYZ and snBLA was performed in human breast cancer 
cells MCF-7 and MDAMB-231 cells. Results showed that the administration of 
nmLYZ and nmBLA caused very little effect on cancer cell killing compared to 
control (administered with none) till a dose of 200 and 333.33µg/ml respectively (Fig. 
5.1A and B). However, snLYZ and snBLA demonstrated a dose-dependent cell 
killing with more than 90 % and 80.86 % cell death at 200 µg/ml and 333.33 µg/ml 
respectively after 24 h administration in MCF-7 cells (Fig. 5.1A and B).  
3 10 30 60 100 200
0
10
20
30
40
50
60
70
80
90
100
110
           [µg/ml]
nmlyz
snlyz
***
***
***
***
MCF-7 (24 h)
IC50 = 31.45µg/ml
(A)
%
 C
e
ll
 v
ia
b
il
it
y
 
77 
 
0
10
20
30
40
50
60
70
80
90
100
110
16.66 33.33
[ µg/ml]
133.33 266.6666.66 333.33
MCF-7 (24 h)
Control
nmBLA
snBLA
IC50 = 88.21 µg/ml
(B)
%
 C
e
ll
 v
ia
b
il
it
y
 
Figure 5.1  Dose-dependent cytotoxic effect of (A) snLYZ and (B) snBLA on the 
MCF-7 cell viability at the end of 24 h. Statistically significant vs control group, *** 
p < 0.001 by One way ANOVA and post Tukey test. All data are expressed as Mean ± 
S.E.M, n = 3. 
 
The IC50 values for snLYZ and snBLA were calculated to be 31.45 and 88.21µg/ml 
respectively at 24 h post administration. Similarly, snLYZ and snBLA demonstrated a 
dose-dependent cell killing with more than 95.34 % and 95.04 % cell death at 100 
µg/ml and 333.33 µg/ml respectively at 48 h post administration (Fig.5.2 A and B).  
snLYZ demonstrated strong anti-proliferative activity among both the protein 
nanoassembly with the maximum cytotoxicity observed at 100 µg/ml compared to 
333.33µg/ml for snBLA. The IC50 values for snLYZ and snBLA were 12.90 and 
51.65 µg/ml respectively at 48 h post administration. Administration of various lower 
doses of snBLA ranging from 16.66 to 133.33 µg/ml did not exhibit any toxicity to 
MCF-7 cells (see Fig.5.2B). 
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Figure 5.2  Dose-dependent cytotoxic effect of (A) snLYZ and (B) snBLA on the 
MCF-7 cell viability at the end of 48 h. Statistically significant vs control group, *** 
p < 0.001 by One way ANOVA and post Tukey test. All data are expressed as Mean ± 
S.E.M, n = 3. 
 
We wanted to validate our results of snLYZ and snBLA in other breast cancer cell 
line such as MDAMB-231. Hence, we performed the cytotoxicity study of snLYZ and 
snBLA in MDAMB-231 cells. 
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Figure 5.3  Dose-dependent cytotoxic effect of (A) snLYZ and (B) snBLA on the 
MDAMB-231 cell viability at the end of 24 h. Statistically significant vs control 
group, *** p < 0.001 by One way ANOVA and post Tukey test. All data are 
expressed as Mean ± S.E.M, n = 3. 
 
From the Fig.5.3A and B we observed that snLYZ and snBLA demonstrated a dose-
dependent cell killing with more than 84.35 % and 87.56 % cell death at 200 µg/ml 
and 333.33 µg/ml respectively at 24 h post administration. snLYZ demonstrated very 
similar levels of anti-proliferative activity at a much lower dose of 200µg/ml 
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maximum compared 333.33µg/ml for snBLA. The IC50 values for snLYZ and snBLA 
were 43.78 and 71.55 µg/ml respectively at 24 h post administration. 
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Figure 5.4  Dose-dependent cytotoxic effect of (A) snLYZ and (B) snBLA on the 
MDAMB-231 cell viability at the end of 48 h. Statistically significant vs control 
group, *** p < 0.001 by One way ANOVA and post Tukey test. All data are 
expressed as Mean ± S.E.M, n = 3. 
 
We also observed the cytotoxic effect of snLYZ and snBLA at 48 h post 
administration in MDAMB-231 cells. The results showed that both the protein 
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nanoassemblies demonstrated exactly similar levels of cytotoxicity at 48 h post 
administration in MDAMB-231 cells (Fig.5.4A and B).  
The IC50 values for snLYZ and snBLA were 31.18 and 43.78 µg/ml respectively at 48 
h post administration. Interestingly, the IC50 values of both snLYZ and snBLA were 
very less in MCF-7 cells compared to MDAMB-231 cells, which clearly indicates that 
snLYZ and snBLA are more potent in MCF-7 cells compared to MDAMB-231 cells, 
although both snLYZ and snBLA are toxic against MCF-7 and MDAMB-231 cells. 
Tamoxifen (TAM), a chemotherapeutic agent is commonly used in breast cancer, was 
also used here as a positive control for comparison.  
From the above cell viability assays of snLYZ and snBLA in MCF-7 cells, we made a 
comparison between their IC50 values (see Fig.5.5). snLYZ demonstrated lower IC50 
values compared to snBLA, indicating higher cytotoxic potential than snBLA at 24 
and 48h. 
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Figure 5.5 Comparison of the IC50 values of snLYZ and snBLA on MCF-7 cells at 
the end of 24 and 48 h. 
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To test whether the cytotoxicity of the protein nanoassembly was specific to cancer 
cells, we performed cytotoxicity study against mouse fibroblast cells 3T3 (see Fig. 
5.6A and B) and human keratinocyte cells HaCaT cells (see Fig.5.7A and B).  
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Figure 5.6 Cell viability assay of protein nanoassembly in 3T3 (mouse fibroblast 
cells) cells (A) snLYZ and (B) snBLA. snLYZ and snBLA did not have any cytotoxic 
effect in normal cells. All data are expressed as Mean ± S.E.M, n = 3. 
 
All the doses of snLYZ and snBLA administered to 3T3 and HaCaT cells showed no 
signs of toxicity. This clearly indicates that snLYZ and snBLA have high 
cytocompatibility with normal cells. 
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Figure 5.7 Cell viability assay of protein nanoassembly in HaCaT (human 
keratinocyte) cells (A) snLYZ and (B) snBLA. snLYZ and snBLA did not have any 
cytotoxic effect in normal cells. All data are expressed as Mean ± S.E.M, n = 3. 
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Indeed, due to their proteinaceous composition both snLYZ and snBLA were least 
expected to induce any toxic effects in normal cells such as HaCaT and 3T3. 
The cytotoxicity of TAM was evaluated in MCF-7 cells at different concentration 
(Fig.5.8). The IC50 of TAM was found to be 6.66 µg/ml.  
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Figure 5.8 Dose-dependent cytotoxic effect of Tamoxifen citrate on the MCF-7 cell 
viability at the end of 24 h. Statistically significant vs control group, *** p < 0.001 by 
One way ANOVA and post Tukey test. All data are expressed as Mean ± S.E.M, n = 
3. 
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A comparison of the IC50 values of snLYZ, snBLA and TAM were presented in Table 
5.1. 
Table 5.1 Comparison of IC50 values of snLYZ, snBLA and TAM in MCF-7 cells. 
Agent IC50 (µg/ml) at 24 h IC50 (µg/ml) at 48 h 
TAM 6.66  
snLYZ 31.45 12.90 
snBLA 88.21 51.65 
 
IC50 values indicates the dose at which 50% of the cells are killed and is a measure of 
potency of the substance administered compared to other known drugs. Hence, using 
IC50 values we can easily make a comparison of potency between the protein 
nanoassembly and TAM. We clearly observed that among the two protein 
nanoassembly snLYZ showed a better IC50 value compared to snBLA at both 24 and 
48 h. This indicates that snLYZ at much lower doses inflicted the same amount of 
cytotoxicity compared to snBLA. Hence, among the two protein nanoassembly 
snLYZ was proved to be more potent compared to snBLA. In order to observe 
whether the cytotoxicity caused by snLYZ and snBLA is specific to their specific 
structure, we had prepared a self assembly of bovine serum albumin (snBSA) (see the 
supplementary figure S12) using the same protocol and observed its effect on the cell 
viability of 3T3 and MCF-7 cells (see the supplementary figure S13). We observed 
from supplementary figure S13 that no toxicity was demonstrated by snBSA. The IC50 
value of TAM was found to be the best among all with an IC50 value of 6.66 µg/ml at 
24 h post administration. Such low IC50 values indicate that Tamoxifen is more potent 
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than both snLYZ and snBLA. However, the side effect of TAM has been a great 
concern and we would study the same in further section. 
5.2.3 Folate conjugation for targeting cancer cells 
In order to increase the specificity of snLYZ for cancer cells expressing folate 
receptors (FR), we prepared conjugate of snLYZ with activated folic acid (NHS-FAa) 
and observed its cytotoxic effect in MCF-7cells. 
We observed an dose-dependent increase in cytotoxicity of snLYZ after conjugation 
with activated folic acid. The snLYZ-FAa conjugate showed dose-dependent increase 
in cytotoxicity compared to snLYZ alone at 24 (see Fig. 5.9) and 48 h post 
administration (see Fig.5.10). snLYZ-FAa inflicted 93.67 % cell death in MCF-7 cells 
compared to 78.28 % cell death induced by snLYZ alone at a dose of 100 µg/ml. 
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Figure 5.9 Cell viability assay of snLYZ-FAa in MCF-7 cells at 24 h post 
administration. Folic acid conjugation enhances cytotoxicity in MCF-7 cells.  
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Statistically significant vs control group, *** p < 0.001 by One way ANOVA and 
post Tukey test. All data are expressed as Mean ± S.E.M, n = 3. 
 
The result clearly indicates that conjugationof snLYZ with FAa improved the 
cytotoxicity of snLYZ significantly. 
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Figure 5.10 Cell viability assay of snLYZ-FAa in MCF-7 cells at 48 h post 
administration. Folic acid conjugation enhances cytotoxicity in MCF-7 cells. 
Statistically significant vs control group, *** p < 0.001 by One way ANOVA and 
post Tukey test. All data are expressed as Mean ± S.E.M, n = 3. 
 
The result was also confirmed from the IC50 values obtained for snLYZ-FAa at 24 and 
48 h respectively. The IC50 value of 15.71 and 7.76 µg/ml for snLYZ-FAa at 24 and 
48 h was found to be less than that of snLYZ (see Table 5.1) at similar time points.  
This clearly indicates that snLYZ-FAa is more potent than snLYZ alone indicating 
that the association of folic acid increased the cytotoxicity probably through the folate 
receptors (FR) present on the surface of MCF-7 cancer cells. The increased uptake 
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resulted in the increase in cytotoxicity of snLYZ-FA against MCF-7 cells. We 
anticipated that the increase in cytotoxicity might be due the presence of FR receptors 
present on the MCF-7 cell surface. The receptors facilitated the internalization of 
snLYZ-FAa by receptor-mediated endocytosis.  
In order to observe the effect of snLYZ-FAa on cells that do not express folic acid 
receptors, we performed cell viability studies in A549 cells. When we  administered 
snLYZ-FAa in A549 cells and observed its effect at the end of 24 h we found reduced 
cytotoxicity of snLYZ-FAa in A549 cells (see Fig.5.11) compared to MCF-7 cells 
(see Figure 5.2.A). The result clearly indicates that folic acid expressing cancer cells 
are more susceptible to the cytotoxicity of snLYZ-FAa, compared to cancer cells that 
do not express folate receptors. 
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Figure 5.11 Cell viability assay of snLYZ and snLYZ-FAa in A549 cells measured 
by MTT assay. Folic acid conjugation did not affect the cytotoxicity in A549 cells. 
Statistically significant vs control group, *** p < 0.001 by One way ANOVA and 
post Tukey test. All data are expressed as Mean ± S.E.M, n =3. 
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In a similar way we also conjugated snBLA with activated folic acid and observed its 
effect on FR + ve MDAMB-231 cells.  
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Figure 5.12 Cell viability assay of snBLA-FAa in MDAMB-231 cells at 24 h post 
administration. Folic acid conjugation enhances cytotoxicity in MDAMB-231cells. 
Statistically significant vs control group, *** p < 0.001 by One way ANOVA and 
post Tukey test. All data are expressed as Mean ± S.E.M, n = 3. 
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Figure 5.13 Cell viability assay of snBLA-FAa in MDAMB-231 cells at 48 h post 
administration. Statistically significant vs control group, *** p < 0.001 by One way 
ANOVA and post Tukey test. All data are expressed as Mean ± S.E.M, n = 3. 
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We observed an increase in cytotoxicity of snBLA upon conjugation with folic acid. 
The snBLA-FAa conjugate showed increased cytotoxicity at 24 (see Fig.5.12) and 
48h (see Fig.5.13) post administration in MDAMB-231 cells compared to snBLA 
alone (Fig. 5.2 B). 
This clearly indicated that the conjugation of folic acid with snBLA improved the 
cytotoxicity of snBLA significantly. The result was also confirmed from the fact that 
the IC50 values of snBLA-FAa were lower than snBLA alone at 24 and 48 h, 
respectively. The IC50 value of snBLA-FAa at 24 and 48 h were 42.04 and 26.96 
µg/ml respectively, which was lower than that of snBLA at similar time points (see 
Table 5.1). In order to increase the specificity of snBLA for cancer cells expressing 
folate receptors (FR), we prepared conjugate of snBLA and activated folic acid (FAa) 
and observed its ytotoxic effect in MDAMB-231 (FR + ve) and A549 (FR - ve) cells. 
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Figure 5.14 Cell viability assay of FAa-conjugated snBLA (A) MDAMB-231 cells 
and A549 cells. (B) Inset shows the percentage of cell viability of A549 and 
MDAMB-231 cells treated with snBLA and snBLA-FAa at a dose of 133.33 µg/ml. 
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Folic acid conjugation enhances cytotoxicity in MDAMB-231cells. Statistically 
significant vs. control group, ***p< 0.001 by One way ANOVA and post Tukey test. 
All data are expressed as Mean ± S.E.M, n = 3. 
 
We observed an increase in anti-proliferative activity by snBLA-FAa in MDAMB-231 
cells (see Fig.5.10 and 5.11) than snBLA alone (Fig.5.2B), however, such increase in 
conjugate cytotoxicity was not observed in A549 cells (see Fig.5.14), inset shows the effect 
of snBLA, snBLA-FAa at a dose of 133.33 µg/ml in A549 and MDAMB-231 cells. This 
fact is due to the expression of folate receptors on the membrane surface of MDA-MB-231 
cells that facilitated the entry of snBLA-FAa inside cells. 
 Since, A549 cells do not express FR, hence, the entry of snBLA inside the cytoplasm 
follows the normal route of entry into cells, i.e., Caveoli mediated, phagocytosis, etc. 
 Therefore, it was established that FA conjugation increased the efficiency of cellular 
uptake in FR +ve cancer cells. Thus such strategies can be used for selective targeting of 
cancer cells. 
The comparison of the IC50 values clearly shows that snBLA-FAa is more potent than 
snBLA alone. The result also indicates that the conjugation of folic acid resulted in an 
increase in the cellular uptake of snBLA resulting in increased cytotoxicity.  
 
91 
 
0
20
40
60
80
100
 snBLA
 snBLA-FAa
 snLYZ
 snLYZ-FAa
100 266.66
µg/ml
%
 C
e
ll
 v
ia
b
il
it
y
 
Figure 5.15 Comparison of cytotoxic effect of snLYZ, snLYZ-FAa in MCF-7 cells 
and snBLA, snBLA-FAa in MDAMB-231 cells by MTT cell viability assay at 24 h 
post administration. All data are expressed as Mean ± S.E.M, n = 3. 
 
In order to support our conclusions we made a comparison of the doses of the protein 
nanostructures snLYZ and snBLA along with their folic acid conjugates producing 
maximum toxicity in MCF-7 and MDAMB-231 cells. We observed an increase in 
toxicity of snLYZ/snBLA-FAa compared to snLYZ/snBLA alone (Fig. 5.15). 
5.2.4 Cellular uptake of snLYZ/snBLA in MCF-7 cells 
We also anticipated that cellular uptake could be a major reason behind cell death. 
To ascertain the cellular uptake of snLYZ, we performed fluorescence imaging of 
cancer cells using fluorescent dyes such as DAPI, Fluorescein diacetate, and acridine 
orange. Cells stained with DAPI clearly showed blue fluorescence for the nucleus in 
live cells and Fluorescein diacetate exhibited green fluorescence for the cytoskeletal 
component of cells. Fig 5.16 shows the uptake of snLYZ in MCF-7 cells.  
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Figure 5.16 Fluorescent images of MCF-7 cancer cells showing internalization of 
acridine orange tagged snLYZ. (A) Control, administered with none; (B) Cell images 
after administration of acridine orange tagged snLYZ uptake for 1 h; (C) Acridine 
orange tagged snLYZ uptake at 3 h; (D) Acridine orange tagged snLYZ uptake at 6 h; 
(E) Acridine Orange tagged snLYZ uptake at 12 h. 
 
Cancer cells at 0th h were presented in Fig.5.16 (A), which showed the intact nucleus 
(blue fluorescence) with uniform cytoskeletal components and intact boundary of 
cells. Fig.5.16 (B-E) clearly showed that with an increase in time (1-12 h), more 
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amount of snLYZ was internalized in cancer cells resulting in the formation of 
cytoplasmic granules causing damage to the cell membrane. 
Babudieri-Callerio earlier reported that native LYZ (0.1 to 5 mg/ml) upon 
administration in human tumorigenic cell lines resulted in the formation of many 
azurophilic granules in the cytoplasm (diameter ~1 µm). The result was anticipated as 
one of the reason behind LYZ-based cell death. Here, a similar kind of granular 
formation was also observed (Fig.5.16 B, C, D, and E). Subsequently, the same group 
reported that the generation of the granular structure within the cytoplasm was due to 
the interaction of LYZ with the endoplasmic reticulum membrane.  
The interaction occurred through an enzymatic mechanism involving homogenization 
of its fibrillar structure. In this study, we observed similar interaction, which resulted 
in overwhelming ROS production and triggered profound cell death. 
Moreover, the appearance of the damaged cytoplasmic membrane with intact and 
slightly swollen nucleus (Fig. 5.16 E), is indicative of cellular necrosis. Interestingly, 
the granular formation within the cytosol seemed to initiate the cytosolic damage. 
Accordingly, after entering into cells, snLYZ caused cytosolic damage and increased 
permeability of the cellular membrane.  
In a similar way we also examined the cellular uptake process of snBLA in MCF-7 
cells. 
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Figure 5.17 Fluorescence microscopic image of MCF-7 cells at (A) 0, (B) 3, (C) 6 
and (D) 12 h post administration of snBLA conjugated with acridine orange. The 
orange fluorescence emitted by the particles inside the cytoplasm are due to the 
internalised snBLA. The internalization of snBLA was observed within 3 h of 
administration. 
Cells stained with DAPI clearly exhibited blue fluorescence for the nucleus in live 
cells (see Fig.5.17 A) and snBLA tagged with acridine orange exhibited orange 
fluorescence (see Fig.5.17 C, D and E). At the end of 12 h post-administration of 
snBLA conjugated acridine orange, we observed the appearance of snBLA particles 
exhibiting orange fluorescence inside the cytoplasm of MCF-7 Breast cancer cells 
(see Fig.5.17 D), indicative of cellular uptake of snBLA in MCF-7 cells.  
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Hence, we anticipated that cellular internalization was probably one of the crucial 
reason of generating toxicity in cells and subsequent cancer cell death for both snLYZ 
and snBLA. For snBLA also, the cytoplasm was found disintegrated with intact 
nuclei, which was also an indicative of necrotic like cell death. Hence, for both 
snLYZ and snBLA the cell death mechanism observed to be similar. 
5.2.5 Reactive oxygen species (ROS) mediated cell death 
In order to understand the cell death mechanism mediated by snLYZ, we 
administered N-acetyl-L-cysteine (NAC) in cell culture medium to examine the 
possibility of cell death caused by reactive oxygen species (ROS). NAC is an 
antioxidant/free-radical scavenger or reducing agent that protects cells against ROS-
mediated death. In our investigation, NAC (2 mM) was used to inhibit ROS-based 
effect. If NAC was administered in the cell medium, ROS generation would be 
inhibited and cell killing induced by ROS would be prevented.  
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Figure 5.18 Cell viability assay of snLYZ in the presence and absence of NAC at 24 
h post administration in MCF-7 cells. Statistically significant vs control group, *** p 
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<0.001 by One way ANOVA and post Tukey test. All data are expressed as Mean ± 
S.E.M, n = 3. 
From Fig. 5.18, it was found that snLYZ at a concentration of 60, 100 and 200 µg/ml 
shows 34.09, 22.27 and 8.27 % cell viability respectively.However, administration of  
NAC (2 mM) caused almost no cell death, clearly indicating a complete ROS-
mediated cancer cell death mechanism by snLYZ. 
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Figure 5.19 Cell viability assay of snBLA in the presence and absence of NAC at 24 
h post administration in MCF-7 cells. The presence of NAC reversed the cytotoxicity 
indicating a ROS based mechanism. Statistically significant vs control group, *** p < 
0.001 by One way ANOVA and post Tukey test. All data are expressed as Mean ± 
S.E.M, n = 3. 
 
Similarly for by snBLA, we pre-treated the cell culture medium with N-acetyl-L-
cysteine (NAC) followed by addition of 333.33 µg/ml to examine the possibility of 
cell death caused by reactive oxygen species (ROS).  
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We observed that the addition of NAC completely reversed the cell killing effect of 
snBLA at 333 µg/ml (see Fig. 5.19). Moreover, the effect of NAC was also found to 
be more pronounced at the end of 48 h (see Fig. 5.19). The result clearly indicates that 
the cell killing effect of snBLA in MCF-7 cells was mediated through ROS. 
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Figure 5.20 Comparison of cell viability in MCF-7 cells at doses of snLYZ and 
snBLA inducing maximum cytotoxic effects in the presence and absence of NAC at 
24 h post administration. All data are expressed as Mean ± S.E.M, n = 3. 
 
It was well established that both snLYZ and snBLA caused cell death through ROS 
generation. Based on the above results we have made a comparison of cytotoxicity of 
both snLYZ and snBLA at their doses inflicting maximum toxicity. We found that 
snLYZ at a dose of 200 µg/ml inflicted maximum toxic effect (91.72 %) compared to 
snBLA (80.85 %) at a much higher dose of 333.33 µg/ml at the end of 24 h post 
administration (Fig.5.20 A and B). 
In both the cases we observed that pre-treating the cells with NAC (2mM) prior to 
administration of snLYZ and snBLA resulted in the complete inhibition of 
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cytotoxicity. This clearly indicates that ROS has a very dominant role in the cell 
killings induced by snLYZ and snBLA. Moreover, comparatively lower amount of 
snLYZ is required to achieve higher level of toxicity compared to snBLA. 
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Figure 5.21 Comparison of cell viability in MCF-7 and MDAMB-231 cells at 24 h 
post administration of snBLA and BAMLET in a dose range of 16.66 - 333.33 µg/ml. 
snBLA was found to have a better cytotoxic profile than BAMLET. All data are 
expressed as Mean ± S.E.M, n = 3. 
 
HeLa cells are the cells derived from one of the most aggressive forms of cancer 
called cervical cancer and cytotoxicity study against this particular cell line will help 
us realize the true potential of snBLA compared to BAMLET. BAMLET was never 
an effective treatment option for treating HeLa cells. Hence, evaluating the cytotoxic 
effect of snBLA on HeLa cells will be a challenge. The cytotoxicity study of our 
prepared snBLA was examined in four different cell lines such as MCF-7 and 
MDAMB-231 (Breast cancer), HeLa (cervical cancer) and A549 (lung carcinoma) 
using a range of concentrations (16.66 to 333.33 µg/ml).  
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In snBLA (Fig.5.21 A, and B), Fig.5.22A and B results clearly showed strong 
cytotoxicity of snBLA against all the cell lines. We also performed the same assay 
with BAMLET using same concentration of BLA (in BAMLET) to compare its 
cellular toxicity with that obtained by snBLA. The IC50 value of BAMLET in MCF-7 
was found to be 105.8 µg/ml. While snBLA shows more than 80% cell death in all 
cell lines after 24 h of administration, BAMLET exhibits comparable toxicity in 
MCF-7 cell line (Fig. 5.21 A), however, in MDAMB-231 (Fig. 5.21 B) and A549 cell 
lines (see Fig. 5.22 B) it demonstrated lower anti-proliferative activity than snBLA. 
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Figure 5.22 Comparison of cell viability of snBLA and BAMLET in (A) HeLa and 
(B) A549 cells at 24 h post administration. snBLA was found to have a better 
cytotoxic profile than BAMLET. All data are expressed as Mean ± S.E.M, n = 3. 
 
It was also observed that BAMLET showed little anti-proliferative activity in HeLa 
cells (17.46 % cell death) (see Fig.5.22 A), and in comparison snBLA demonstrated 
90% cell death. Similarly, BAMLET demonstrated lower anti-proliferative activity in 
A549 cells (67.12 % cell death) (see Fig.5.22 B), compared to snBLA which 
demonstrated 83.98 % cell death. A cancer therapeutic agent should be highly 
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selective and toxic towards cancer cells with various levels of invasiveness. HeLa 
cells are highly invasive than MDAMB-231, A549 and MCF-7 and hence, here we 
conclude that snBLA has a higher anti-proliferative potential in cancer cells compared 
to BAMLET.  
We also examined snBLA and BAMLET in normal cell lines such as HaCaT (human 
keratinocyte cells) and 3T3 (murine fibroblast cells). snBLA showed less toxicity 
compared to BAMLET at similar concentrations (see Fig.5.23 A and B). 
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Figure 5.23 Comparison of cell viability of snBLA and BAMLET in (A) HaCaT and 
(B) 3T3 cells at 24 h post administration. snBLA was found to have a better cytotoxic 
profile than BAMLET. All data are expressed as Mean ± S.E.M, n = 3. 
 
In order to understand whether ROS was involved in the process of cancer cell death, 
we administered NAC in MCF-7 and MDAMB-231 culture medium and observed the 
effect of snBLA both in the presence and absence of NAC (see Fig.5.24).  
We observed that the administration of NAC completely inhibited the ROS-based cell 
death induced by snBLA in MCF-7 cells (Fig.5.22 A and B) and in MDAMB-231 
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cells (Fig.5.25 A and B). Since NAC is a ROS inhibitor, we concluded that snBLA 
generates sufficient ROS in cancer cells which subsequently triggers rapid cell death 
of MCF-7 cells.  
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Figure 5.24 Comparison of cytotoxic effects of snBLA and BAMLET due to ROS 
generation in MCF-7 cells at 24 h post administration. The presence of NAC reversed 
the cytotoxicity indicating a ROS based mechanism in snBLA, however, the presence 
of NAC partially reversed the cytotoxicity indicating a partial contribution of a ROS 
based mechanism. All data are expressed as Mean ± S.E.M, n = 3. 
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Figure 5.25 Comparison of cytotoxic effects of snBLA and BAMLET due to ROS 
generation in MDAMB-231 cells at 24 h post administration. The presence of NAC 
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reversed the cytotoxicity indicating a ROS based mechanism in snBLA, however, the 
presence of NAC partially reversed the cytotoxicity indicating a partial contribution 
of a ROS based mechanism. All data are expressed as Mean ± S.E.M, n = 3. 
 
We also performed the same experiment with BAMLET and we observed a partial 
regain of cell viability in MCF-7 cells (Fig.5.24 A and B) and MDAMB-231 cells 
(Fig.5.25 A and B).Therefore, the results indicated that BAMLET mediates cancer 
cell death through some other mechanism besides ROS-based mechanism.  
Multiple reports ae available related to cell death induced by BAMLET, however, 
they all were prepared using various methods. The BAMLET which we prepared here 
(Kamijima et al., 2008) were already reported to cause apoptosis-mediated cell death. 
However, lysosomal-mediated cell death induced by BAMLET was also observed 
when prepared using other methods (Knyazeva et al., 2008; Spolaore et al., 2010; 
Svensson et al., 2000). Therefore, our result also validates the point that BAMLET 
have multiple mechanism of cell death. However, snBLA which has higher potential 
of cancer cell death than BAMLET, triggers only ROS pathway to generate ample 
ROS that surpassed the cellular resistance to combat ROS-based stress. 
We have observed from our earlier experiments such as the snBLA uptake study (see 
Fig. 5.17) and found a ROS mediated cancer cell death mechanism (see Fig.5.24 A 
and B) and (see Fig.5.25 A and B).  
However, from the uptake study, we found that the cell and nucleus size was 
increased after the treatment of snBLA which is in contrary to the normal apoptosis 
process where cell volume shrinkage is observed. The above morphological changes 
are associated with cell necrosis rather than apoptosis. Hence, the role of Caspase-3 
that is associated with apoptosis required further investigation. 
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5.2.6 Role of Caspase-3 mediated apoptotic cell death 
We performed independent cell viability assay in the presence of caspase-3 inhibitor 
(potent, cell-permeable, and irreversible; C₂₁H₃₁ Cl N₄O₁₁, molecular weight of 
551.0) that prevents caspase-3 mediated apoptosis and gallic acid (GA) which induces 
caspase-3 mediated apoptosis in MDAMB-231 cells to confirm whether the 
cytotoxicity was due to apoptosis or any other mechanism.  
GA was used as a positive control, since it causes apoptosis in a caspase-3 mediated 
mechanism of action. We have also used the caspase-3 inhibitor to rule out the 
contribution of apoptosis through a caspase-3 mediated process. Various 
combinations of treatment both in the presence of gallic acid and caspase-3 inhibitors 
were administered along with snBLA in MDAMB-231 cells (see Fig.5.26). 
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Figure 5.26  MTT assay of snBLA in MDAMB-231 cells both treated in the presence 
and absence Caspase-3 inhibitor, Gallic acid (GA), C (Caspase inhibitor) at the end of 
24h. Statistically significant vs control group, ***p< 0.001 by One way ANOVA and 
post Tukey test. All data are expressed as Mean ± S.E.M, n = 3. 
From the results (Fig. 5.26), we see that snBLA (80.43 % cytotoxicity) in 
combination with GA (90.54 % cytotoxicity) increased the cytotoxicity in MDAMB-
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231 cells. However, snBLA in the presence of caspase-3 inhibitor (78.83%) produced 
similar levels of toxicity as that of snBLA alone. We observed that the cell death 
induced by snBLA was Caspase-3 independent which clearly ruled out the possibility 
of cell death due to apoptosis. 
We also examined Caspase 3 expression by Western Blotting at the end of 12 h post 
incubation to ascertain our results obtained from Fig.5.27. We found that the basal 
expression level of Caspase 3 hardly changed compared to control, however, the 
caspase-3 level slightly increased for BAMLET. Caspase 3 has direct correlation with 
apoptosis (Saladi et al., 2013). 
 -actin
Caspase 3
Hsp 90
C
o
n
tr
o
l
n
m
B
L
A
s
n
 B
L
A
B
A
M
L
E
T
1 2 3 4
 
Figure 5.27 Western blot analysis of Caspase 3 and Hsp90 expression in MDAMB-
231 cells treated with snBLA and BAMLET. The expression of Hsp 90, Caspase 3 is 
observed in the samples labelled vertically, Lane 1 (control), Lane 2 (nmBLA), Lane 
3 (snBLA) and Lane 4 (BAMLET). β- actin is used as a loading control. 
Since, cell death induced by BAMLET is mainly through apoptosis, we found a 
higher expression level of Caspase-3 in BAMLET (see Fig. 5.27). As, the expression 
level of Caspase-3, did not increase after the treatment of snBLA and remains same 
as that of the basal state, cell death mediated by apoptosis is totally ruled out and cell 
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necrosis remains the only mechanism of cell death. Moreover, the Hsp90 expression 
level was slightly increased after the treatment of snBLA, however the expression of 
Hsp-90 was more pronounced with BAMLET treatment (see Fig. 5.27). Hsp90 
expression positively correlates with the measure of the stress. Hence, the result 
clearly indicates that the increased expression of Hsp90 after treatment of snBLA was 
due to the generation of excessive stress due to ROS formation in MDAMB-231cells. 
5.2.7 Hemolysis assay: 
It was essential to know the hemocompatibility nature of snLYZ and snBLA, and 
hence, hemolytic analysis was performed using Triton-X (1%) as positive control and 
saline water (0.9% NaCl) as a negative control. 
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Figure 5.28 Hemolysis assay results of various samples. (A) nmLYZ and 0.1% GTD, 
(B) snLYZ, (C) Tamoxifen. Appropriate (-ve) control RBC and (+ve) control TritonX 
was used. All data are expressed as Mean ± S.E.M, n = 3. 
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We clearly observed that nmBLA and snBLA did not produce hemolysis till a 
concentration as high as 333.33 µg/ml (see Fig.5.29 A and B). However, BAMLET a 
protein based formulation shows high hemotoxicity from 16.66 µg/ml onwards (see 
Fig.5.29 C).  
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Figure 5.29 Hemolysis assay results of the samples. (A) nmBLA, (B) snBLA, (C) 
BAMLET and (D) Oleic acid. Appropriate (-ve) control RBC and (+ve) control Triton 
X was used. All data are expressed as Mean ± S.E.M, n = 3. 
 
It is interesting to note that snBLA also contains the same protein component bovine 
α-lactalbumin, and it does not produce haemolysis as that of BAMLET. Oleic acid 
(OA) may be the major contributor towards haemolysis from BAMLET as OA 
induces haemolysis from concentrations as low as 1µM (see Fig.5.29D). Hence, 
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snBLA is a better performer than BAMLET from all aspects such as cytotoxicity 
against cancer cells, cytocompatibility and hemocompatibility. 
Our objective was to assess the possibility of using snLYZ and snBLA as a potential 
Breast cancer therapeutic agent for human use and in order to examine that it was 
essential to study its hemocompatible property. Both snLYZ and snBLA did not show 
hemolytic activity till a concentration as high as 1000 and 333.33µg/ml. However, 
TAM showed signs of haemolysis beyond the concentration of 16.8 µg/ml. Triton X 
(1%) was used as positive control showing 100% haemolysis. 
It was clear from the results that snLYZ showed negligible hemolytic potential 
compared to TAM. The reason behind the hemocompatible nature of snLYZ was due 
to its proteinaceous composition. The mean size of the protein nanoassembly is 300 
nm with spherical shape which would facilitate the smooth flow in blood and provides 
least resistance against flow. Moreover, the zeta potential values are +40 mV (snBLA) 
and -39.1 mV (snLYZ), respectively which also clearly indicate that they are highly 
stable in the solution without forming aggregation. All the mentioned properties 
facilitate smooth and prolonged circulation in blood. Moreover, we also demonstrated 
that folate conjugated snLYZ and snBLA can be used as targeted therapy in cancer 
which would trigger the tumor accumulation of protein nanoassemblies. 
Based on our results obtained in Fig. 5.30, we proposed a model of how our 
developed snLYZ/snBLA might have killed cancer cells efficiently. 
In normal cells, the cellular internalization takes place by phagocytosis, 
caveolar/clarithrin mediated endocytosis, micropinocytosis, and pinocytosis 
mechanisms followed by formation of early endosomes, late endosomes and 
lysosomes. snLYZ/snBLA is released in to the cytoplasam but the basal levels of 
108 
 
antioxidant enzymes such as SOD (Superoxide dismutase) and GST (Glutathione S-
transferase) prevent its interaction with the fibrillar cell membrane of the endoplasmic 
reticulum, hence, no toxicity and cell death.  
 
Figure 5.30 Proposed model of how nanoassembly proteins (snLYZ and snBLA) and 
snLYZ/snBLA-FAa and cause cell death in cancer cell. (A) In normal cells, (B) In 
cancer cells. 
 
This was also evident from our haemolysis assays where normal RBC’s tolerated high 
concentration of snLYZ till 1mg/ml and snBLA till 333.33µg/ml without hemolysis. 
In cancer cells, the extracellular and intracellular environment is slightly acidic 
(McCarty and Whitaker, 2010) with intracellular being more acidic in nature due to 
accumulation of various oxidation end products (Bareford and Swaan, 2007; 
Madhusudhan et al., 2014; Ulbrich and Subr, 2004). Hence, the cancer cells are 
already in a highly stressed state due to higher intracellular ROS generation from 
oxidation end products.  
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The mechanism of entry of snLYZ/snBLA into the cancer cells is the same as that of 
normal cells. However, during intracellular release of snLYZ/snBLA the basal levels 
of SOD and GST are already exhausted. Since no more SOD and GST is available for 
protecting the cancer cell from further ROS generation, snLYZ/snBLA probably 
interacts with fibrillar cell membrane of the endoplasmic reticulum and causes 
formation of granular cytoplasm and increased permeability of the cell membrane and 
cell death. 
Although protein nanoassembly caused insignificant level of haemolysis to normal 
human erythrocytes or normal cells like HaCaT, it caused a rapid ROS dependent 
cancer cell death. The result suggests that snLYZ/snBLA prevents the cancer cell-
specific mechanism of counteracting additional ROS generation, perhaps through 
extra antioxidant production. Liu et. al., earlier demonstrated that LYZ ameliorated 
oxidative stress in normal cells. LYZ by binding to agents such as advanced glycation 
end products (AGE) generated ROS using its unique 18 amino acid domain (Liu et al., 
2006). 
It is plausible that in snLYZ, such domain function was diminished due to 
conformational changes, which further reverted to a partially unfolded state that 
suppressed the extra antioxidant generation mechanism in cancer cells. 
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Chapter 6          
In-vitro drug loading, release studies and evaluation of their 
cytotoxicity 
 
6.1 Materials and Methods 
 
6.1.1 Materials 
N-acetylcysteine (NAC), Glutaraldehyde (GTD) (25%), Tamoxifen citrate (TAM), 
Bovine α-lactalbumin were purchased from Sigma-Aldrich, India. Lysozyme, 
Micrococcus lysodekticus, MTT assay kit, Ethanol, DMEM, Fetal bovine serum 
(FBS), antibiotics, HiMedia India Pvt. Ltd. Milli-Q water was used in all the 
experiments. T-25 flasks, 96 well plates and all other plasticwares were purchased 
from Tarsons Pvt. Ltd.MCF-7 (Breast cancer cell line) cells were procured from 
NCCS, Pune, India. All the glasswares used in the study were purchased from 
Borosil, India. All other reagents were of analytical grade. 
6.1.2 Methods 
 
6.1.2.1 Preparation of self-assembled protein and Tamoxifen conjugate 
For the preparation of snLYZ/snBLA-TAM conjugate, 2.0 mg/ml of the protein 
nanoassembly solution was taken and a varying amount of TAM was added. The 
solution containing the protein nanoassembly and TAM was stirred for 5 min at 
500rpm. Glutaraldehyde was added to the solution for cross-linking to achieve a final 
crosslinker concentration of 0.1%. In order to facilitate the proper crosslinking 
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between the protein nanoassembly and TAM, the solution was kept under stirring at 
500 rpm for 8 h.  
At the end of 8 h the solution was centrifuged at 25,000 g for 5 min and the 
supernatant was taken for the estimation of the concentration of TAM. The amount of 
the drug present in the supernatant was estimated by measuring the absorbance of the 
solution at 235 nm. The concentration of TAM was extrapolated from the absorbance 
values of TAM (Abs. vs. Concentration) standard curve. 
The amount of ‘drug loaded’ was calculated from the following formula. 
 
Amount of drug loaded = Amount of drug added for loading - Amount of drug present in the supernatant 
                                                                                                                                             .............(6.1)
 
 
6.1.2.2 Drug loading study 
 
Various amounts of TAM (0.5 - 6.6 mg) were added for loading on the protein 
nanoassembly snLYZ and snBLA by the above method. The amount of drug loaded 
was estimated from the Eqn. (6.1), mentioned in the above section. Based on the 
amount of drug loaded, we can calculate the drug loading efficiency by using Eqn. 
(6.2), mentioned below. 
 
(Amount of drug used for loading Amount of free drug in solution)
Drug loading efficiency (%) X 100.......(6.2)
Amount of drug carrier used in formulation

  
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6.1.2.3 pH-responsive drug release studies 
 
In order to observe the drug release from the snLYZ/snBLA-TAM conjugate, we 
performed both the cumulative and non-cumulative release of TAM from the 
formulation at various ph. For performing cumulative drug release study, the 
snLYZ/snBLA-TAM conjugate (2.0 mg/ml) was kept in a dialysis bag and kept in a 
beaker containing buffer of pH 3.0, 4.0, 5.0, 6.0 and 7.4, respectively. The dialysis 
bag containing the snLYZ/snBLA-TAM conjugate was clipped with the wall of the 
beaker and dipped inside the buffer solution. The contents of the beaker were kept for 
stirring at 60 rpm. Samples of the buffer were collectedfrom the beaker at 1, 2, 3, 6 
and 12 h to calculate the amount of drug release from the snLYZ/snBLA-TAM 
conjugate kept in the dialysis bag. The concentration of the drug in the supernatant 
was calculated from the standard curve of TAM (Abs. vs. Conc.).  
 
Non-cumulative drug release was performed at various time points such as 1, 2, 3, 6, 
12, 24 and 30 h. Here, other procedures kept same as mentioned above for cumulative 
drug release study except an equivalent volume of buffer was replaced for the volume 
of sample taken from the beaker for estimation of TAM content as well as to maintain 
a concentration gradient of drug between ‘loaded state’ and in ‘solution state’ for 
maximum drug release. 
Here, we wanted to define the state of snLYZ/snBLA-TAM conjugate after the 
maximum amount of TAM released from snLYZ/snBLA-TAM conjugate at pH 6.0 
(till a point where no more drug release was observed) as the ‘reconstituted state’ of 
snLYZ/snBLA-TAM conjugate. 
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6.1.2.4 Preparation of reconstituted protein nanoassembly 
The reconstituted snLYZ/snBLA-TAM conjugate was prepared by performing the 
non-cumulative drug release from the snLYZ/snBLA-TAM conjugate in an acidic 
environment, i.e., at pH of 6.0. The amount of drug from snLYZ/snBLA-TAM 
conjugate was allowed to release at pH 6.0 for 30 h (till no further drug release was 
observed). The solution containing the snLYZ/snBLA-TAM conjugate was 
centrifuged at 20,000 g for 10 min. The supernatant solution containing the drug was 
removed and the pellet was resuspended in 1 ml of Milli-Q water and termed as 
‘reconstituted snLYZ/snBLA’. 
 
6.1.2.5 Characterization of ‘reconstituted snLYZ’ 
The solution of snLYZ-TAM conjugate was subjected to in-vitro drug release at pH 
6.0. After the drug release process was completed, supernatant containing the drug 
was removed and pellet was resuspended with fresh buffer. The process was repeated 
at different time points (1, 2, 3, 6, 12 and 24 h) till no further release of the drug was 
observed. The ‘reconstituted snLYZ/snBLA’ was characterized using both tryptophan 
(Trp) as well as ANS fluorescence spectroscopy. Fluorescence emission spectra were 
recorded in the range of 300 to 400 nm for fluorescence measurement. The excitation 
and emission slit widths were set at 5 and 10 nm, respectively.  
 
6.1.2.6 Activity assay of nmLYZ and snLYZ 
Cells of Micrococcus lysodekticus (9 mg) were suspended in 30 ml of 100 mM 
sodium phosphate buffer pH 7.4, shortly before the assay. Each of the microplate 
wells contained 50µl sample and 200 µl of micrococcus cell suspension. The plate 
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was gently shaken for 1.0 min in a microplate reader (iMark, Bio-Rad) followed by 
measurement of absorbance at 450 nm and continued for 10 min at 1 min interval. 
Lysozyme activity (Ng et al., 2013) was measured by measuring the change in O.D 
(absorbance) over a period of 10 min and is represented by the following formula. 
initial (10 min)-------------------------------------(6.3)Lys activity (Change in O.D) = O.D  - O.D  
 
6.1.2.7 Cell viability assay of various formulations of snLYZ/snBLA-TAM 
conjugates containing different ratios of snLYZ/snBLA:TAM and their 
reconstituted forms 
The cytotoxicity of snLYZ/snBLA-TAM conjugate was assessed in breast cancer cell 
line MCF-7 using MTT assay. MCF-7 cells were cultured in DMEM (Dulbecco’s 
Minimum Essential Medium) and supplemented with 10% foetal bovine serum, 2 mM 
glutamine and 0.1 mg/ml penicillin and streptomycin. Cells were cultured in T-25 
flasks and were maintained at 370C in humidified, 5% CO2 atmosphere in a CO2 
incubator. The MCF-7 cells were cultured till 80% confluence was achieved. The 
cells were trypsinised and seeded at a density of 1x104 cells/ml. The cells were seeded 
in a 96 well plate with 100 µl of DMEM in each well and were allowed to proliferate 
for 24 h. Various test samples were administered to the MCF-7 cells and the end point 
effect was monitored by MTT assay at the end of next 24 h and 48 h. MTT (10 µl of 5 
mg/ml stock) was added 6 h before the end point. At the end point, media was 
removed and 100 µl of DMSO was added to dissolve the formazan formed and the 
absorbance was measured at 595 nm. The absorbance values were recorded and 
percentage cell viability of MCF-7 cells was calculated from the absorbance values 
and the result was plotted. 
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6.1.2.8 Evaluation of the mechanism of toxicityof snLYZ/snBLA and 
snLYZ/snBLA-TAM conjugates 
To examine the generation and effect of reactive oxygen species (ROS) in MCF-7 cell 
death, we applied N-acetyl-cysteine (NAC), a well-known ROS inhibitor (Mayer and 
Noble, 1994) in cell culture medium. NAC was added to a final concentration of 2 
mM in MCF-7 culture and cells were allowed to proliferate as described above. After 
24 and 48 h post-administration of snLYZ/snBLA and snLYZ/snBLA-TAM in MCF-
7 cells, MTT assay was performed and the results compared with the samples without 
NAC.  
 
6.1.2.9 Hemolysis assay of snLYZ/snBLA and snLYZ/snBLA-TAM conjugates 
To perform, the hemocompatibility assay, an expert technician under the supervision 
of an invited physician collected 5 ml of B +ve human blood. Blood was collected in a 
centrifuge tube containing 2 mg of disodium EDTA (anti-coagulant). The content was 
gently resuspended and centrifuged at 1000 g for 10 min. The supernatant was 
removed and the RBC collected at the bottom of the centrifuge tube was washed three 
times by gentle resuspension with 10 times the volume of pyrogen free saline (0.9% 
NaCl), and followed by centrifugation at 1000 g for 10 min at room temperature.  
The RBC pellet was gently resuspended in pyrogen free saline and was diluted to 
0.8% (v/v). The resuspended RBC solution (3 ml) was placed in sterile glass vials and 
various test samples were added to evaluate their hemolytic potential.  
Triton X (1%) was used as a positive control for monitoring maximum hemolysis and 
RBC suspension treated with sodium phosphate buffer, pH 7.4 was used as a negative 
control. The percentage hemolysis was calculated at 1 h and the graph was plotted 
between percent hemolysis and time (h). 
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6.2 Results and Discussion 
6.2.1 Preparation of snLYZ/snBLA-TAM conjugates 
The snLYZ/snBLA-TAM conjugates were prepared by the method mentioned in 
section 6.1.The drug loaded snLYZ-TAM was characterized using AFM imaging (see 
supplementary Fig S10). 
6.2.2 Drug loading efficiency 
Many scientists have recently reported that protein nanoparticles can be used as drug 
carriers (Avachat et al., 2014; Gradishar et al., 2005). Although, we have 
demonstrated here the selective cytotoxic nature of snLYZ and snBLA for cancer 
cells, we also wanted to observe the drug-loading and release potential of snLYZ and 
snBLA. TAM loading onto the snLYZ and snBLA was examined by loading of 
various amount of drug onto the fixed amount of snLYZ and snBLA concentration 
(2.0 mg/ml) using 0.1% GTD as cross linker.  
It was observed that saturation level of drug loading was achieved at 2.58 mg of TAM 
amount onto 2 mg of snLYZ (beyond which no further loading was observed) (see 
Table 6.1 and Fig 6.1 ), indicates more than 100% drug loading w/w.  
Such exceptionally high loading must be due to the cross linking of TAM and surface 
characteristics of snLYZ molecules. The drug (Tamoxifen) loading capacity (payload) 
of snBLA and snLYZ was calculated using Eqn. no. 6.1 and the pH-responsive drug 
release profile was studied at pH 6.0. Since, pH 6.0 is close to physiological pH 
environment of cancer cells, the in-vivo drug release study was performed at pH 6.0 
to simulate the condition 
118 
 
Table 6.1 In vitro drug loading of Tamoxifen (TAM) on snLYZ and its release at pH 
5.0 and 6.0. The duration of drug loading was 8 h. 
 
Amount 
of 
drug 
added 
(µg) 
Amount of 
snLYZ (µg) 
Amount of 
drug loaded 
(µg) 
Drug 
Loading 
efficiency 
(%) 
Amount of 
drug (µg) 
release at 
pH 5.0 
Amount of 
drug 
(µg)release 
at pH 6.0 
6660 
2000 
 
2578.49 128.92 1317.6 902.5 
2500 2498.22 124.91 1276.6 874.4 
2000 1998.11 99.91 1021 699.3 
1500 1497.79 74.89 765.4 524.2 
1000 998.11 49.91 510 349.3 
500 498.43 24.92 254.7 174.5 
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Figure 6.1 Estimation of the maximum loading capacity of the protein nanoassembly, 
snLYZ. All data are expressed as Mean ± S.E.M, n = 3. 
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An amount of 2 mg of snBLA was used for crosslinking with 4 mg of TAM. After 8 h 
of loading of TAM by crosslinking, we observed almost 3.926 mg of drug was 
successfully loaded onto it, which was almost double the weight of snBLA and higher 
than snLYZ. Further, various amount of TAM was loaded onto snBLA and the 
loading efficiency was estimated using the Eqn.6.2 (mentioned in “Materials and 
Methods” section). The drug loading data was presented Table 6.2. 
From our study we found that snBLA exhibited higher drug loading efficiency than 
snLYZ. The amount of loading of drug onto protein nanoassembly depends on the 3-
D structure of individual protein unit in the nanoassembly as well as their surface 
character. 
Table 6.2 In vitro drug loading of Tamoxifen (TAM) on snBLA and its release at pH 
6.0. The duration of drug loading was 8 h. 
 
Amount of 
drug added (µg) 
Amount of 
snBLA (µg) 
Amount of drug 
loaded (µg) 
Loading 
efficiency 
(%) 
Amount of 
drug 
(µg)release 
at pH 6.0 
6000 
2000 
 
3931 93.1 2507.98 
4000 3926 192.6 2465.52 
2000 2000 100 716 
250 250 12.5 91.27 
100 100 5 36.5 
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Figure 6.2 Estimation of the maximum loading capacity of the protein nanoassembly, 
snLYZ. All data are expressed as Mean ± S.E.M, n = 3. 
 
6.2.3 In vitro pH-dependent release 
Since cancer cells achieves an acidic pH intracellularly and extracellularly, a pH-
dependent drug release study was essential to evaluate the conditional drug-release 
potential of snLYZ/snBLA-TAM conjugate. Although, the pH-dependent in vitro 
drug release study was performed till 12 h, the time-dependent drug release profile at 
all the pH used in the study showed that drug release process attained a steady state 
after 6 h (Fig. 6.3) of release.  
For the drug release study, snLYZ-TAM was used in the ratio of 1:1 w/w. This 
formulation was used for drug release study under varying pH conditions. The result 
clearly revealed that with lowering the pH value, increased the amount of drug 
released and it was found to be 3.5 %, 48.9 %, 65.45%, 79.47% and 91.29% at pH 
7.4, 6.0, 5.0, 4.0 and 3.0 respectively (see Fig. 6.3) which indicates pH responsive 
drug release potential of snLYZ-TAM conjugate. Such pH sensitive release helps in 
targeted drug delivery in cancer due to the acidic environment of cancer cells. 
121 
 
0 1 2 3 4 5 6 7 8 9 10 11 12
0
20
40
60
80
100
pH 3
pH 4
pH 5
pH 6
pH 7.4
Time, h
%
 T
a
m
o
x
if
e
n
 c
it
ra
te
re
le
a
s
e
 
Figure 6.3 Percentage release of TAM from snLYZ-TAM conjugate at various pH 
with time till 12 h. A pH dependent increase in drug release was observed in snLYZ-
TAM conjugate. All data are expressed as Mean ± S.E.M, n = 3. 
 
This may be due to the fact that the crosslinkages of glutaraldehyde (GTD) between 
the protein nanoassembly and the drug were weak at acidic pH. Usually crosslinkages 
due to GTD are highly stable in an alkaline pH but become unstable at acidic pH. 
Hence, the pH dependent drug release was triggered due to the weakening of the 
glutaraldehyde crosslinkages. 
The non-cumulative drug release for both snLYZ-TAM and snBLA-TAM conjugates 
were performed at pH 6.0. In order to observe the maximum amount of drug release at 
an environment closely similar to the cancer cells, non-cumulative release of TAM 
from snLYZ-TAM conjugate was performed at pH 6.0. We observed that 64.82 % of 
the loaded drug was released at pH 6.0, till 24 h, beyond which, no further release of 
the drug was observed (see Fig. 6.4). 
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Figure 6.4 Percentage non-cumulative release of TAM from snLYZ-TAM conjugate 
at pH 6.0 with time till 30 h. No further release of drug was observed beyond 24 h 
indicating the maximum possible release of the drug. All data are expressed as Mean 
± S.E.M, n = 3. 
 
This result clearly showed that 35.18 % of the drug was still present in snLYZ-TAM 
conjugate. This may be due to the fact that still a few crosslinkages between the 
protein nanoassembly and the drug existed, which were intact at pH 6.0.  
The pH-dependent in vitro drug release study for snBLA-TAM was also performed 
till 12 h. However, the time-dependent drug release profile at pH (3-7.4) showed that 
drug release process attained a steady state at 6 h (Fig. 6.5). The cumulative drug 
release observed at pH 3, 4, 5, 6 and 7.4 were 84.09, 68.7, 60.18, 44.52 and 1.4 % 
respectively (see Fig. 6.5). 
Here, we also observed a similar trend of drug release pattern for snBLA-TAM where 
increased amount of drug was released with lowering of pH. The results showed that 
with the decrease in pH, the amount of drug release was increased from snBLA-TAM. 
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The same reason was attributed here for snLYZ-TAM also holds true here i.e., due to 
the weakening of the GTD crosslinkages. 
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Figure 6.5 Percentage cumulative release of TAM from snBLA-TAM conjugate at 
various pH (3-7.4) with time till 12 h. A pH dependent increase in drug release was 
observed in snLYZ-TAM conjugate. All data are expressed as Mean ± S.E.M, n = 3. 
 
Non-cumulative release of various formulations of snBLA-TAM conjugates (1:1, 4:1 
and 10:1 w/w) was performed at pH 6.0 till 30 h in order to observe the maximum 
amount of possible drug release. The results showed that 63.81, 59.75 and 55.19 % of 
the drug was released from snBLA-TAM formulation of 1:1, 4:1 and 10:1 w/w 
respectively (see Fig. 6.6). We also observed that with the increase in the amount of 
protein nanoassembly in the formulation from 1:1 to 10:1, gradually the amount of 
drug release was decreased at pH 6.0. The reason may be due to the increased number 
of cross-linkages of GTD formed between snBLA and TAM. Since, the cross-linking 
between snBLA and TAM was increased, limited number of cross-linkages exposed 
to pH 6.0 was broken and hence, lower amount of TAM was released. 
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Figure 6.6 Percentage non-cumulative release of TAM from snBLA-TAM conjugate 
at pH 6.0 with time till 30 h. No further release of drug was observed beyond 24 h 
indicating the maximum possible release of the drug. All data are expressed as Mean 
± S.E.M, n = 3. 
 
Since the protein structure is inherently very sensitive to pH change, here, although 
sufficient crosslinkages were responsible to form a stable protein-drug conjugate, the 
crosslinkages in snLYZ molecule perhaps could not provide sufficient resistance 
against the change in pH from 7.4 to 6.0. Such a change, must have induced the 
breakage of crosslinkages followed by a little conformational distortion of snLYZ that 
initiated the drug release process. However, it was not possible to break the 
crosslinkages, which were formed deeper inside the structure, which remained bound 
with the snLYZ molecules, and hence only ~65% of the total drug was released at pH 
6.0.  
The protein nanoassembly is stable at pH 3.0. In the present case, our protein self-
assembly changes its structure at low pH (not as drastic as its native state) in tumor 
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environment such that it releases drug molecules instantly but not completely. Such 
partial release of drug brings permanent change of protein structure (we called it 
‘reconstituted snBLA/snLYZ) and the nano-assembly which hitherto did not act as 
anticancer agent, would turn lethal to cancer cells. Such dual anticancer therapeutic 
mechanism is unique in our study instead merely a ‘pH-dependant drug release-based 
anticancer therapy’ however upon prolonged circulation and in the presence of 
intracellular proteases the protein nanoassembly will eventually degrade leading to the 
complete release of the drug 
6.2.4 Activity assay of LYZ in reconstituted snLYZ-TAM 
As observed in the Chapter No.4, LYZ activity was assessed at pH 5.0. Here we 
wanted to know the LYZ activity of various samples like snLYZ-TAM (1:1) and 
‘reconstituted snLYZ’. The result could provide the activity of catalytic sites of LYZ 
in various samples. Accordingly we performed activity assay at pH 5.0. 
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Figure 6.7 LYZ activity of various states of LYZ in snLYZ measured by 
Micrococcus lysodekticus assay. Both snLYZ and ‘reconstituted snLYZ’ retain partial 
LYZ activity. All data are expressed as Mean ± S.E.M, n = 3. 
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It was found that the snLYZ-TAM conjugate regained fair amount of lytic activity 
after releasing ~65% of total loaded drug at pH 5.0(we can call it reconstituted 
snLYZ)(see Fig. 6.7). The reactivation efficiency was above 50%. 
The result indicates that the active sites of LYZ was exposed to the solution due to the 
release of more than ~65% TAM, which were possibly earlier covered by the TAM 
molecules. Here, the post drug release state of snLYZ-TAM conjugate was referred as 
‘reconstituted snLYZ’.  
The tryptophan (Trp) fluorescence study of ‘reconstituted snLYZ’ revealed that the 
microenvironment around the Trp residues was not changed substantially as the 
fluorescence spectra showed close resemblance with snLYZ-TAM fluorescence 
spectra (Fig.6.8).  
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Figure 6.8 Tryptophan fluorescence spectra of nmLYZ, snLYZ, snLYZ-TAM and 
‘reconstituted snLYZ’ recorded between 300–400 nm. The drop in fluorescence 
intensity of snLYZ, snLYZ-TAM and ‘reconstituted snLYZ’ indicates probable 
translocation of Trp residues to the surface of the protein structure or to a more 
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hydrophobic region. All data were expressed as the mean of three readouts generated 
from the instrument. 
 
However, the small increase in the Trp fluorescence intensity of ‘reconstituted 
snLYZ’ may be due to the release of the drug which caused a structural change of 
LYZ molecules exposing some of the Trp residues to the outer surface of the protein 
nanoassembly. The ‘reconstituted snLYZ’ still contain ~35% of initial loaded drug 
which, would probably release only after the degradation of snLYZ.  
The Trp fluorescence intensity of snLYZ was quenched substantially compared to that 
of nmLYZ. This may be due to the structural change in the snLYZ where Trp residues 
might have translocated to a more polar region. 
When, ANS-bound fluorescence measurement of ‘reconstituted snLYZ’ was 
recorded, the spectra clearly demonstrated a higher hydrophobicity (because higher 
ANS fluorescence intensity indicates higher surface hydrophobicity) than snLYZ-
TAM conjugate, which indicates a state where more non-polar residues of snLYZ 
were relocated on the surface (Fig.6.9) during drug release process.  
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Figure 6.9 Protein bound ANS fluorescence spectra of nmLYZ, snLYZ, snLYZ-
TAM and ‘reconstituted snLYZ’. The surface hydrophobicity of samples increased in 
the following order, snLYZ < snLYZ-TAM < ‘reconstituted snLYZ’. Some of the Trp 
residues on the surface of the ‘reconstituted snLYZ’ got exposed to ANS after the 
drug release from snLYZ, hence an increase in fluorescence intensity. All data were 
expressed as the mean of three readouts generated from the instrument. 
 
We also performed the similar experiment on snBLA-TAM. Fig 6.10 showed the Trp 
fluorescence spectra of snBLA-TAM and ‘reconstituted snBLA’. We observed an 
increase in fluorescence intensity of ‘reconstituted snBLA’ compared to snBLA-
TAM. Such result may be due to the release of the drug, TAM from the snBLA-TAM 
conjugate, resulting in a structural change of the ‘reconstituted snLYZ’. The resulting 
structural change induced the movement of Trp residues to a more non polar region or 
to the core of the protein nanostructure thereby increasing the intensity of 
‘reconstituted snLYZ’. 
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Figure 6.10 Tryptophan fluorescence spectra of nmBLA, snBLA, snBLA-TAM and 
reconstituted snLYZ. The drop in intensity of snLYZ, snLYZ-TAM and reconstituted 
snLYZ indicates translocation of Trp residues to a more hydrophobic region. All data 
were expressed as the mean of three readouts generated from the instrument. 
 
Further, the small amount of peak change observed in ‘reconstituted snBLA’ 
(Fig.6.10) might be due to structural change of snBLA induced by the drug release 
process.  
Further we wanted to observe the surface hydrophobicity character of snBLA-TAM 
and its ‘reconstituted state’ and accordingly, ANS bound fluorescence spectra was 
recorded. The snBLA-TAM bound ANS fluorescence intensity was found to reduce 
marginally compared to ‘reconstituted snBLA’ (Fig.6.11). This may be due to the 
slight change that occurred in ‘reconstituted snBLA’ following drug release which 
resulted in the translocation of the hydrophobic residues on to the surface of snBLA.  
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Figure 6.11 ANS fluorescence spectra of nmBLA, snBLA, snBLA-TAM and 
reconstituted snBLA. The surface hydrophobicity increased in the following order, 
nmBLA < snBLA-TAM < ‘reconstituted snBLA’< snBLA. All data were expressed 
as the mean of three readouts generated from the instrument. 
 
6.2.5 Cytotoxicity study of snLYZ-TAM 
 
It was essential to know the cytotoxic potential of drug-loaded snLYZ and post drug 
release state of snLYZ-TAM conjugate (referred as ‘reconstituted snLYZ’). It was 
understood that drug molecules were loaded through crosslinking with snLYZ, 
however, the release of TAM (~65% release) at low pH like 6.0 left a specific 
conformational state of snLYZ. Here, we examined the cytotoxic potential of 
‘reconstituted snLYZ’ in MCF-7 cells. In cells, reconstituted snLYZ might either be 
degraded or be reused as free snLYZ. However, here we realized that its anticancer 
potential must be investigated. 
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Therefore, in this section, the cytotoxicity potential of various samples like snLYZ, 
snLYZ-TAM and ‘reconstituted snLYZ’ was assessed in MCF-7 breast cancer cells 
and compared. In this experiment, the amount of snLYZ-TAM (used 4:1 ratio w/w) 
conjugate was used in an increasing manner, from 60 to 200 µg/ml in the conjugate.  
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Figure 6.12 Cell viability assay of free TAM, nmLYZ, snLYZ and snLYZ-TAM 
conjugates in MCF-7 cells. Three different snLYZ concentration (A) 60, (B) 100 and 
(C) 200 µg/ml along with TAM (15, 25, 50 µg/ml) were used with protein: TAM and 
maintained at 4:1 ratio. The increased amount of TAM in the conjugate increased the 
cytotoxicity in MCF-7 cancer cells. Statistically significant vs control group, ***p< 
0.001,*p<0.05 by One way ANOVA and post Tukey test. All data are expressed as 
Mean ± S.E.M, n = 3. 
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Fig. 6.12 A clearly demonstrated that at lower concentration of snLYZ (60 µg/ml) in 
snLYZ-TAM, the conjugate produced a better cell killing effect (72.55%) than the 
free snLYZ (64.91%). With the increase of snLYZ amount in conjugate (from 60 to 
100 µg/ml), the snLYZ-TAM demonstrated better cytotoxicity (85.64%) compared to 
free snLYZ (75%) (see Fig.6.12 B). However, at snLYZ concentration of 200 µg/ml 
(Fig. 6.12 C) in conjugate (where 50µg/ml TAM was used), the cell killing effect 
from both free snLYZ (91.73%) and snLYZ-TAM (91.99%) conjugate was found 
almost equal.  
NAC was incorporated in the media in order to validate the ROS mediated cell death. 
The presence of NAC reduced the cytotoxicity of all the formulations of snLYZ-TAM 
conjugate leading to the conclusion that the cytotoxicity of snLYZ-TAM was 
predominantly ROS based (Fig. 6.12).  
Further, we also assessed the cytotoxicity of reconstituted snLYZ in MCF-7 cells and 
compared with other formulations of snLYZ-TAM (see Fig. 6.13).  
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Figure 6.13 Effect of reconstituted samples of snLYZ on the cell viability of MCF-7 
cells and comparison of their cytotoxic effect with other formulations. The presence 
of NAC reversed the cytotoxicity of snLYZ in cancer cells, however, in case of 
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snLYZ-TAM it was however, in case of snLYZ-TAM it was observed to be partially 
reversed. All the data are expressed as Mean ± S.E.M, n = 3. 
 
From Fig.6.4 the non-cumulative drug release at pH 6 was found to be 64.82%. The 
post-drug release state of snLYZ-TAM is referred to as ‘reconstituted snLYZ’. We 
applied snLYZ-TAM conjugate where 100 µg/ml of snLYZ and 50 µg/ml of TAM 
(2:1, protein: drug) conjugated, to MCF-7 cells. The reason of using 2:1 ratio was to 
see the effect of higher TAM on cell killing in the formulation and to see the effect of 
reconstituted snLYZ. Since, the non-cumulative drug release is around 60 % at pH 
6.0, we calculated a release of 60% from 50 µg of loaded TAM i.e. 30µg. Hence, 30 
µg/ml of TAM was kept as control (see Fig.6.13).  
We observed that snLYZ-TAM conjugate demonstrated better cytotoxicity (91.29%) 
compared to snLYZ (79.39%) alone (Fig. 6.13). In the presence of NAC the 
cytotoxicity was reduced to only 29.22%.This fact clearly indicated that snLYZ had a 
major contribution (~62%) in the toxicity generated by snLYZ-TAM as TAM did not 
mediate ROS generation, while snLYZ solely generated ROS. However, since 
complete inhibition of cytotoxicity was not observed, a smaller (29%) contribution of 
TAM in the cytotoxicity produced by snLYZ-TAM cannot be ruled out. 
The results further showed that the ‘reconstituted snLYZ’ demonstrated comparable 
level of cytotoxic effect (29.22%) as like free TAM (26.16%), however with 
completely ROS-based mechanism as reflected from Fig 6.13. It is interesting to note 
that ‘reconstituted snLYZ’ produces similar levels of cytotoxicity with less amount of 
residual drug (10.5 µg/ml, ~ 35% drug retained) compared to free TAM (30 µg/ml). 
The reason was the crosslinked TAM molecules which were unreleased in the 
reconstituted snLYZ and hence, could not show the cytotoxic effect. 
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The fact indicated, residual TAM molecules in ‘reconstituted snLYZ’ had little 
contribution in cell killing compared to snLYZ in snLYZ-TAM and hence, the 
majority of the cytotoxic effect was due to the sole contribution of snLYZ. 
6.2.6 snBLA-TAM based design of various formulations 
We have already demonstrated increased cytotoxicity of snBLA nanoassembly in 
breast cancer cells. snBLA has already shown excellent drug release properties at 
acidic pH, however, TAM has potential toxicity problems at high doses. Therefore, we 
designed various low dose formulations of snBLA:TAM (1:1, 4:1 and 10:1 w/w ratio) 
for finding possible synergistic effect against breast cancer cells. The objective was to 
prepare a formulation with least hemolytic activity and enhanced cytotoxicity in 
cancer cells.  
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Figure 6.14 MTT based cell viability assay of snBLA, snBLA-TAM and TAM in 
MCF-7 cells at 24 h post administration. The ratio of snBLA: TAM used is 1:1 (w/w). 
The loading of the drug TAM in snLYZ increased the cytotoxicity at all doses. All 
data are expressed as Mean ± S.E.M, n = 3. 
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When we examined the cytotoxicity of snBLA-TAM (1:1) in MCF-7 cells, we 
observed increased toxicity at all doses of snBLA-TAM (1:1) compared to drug free 
snBLA (see Fig.6.14). This improved cytotoxic profile which may be due to the 
incorporation of low doses of TAM in the formulation snBLA-TAM (1:1) that 
probably acted in a synergistic manner along with snBLA.  
Further, since the drug TAM was released at an acidic pH, snBLA-TAM (1:1) might 
have released the fair amount of drug in the acidic environment of the cancer cells. 
TAM was released in the acidic environment of cancer cells which contributed to the 
toxicity. This process was followed by the toxic effect produced by snBLA in cancer 
cells. Contribution of both TAM and snBLA mediated cytotoxicity may be the reason 
behind the overall increase in the toxicity. 
In order to observe the change of cytotoxic effect by varying the drug loading in 
snBLA, we prepared three different formulation of ‘snBLA-TAM’ containing various 
ratios of protein to drug ratio such as 1:1, 4:1 and 10:1. We found that all formulations 
of snBLA-TAM (1:1, 4:1 and 10:1) exhibited higher cytotoxicity than snBLA alone 
(see Fig. 6.15).  
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Figure 6.15 MTT based cell viability assay of various formulations of snBLA-TAM 
in MCF-7 cells at 24 h post administration. snBLA-TAM formulations having 
snBLA: TAM ratios of 1:1, 4:1 and 10:1 were administered in MCF-7 cells. snBLA-
TAM (4:1) maximum cytotoxic effect. All data are expressed as Mean ± S.E.M, n = 3. 
 
Moreover, we observed highest cell killing potential induced by snBLA-TAM (4:1) 
that demonstrated more than 90 % cancer cell death of MCF-7 cells at 24 h at a 
snBLA concentration of 333.33 µg/ml (see Fig.6.15). 
The increase in cell killing activity must have generated from the drug, TAM in the 
formulation. The cell killing activity of snBLA-TAM (4:1) formulation showed 
higher toxicity than the formulation of snBLA-TAM (1:1). To understand the reason, 
we examined the cytotoxicity of the post-drug release state (reconstituted state) of 
each formulation. 
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Figure 6.16 MTT based cell viability assay of various reconstituted forms of snBLA-
TAM in MCF-7 breast cancer cells. The various ratios of the snBLA: TAM used were 
1:1, 4:1 and 10:1 (w/w). The reconstituted snBLA-TAM (4:1) demonstrated 
maximum cytotoxic effect. All data are expressed as Mean ± S.E.M, n = 3. 
 
From Fig 6.16 we observed that the ‘reconstituted snBLA’ having the snBLA:TAM 
ratio of 4:1 exhibited highest cytotoxicity in MCF-7 cells, followed by 1:1 and 10:1. 
The result clearly showed that the same amount of snBLA used with three different 
amount of TAM, the ‘reconstituted snBLA’ formulation and with optimal amount of 
snBLA in the ‘reconstituted snBLA’ (4:1) could generate highest cytotoxicity in 
MCF-7 breast cancer cells. Since, both protein assembly as well as chemotherapeutic 
drug were used in the formulation and both pre and post-drug release state was 
examined for evaluating the cytotoxicity in cancer cells, further assessment on the cell 
death mechanism should be performed. 
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6.2.7 Mechanism of cytotoxicity of reconstituted snBLA 
 
We found that the ‘reconstituted snBLA’ (4:1) (Fig 6.16) demonstrated highest 
cytotoxic effect in MCF-7 cancer cells (more than 90% cell death). To understand the 
mechanism of cell death by various formulations of snBLA-TAM and their 
reconstituted state, we performed cell viability assay in the presence of NAC (Fig 
6.17A and B). NAC is a ROS inhibitor and its administration would inhibit cell death 
due to ROS effect. 
We observed that with the increase of loaded TAM amount, the ROS contribution 
towards cell death was reduced, indicated TAM contribution that was not mediated by 
ROS. Since, TAM was present on the surface of snBLA, the contribution of ROS 
generated by snBLA will be minimal in snBLA-TAM compared to snBLA alone 
where the surface is exposed to generate ROS in cancer cells. 
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Figure 6.17 MTT assay based assessment of ROS mediated cell killing induced by 
various formulations of snBLA. (A) snBLA:TAM (1:1, 4:1 and 10:1). (B) 
Reconstituted snBLA (1:1, 4:1 and 10:1). The reconstituted snBLA demonstrated to 
snBLA alone. Statistically significant vs control group, ***p< 0.001 by One way 
ANOVA and post Tukey test. All data are expressed as Mean ± S.E.M, n = 3. 
 
However, in ‘reconstituted snBLA’ where 40% TAM was still retained but cannot be 
released, ROS-based death was found predominant (Fig. 6.15B), indicated the death 
caused by snBLA (reconstituted). Thus, we proved that snBLA-TAM (4:1) was the 
best formulation among all. Further we also wanted to evaluate its hemocompatibility 
in human erythrocytes. When we examined the effect of reconstituted snBLA in 
human erythrocytes, the reconstituted formulations did not show any hemolytic 
activity (see Supplementary Fig.S9), which proved its hemocompatibility.  
Such fact collectively confirmed a unique multifaceted character of snBLA which 
exhibited lethal activity against cancer, however turns inactive in snBLA-TAM 
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conjugate (as evidenced from Fig. 6.17A), and regains its cytotoxic activity in cancer 
cells in its reconstituted state (Fig. 6.17B). Therefore, such nanomaterials can be used 
both as therapeutic agent as well as drug delivery system simultaneously which can 
exhibit a highly efficient protein based therapeutic strategy in breast cancer. 
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Chapter 7 
Preparation and Characterization of GOns and BLA 
functionalized GOns 
7.1 Materials and Methods 
 
7.1.1 Materials 
Citric acid, bovine α-lactalbumin, glutaraldehyde (GTD, 25%), N-acetyl-L-cysteine 
(NAC) and fluorescein diacetate were purchased from Sigma-Aldrich, India. MTT [3-
(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide] assay kit, DMEM, 
fetal bovine serum, (FBS), DAPI, acridine orange,1-anilino napthalene-8-sulfonic 
acid (ANS), ethanol, sodium cacodylate, sodium hydroxide, ethanol, hydrochloric 
acid and sodium phosphate buffer were purchased from HiMedia India Pvt. Ltd. We 
used HPLC grade water in all the experiments. All other reagents were of analytical 
grade. All glassware used in the present study was purchased from Borosil, India. 
7.1.2 Methods 
 
7.1.2.1 Preparation of graphene oxide nanosheets (GOns) by pyrolysis of citric 
acid 
GOns was prepared directly by the pyrolysis of citric acid (CA) as described by Dong 
et al. (Dong et al., 2012), however with a little modification. Briefly, 2g CA was 
added into a 5ml test tube and heated at 200 0C using a microwave oven. About 5 min 
later, the CA attained a pale yellow liquid state and then to orange in 30 min. After 2 
h, a black solid mass was formed. The black solid mass was dissolved in 50 ml of 10 
mg/ml NaOH solution kept under constant sonication. The pH of the solution was 
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adjusted to 7.4 by the addition of HCl (1M). The solution was sonicated for 10 min 
before use. 
7.1.2.2 Preparation of BLA functionalized GOns (FGOns) 
FGOns was prepared with slight modification of the protocol described by Arroyo-
Maya et al (Arroyo-Maya et al., 2012). A volume of two ml of 2 mg/ml aqueous 
solution of BLA was stirred at 500 rpm using a magnetic stirrer at room temperature 
for 10 min followed by addition of 8 ml ethanol (desolvating agent) gradually at the 
rate of 0.5 ml/min. After desolvation, GOns was immediately added at equivalent 
concentrations of protein followed by the addition of glutaraldehyde to a final 
concentration of 0.1% and stirred continuously (500 rpm) at room temperature for 8 
h. The prepared nanoconjugate was purified by 3 cycles of centrifugation at 20,000 g 
for 30 min. Finally, the pellet was resuspended in 2 ml of deionized water. Field 
Emission Scanning Electron Microscope (FESEM) was used to determine the shape 
and morphology of the prepared FGOns. 
7.1.2.3 Preparation of acridine orange conjugated GOns and FGOns for 
observing the cellular uptake in cancer cells. 
The samples of GOns and FGOns are stirred in a solution containing acridine orange 
(20 µg/ml) respectively. Glutaraldehyde (GTD) was added to a final concentration of 
0.1% in both the solutions. Both the solutions were stirred for 4 h for the complete 
cross-linking process. At the end the samples were centrifuged at 20,000g for 20 min. 
The pellet was washed with Milli Q water. The centrifugation process was repeated 
four times for removing the residual GTD. The pellet containing GOns-acridine 
orange and FGOns-acridine orange were resuspended in Milli-Q water for further use. 
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7.1.2.3.4 Characterization of GOns and FGOns 
UV-Visible spectroscopic measurement was taken using10µg/ml of GOns solution in 
the wavelength range of 200-800nm. Using the excitation maxima from the UV-
Visible spectroscopy, fluorescence emission spectra were obtained using the same 
concentration of GOns in the range of 240-500 nm. The excitation and emission slit 
width were used at 10nm. The photoluminescence spectra of GOns were analyzed by 
exciting GOns from 300-500 nm keeping the slit width for excitation and emission at 
10 nm. 
7.1.2.3.4.1 Electron Microscope analysis 
High-resolution microscopic images of various samples were captured using Field 
emission scanning electron microscope (FESEM, NOVA NANO SEM 450). A 
volume of 10 µl of GOns and FGOns (1 mg/ml) was spread on a glass slide and dried 
in a desiccator. The glass slides with GOns and FGOns were fixed on a carbon-coated 
tape attached to the aluminium stub, after drying. The aluminium stub was placed in a 
gold sputtering unit for 30 s. The samples were subsequently placed in the FESEM 
(NOVA NANO SEM 450) sample chamber, and images were captured at a voltage of 
5 kV. 
7.1.2.3.4.2 Atomic Force Microscopy 
AFM imaging was carried out using a Bioscope Catalyst AFM (Bruker Corporation, 
Billerica, MA). GOns (10 µl of 1 mg/ml stock) was placed on a fresh mica sheet and 
dried under continuous flow of N2 gas. The mica sheets were gently washed with 
Milli-Q water. The mica sheets were dried in a desiccator overnight. The standard 
tapping mode was used for capturing the images of different samples. The nominal 
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spring constant of the cantilever used was 20-80 N/m, and a scan rate of 0.5 Hz with 
512 samples per line was used for imaging the samples.  
 
7.1.2.3.4.3 X-ray diffraction (XRD) and Raman spectra analysis 
XRD of GOns was analyzed by Rigaku made X-ray diffractometer with 
monochromatic CuKα, radiation (λ=1.5406 Å). Data were collected from 5° to 40° at 
a scan rate of 0.1° min-1. Raman spectra of GOns was recorded by a micro Raman 
setup equipped with an air cooled Ar+ laser (model 177-G1205, Spectra Physics, 
USA) at λ=532 nm laser power (1.7 mW), 50 x objective lens, 0.9 NA, as the 
excitation light source, a single monochromator (TRIAX 550, JY, France), and a 
CCD detector. Experiments were performed at 25ºC. 
7.1.2.3.4.4 DLS particle size and zeta-potential analysis 
The average particle size analysis and ζ-potential measurement of the aqueous 
suspensions of GOns and FGOns were performed in a Malvern Zetasizer Nano-ZS 
dynamic light scattering (DLS) analyzer. GOns (10 µl of 1 mg/ml stock) and FGOns 
were taken separately, each was diluted with 1990µl of deionized water, and applied 
to DLS for size analysis. 
7.1.2.3.4.5 Fourier Transform Infra-red (IR) spectroscopy 
The spectra were recorded using the ALPHA-FT-IR (BRUKER) spectrometer 
equipped with ATR accessory. A sample volume of 100 µl of native BLA, GOns and 
FGOns were used for analysis. The samples were analyzed at pH 7.0 in ATR mode. 
The spectral range was used between 4000 cm−1and 500 cm−1 with a resolution of 2 
cm−1 and 25 scans per spectrum. 
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7.1.2.3.4.6 Circular Dichroism (CD) and fluorescence measurement 
CD spectra of FGOns (GOns:BLA is 1:1 w/w %) was measured using a JASCO, 
Model J-1500 polarimeter with BLA as control. The solution was incubated for 1 h in 
20 mM sodium cacodylate buffer, pH 7.4. All the measurements were carried out at 
room temperature (25ºC) under a constant flow of N2. Each spectrum depicted the 
average of three accumulations recorded between wavelengths of 200 and 250 nm, 
with a 0.2 nm resolution, a bandwidth of 1.0 nm, a scan speed of 100 nm/min and a 
cuvette of path length of 0.1 cm.  
The buffer contribution was subtracted from each measurement. The CD spectrum 
was reported in mdeg (obtained from the instrument). The percentage of secondary 
structural components (α-helix, β-sheet and random coil) were calculated using the 
software provided along with the instrument. 
For fluorescence spectroscopy measurement, 20 mM sodium phosphate buffer at pH 
7.4 was used. The change in the fluorescence spectra of BLA samples was measured 
after 1h of incubation using a Perkin-Elmer LS-55 Luminescence Spectrometer at 
25°C. Excitation wavelength was kept at 290 nm. The tryptophan (Trp) fluorescence 
spectrum of BLA was recorded in the range of 300 to 400 nm. The excitation and 
emission slit widths were set at 5 and 10 nm, respectively. Background corrections 
were made with buffer without protein in all cases. 
To examine the surface hydrophobic character of FGOns, we measured protein-bound 
fluorescence of ANS. ANS is an anionic fluorescence dye that readily interacts with 
the hydrophobic residues of proteins and exhibits increased fluorescence. Hence, a 
higher amount of ANS bound fluorescence is a measure of the increase in surface 
hydrophobicity of the protein. Before measurement, the samples were incubated with 
ANS for 1 h. The samples were excited at 350 nm, and the ANS fluorescence was 
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measured in the range of 400 to 700 nm. The excitation and emission slit width were 
kept at 10 nm. 
7.5 Results and Discussion 
7.5.1 Synthesis of GOns and functionalized GOns (FGOns) 
GOns was prepared by controlled pyrolysis of citric acid. The different stages of GOns 
production were shown in Fig. 7.1A. FGOns was prepared by crosslinking of BLA 
with GOns using 0.1% glutaraldehyde (GTD). The different stages involving the 
preparation of GOns and FGOns are shown in Fig. 7.1B. 
 
Figure 7.1 Different steps in the preparation of (A) graphene oxide nanosheets 
(GOns) using controlled pyrolysis of citric acid. (B) GOns functionalization method. 
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7.5.2 Preparation of Acridine orange conjugated GOns and FGOns for 
observing the cellular uptake in cancer cells. 
The acridine orange conjugated GOns and FGOns were prepared as per the protocol 
mentioned in the “Materials and Methods section”. Acridine orange will add orange 
fluorescence to the GOns/FGOns-acridine orange conjugates and the fluorescence can 
be visually observed very easily using the fluorescent microscope and confocal 
microscope.  
7.5.3 UV absorbance, photoluminescence and fluorescence spectroscopy 
The UV-Vis spectroscopic measurement clearly revealed (Fig. 7.2A) a broad peak at 
230 nm that corresponds to the π- π * plasmon peak. The optical absorption of GOns is 
mainly dominated by the π- π * plasmon peak near 230 nm (Eda et al., 2010). A 
characteristic shoulder peak, which is usually present in the GOns spectra, was not 
identified in our results (see Fig.7.2A).  
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Figure 7.2 Characterization of GOns based on UV-Vis and fluorescence 
spectroscopy (A) UV-Vis absorption and fluorescence spectra of GOns synthesized 
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using controlled pyrolysis of citric acid. Both excitation and emission slit widths for 
fluorescence spectroscopy measurement was used as 10 nm each. (B) The 
photoluminescence spectra of GOns at various excitation wavelengths. All data are 
expressed as mean of three readouts generated from the instrument. 
This broadening of the peak at 230 nm and unidentifiable shoulder peak at 310 nm 
was mainly due to the formation of multi-layered GOns (Lai et al., 2012). The peak of 
GOns is normally sharp and prominent at 230 nm for single layered GOns, however, 
in our case, the GOns is 5 layer thick (Fig.7.3B) and hence a broad peak is obtained. 
The fluorescence spectrum was also obtained by exciting GOns at 230 nm. The 
fluorescence emission spectra shows the presence of two peaks at 318 and 440 nm 
(see Fig.7.2A) that are the characteristic fluorescence emission peaks of GOns 
(Kozawa et al., 2013).  The peaks observed close to 318 nm and 440 nm are not sharp 
and due to the formation of multilayered (05 layers) GOns (see Fig7.3B). Fig. 7.2 B 
shows the characteristic photo-luminescence spectra of GOns at various excitation 
wavelengths.  
7.5.4 AFM, FESEM imaging, XRD, Raman scattering DLS size distribution 
and zeta-potential measurement 
AFM results shown in Fig.7.3A revealed that the width of GOns was in the range of 
100-200 nm with an average height of 5.0 nm (Fig.7.3B) that is equivalent to almost a 
stack of five layers of single-layered GOns (Lai et al., 2012). The inset showed the 
height and 3D morphology of GOns. 
The AFM image shows the irregular shape of GOns with sharp edges. The fact was 
also supported by the FESEM images where we can easily see the sharp edges of 
GOns (see Fig.7.4A). 
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(A) (B)
 
Figure 7.3 Characterization of GO nanosheet (GOns) by AFM imaging. (A) AFM 
image of GOns. (B) 3D surface morphology of GO nanosheets. 
  
(A) (B)
 
Figure 7.4 Characterization of GO nanosheet (GOns) by FESEM imaging. (A) 
FESEM image of GO sheet. (B) FESEM images of functionalized GOns (FGOns) 
inset shows the magnified image of FGOns. 
The FESEM images of GOns (Fig.7.4 A) and FGOns (Fig.7.4 B) also confirmed the 
nanosheet formation with sharp edges of GOns and smooth edges of FGOns. 
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Figure 7.5 Characterization of GO nanosheet (GOns) by (A) Raman spectra of GOns; 
the G peak at 1580 cm-1 and the D peak at 1350 cm-1. (B) XRD analysis of GOns; the 
sharp diffraction peak for GOns was observed at 2θ = 10.800. 
Fig.7.5 A shows the typical Raman spectra of GOns. We observed that the G peak was 
at 1580 cm-1 and the D peak at 1350 cm-1. The Fig.7.5 B shows the XRD spectra in 
which the sharp diffraction peak for GOns was observed at 2θ =10.80°. XRD analysis 
is an important tool for the identification of different states of GOns. While 2θ ~10° is 
assigned for the oxidized state of GOns, 2θ ~ 23° is assigned for reduced GOns. 
The hydrodynamic size distribution of GOns showed the average particle size of 150 
nm in a size range of 122-190 nm (see Fig.7.6 A). However, functionalized GOns 
(FGOns) showed an average size of 300 nm in a range of 141-458 nm (see Fig.7.6 B). 
The size distribution closely matched with results obtained from FESEM and AFM 
images. In order to understand the stability of GOns and FGOns we measured the zeta 
potential of both in solution. The zeta potential value of both GOns and FGOns were 
estimated to be -31.2 mV and -39.6 mV, which indicated their stability in suspension. 
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Figure 7.6 Distribution of hydrodynamic diameter analysed by DLS particle size 
analyser of (A) GOns (122-190 nm), (B) FGOns (141-458 nm). 
 
FESEM images of FGOns clearly showed the formation of smooth edges of GOns 
(Fig. 7.4 A and B) using BLA coating. It has been already reported that the sharp 
edges of GOns caused the damage of bacterial membrane (Akhavan and Ghaderi, 
2010; Hu et al., 2010). FESEM images of synthesized GOns also showed sharp edges 
that can damage human cells including erythrocytes using a similar kind of 
mechanism. 
7.5.5 FTIR analysis of GOns and FGOns 
FTIR spectra of native BLA, GOns and FGOns were shown in Fig.7.7. The presence 
of various functional groups containing oxygen were confirmed for GOns at 3477 cm-1 
(OH stretching vibrations), at 1722 cm-1 (stretching vibrations from C=O, 
carbonyl/carboxy), at 1203 cm-1 (stretching vibrations from C-O, epoxy) and at 1042 
cm-1 (C-O stretching vibration, alkoxy) (Xu et al., 2008). In addition to these peaks, C-
O stretching vibration (1388 cm-1, carboxy) was also observed. 
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Native BLA (Fig. 7.7) showed the presence of characteristic peaks of Amide I and 
Amide II that typically exist in proteins. These peaks arise from the amide bonds that 
act as a link between the amino acids.  
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Figure 7.7 FTIR analysis based characterization of GOns, BLA and FGOns (BLA 
cross-linked GOns). The characteristics peaks for GOns, BLA and FGOns are 
observed. 
The Amide I signal produced due to mainly stretching vibrations of the C=O bond and 
C-N bond while Amide II band arose due to the bending vibrations of the N-H bond 
and fewer contributions coming from C-N and C-C  stretching vibrations. O-H 
stretching vibration was also observed at 3464 cm-1. FGOns sample upon analysis, 
revealed the loss of characteristic peaks of Amide I and Amide II along with the loss 
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of O-H stretching vibration (Fig.7.7). Comparing GOs and FGOns we observe that 
upon functionalization peaks for C-O (alkoxy, 1040-1046cm-1) and C-O stretch 
(carboxy, 1388cm-1) in GOns were missing in GOns possibly due to coating of BLA. 
Moreover, the loss of Amide I and Amide II peaks in FGOns may be due to the 
crosslinking with glutaraldehyde.  
Other peaks that were retained for GO were at 1046 cm-1 (C-O stretching vibration, 
alkoxy), at 1388 cm-1(carboxy) C-O stretching vibration and at 1722 cm-1 (stretching 
vibrations from C=O, carbonyl/carboxy). The information also confirmed the presence 
of both BLA and FGOns. 
7.5.6 Circular dichroism (CD) and Trp fluorescence spectroscopy of BLA in 
FGOns 
BLA is a small monomeric protein of 14 kDa molecular mass containing four Trp 
residues and four disulfide bonds (Engel et al., 2002). Therefore, BLA is a suitable 
candidate to study the conformational change using both CD, as well as fluorescence 
spectroscopy.  
Moreover, four disulfide bonds can provide stability to the structure, which also 
favours its use to functionalize GOns in biomedical applications. The CD spectra 
measured at far UV region i.e. 200 to 250 nm clearly showed the secondary 
structural change of BLA in FGOns (see Fig. 7.8).  
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Figure 7.8 Circular Dichroism based spectroscopy of (A) FGOns and (B) interaction 
of native BLA with GOns. Significant change in secondary structure was observed in 
FGOns and nmBLA treated with GOns. All data were expressed as the mean of three 
readouts generated from the instrument. 
 
The α-helix and β-sheet contents were also estimated using the software provided 
along with the instrument and shown in Table 7.1.  
 
Table 7.1 The change of BLA secondary structural components in FGOns samples 
measured by CD spectroscopy. 
BLA (0.3mg/ml) α-helix (%) β-sheet (%) 
BLA 26.5 10.3 
BLA in FGOns (BLA: GOns, 1:1, w/w %) 
14.4 35.9 
 
Substantial reduction of overall CD signal was observed associated with the gross 
increase in % of β-sheet (from 10.3 to 35.9%) and decrease in % of α-helix contents of 
BLA in FGOns (see Table 7.1). 
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Table 7.2 The change of BLA secondary structural components during interaction 
with GOns measured by CD spectroscopy. 
BLA ( 0.3 mg/ml) α helix (%) β -sheet (%) 
BLA 26.5 10.3 
BLA + GOns(1 µg/ml) 20 36 
BLA + GOns(5 µg/ml) 13.6 51.1 
BLA + GOns(10 µg/ml) 12.8 50.2 
BLA + GOns(20 µg/ml) 12.4 51.7 
BLA + GOns(50 µg/ml) 11.3 49.9 
 
 
The increase in β-sheet probably provided higher stability as obtained from zeta 
potential measurement. To understand the specific conformational change that took 
place in BLA due to crosslinking with GOns, we also monitored the physical 
interaction between free BLA and GOns (without GTD) using CD spectroscopy (see 
Fig. 7.8 B).  The experiment revealed the increase in % of β-sheet and decrease in % 
of α-helix contents (Table 7.2). However, overall CD signal was found higher than 
free BLA with β-sheet content as high as ~52% at 20 µg/ml of GOns concentration 
(see Table 7.2). Therefore, CD results concluded that crosslinking of BLA with GOns 
caused havoc overall structural change of BLA, which was different from the 
structural change induced to BLA during its physical interaction with GOns. 
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Figure 7.9 Tryptophan fluorescence measurement of (A) FGOns, and (B) The 
solution of native BLA with increasing concentrations of GOns. The drop in 
fluorescence intensity was due to translocation of Trp residues to a more hydrophobic 
region. All data were expressed as the mean of three readouts generated from the 
instrument. 
 
The drop in BLA fluorescence in FGOns (Fig.7.9A) and during interaction with 
increasing of GOns concentration compared to nmBLA also revealed their 
conformational change (see Fig.7.9 B) around the Trp residues.  
Such a decrease in the Trp fluorescence may be attributed to the translocation of the 
Trp residues on the surface of the protein to an environment having more polar 
residues which quenches the fluorescence. As the Trp fluorescence is directly 
contributed from the Trp residues present on the surface of the protein any increase in 
the number of Trp residues present on the surface of the protein may result in the 
quenching of the Trp fluorescence intensity. 
However, in Fig.7.9 B, no peak shift of the spectra was observed, indicating BLA 
fluorescence was quenched by GOns. In fact, it has already been reported that GOns is 
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a universal quencher, and it interacts with proteins through static as well as dynamic 
quenching (Li et al., 2012). 
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Figure 7.10 (A) Optimization of ANS concentration for fluorescence spectra of native 
BLA, and FGOns, and (B) Protein bound ANS fluorescence spectra of native BLA 
and FGOns. Small drop in surface hydrophobicity was observed in case of FGOns. 
All data were expressed as the mean of three readouts generated from the instrument. 
To understand the surface hydrophobic character of FGOns, extrinsic fluorescence 
using 1-anilino napthalene-8-sulfonic acid (ANS) was also performed. The optimized 
concentration of ANS was determined to be 90 µM (see Fig. 7.10A) which exhibited 
maximum fluorescence. Fig. 7.10B clearly showed that protein-bound ANS 
fluorescence intensity was reduced for FGOns compared to free BLA,which revealed 
that the surface hydrophobicity of FGOns was slightly less than the same amount of 
free BLA. This information also proved that the BLA functionalization of GOns 
conferred FGOns with increased water dispersibility. Therefore, collectively it can be 
concluded that crosslinking of BLA with GOns during the preparation of FGOns 
induced gross overall structural change of the protein. 
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Chapter 8 
Preparation and Characterization of ZnO nanoparticles and 
their functionalization with BLA 
 
8.1  Materials and Methods 
 
8.1.1 Materials 
 
 Bovine α lactalbumin (BLA), Glutaraldehyde (GTD, 25%) and Zinc nitrate 
hexahydrate were purchased from Sigma-Aldrich, India. Ethanol, Sodium 
cacodylate, sodium hydroxide and sodium phosphate buffer were purchased from 
HiMedia India Pvt. Ltd. We used Milli-Q water in all the experiments. All other 
reagents were of analytical grade. All glassware used in the present study was 
purchased from Borosil, India. 
8.1.2 Methods 
 
8.1.2.1 Preparation of ZnO (ZnONP): 
ZnONP was synthesized from zinc nitrate hexahydrate by wet chemical method with 
slight modifications (Nair et al., 2009). Zinc Nitrate hexahydrate (10mM) was 
sonicated in water to obtain a clear solution. NaOH (20mM) was added dropwise to 
the zinc nitrate solution with continuous stirring for 4-5 h. The precipitate formed 
was centrifuged at 10000 g for 10 min, washed three to four times, and collected 
after drying at 800C. The ZnONP was diluted to the desired concentration and 
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sonicated for 15 min at 100Hz before use. Although many expensive ZnONP are 
commercially available, however the detailed synthesis protocol are not available 
which is one of the major limitations of using the commercially available forms of 
ZnONP. Moreover, ZnONP upon prolonged storage in powdered form suffers from 
caking effect which results in the cake formation in the containers. Hence, we 
synthesized ZnONP using low-cost chemical synthesis method with slight 
modifications  
 
8.1.2.2 Preparation of Bovine α-lactalbumin conjugated ZnO nanoparticles i.e., 
Functionalized Zinc oxide nanoparticles (FZnONP): 
For the preparation of FZnONP, 4 mg of BLA was dissolved, in 2ml of deionised 
water. The solution was stirred for 5min at 500 rpm followed by addition of ethanol 
(8ml) dropwise with constant stirring. Immediately 4 mg of ZnONP was added 
followed by addition of glutaraldehyde (final concentration 0.1%). 
The contents were constantly stirred for 8 h at 500rpm. The solution was subjected to 
five cycles of centrifugation at 25000g for 30 min. The pellet formed was redispersed 
in 1ml of deionised water and stored at 40C for further use. 
 
8.1.2.3 Characterization of ZnONP and FZnONP by FESEM analysis 
High-resolution microscopic images of ZnONP and FZnONP, were captured using 
Field emission scanning electron microscope (NOVA NANO SEM 450). A volume 
of 10µl of ZnONP and FZnONP (1 mg/ml) was spread on a glass slide and dried in a 
desiccator. After drying, the glass slides with ZnONP and FZnONP were fixed on a 
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carbon-coated tape attached to the aluminium stub. The aluminium stub was placed 
in a gold sputtering unit for 30 sec. The samples were placed in the instrument 
sample chamber, and images were captured at a voltage of 5 kV. 
 
8.1.2.3.1 DLS particle size analysis and zeta-potential analysis 
The average particle size analysis and ζ-potential measurement of the aqueous 
suspensions of ZnONP and FZnONP were performed in a Malvern Zetasizer Nano-
ZS dynamic light scattering (DLS) analyzer. Ten microlitres of ZnONP and FZnONP 
was added with 1990µl of deionized water, and analysed for size analysis. 
 
8.1.2.3.2 FTIR analysis 
The FTIR spectra were recorded using the ALPHA-FT-IR (BRUKER) spectrometer 
equipped with ATR accessory. Samples of 100 µl of BLA (native), BLANP and 
FZnONP were analyzed at pH 7.0 in ATR mode. The spectral range was used between 
4000 cm−1and 500 cm−1 with a resolution of 2 cm−1 and 25 scans per spectrum. 
 
8.1.2.3.3 Circular Dichroism (CD), Tryptophan fluorescence (Trp) and ANS 
fluorescence measurement 
CD spectra of FZnONP, was recorded using a JASCO J-1500 CD spectrometer. To 
monitor the secondary structural changes of BLA, BLANP and FZnONP, we used 20 
mM sodium cacodylate buffer, pH 7.4 for the CD signal measurement under a 
constant flow of N2 gas. All the measurements were carried out at room temperature 
(25ºC). Each spectrum represented the average of three readouts recorded between 
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wavelengths of 200-250 nm, with a resolution of 0.2 nm, a bandwidth of 1.0 nm, a 
scan speed of 100 nm/min and a standard sensitivity using a cuvette of path length of 
0.1 cm. 
The buffer contribution was deductedfor each measurement. The CD spectrum was 
reported in mdeg (obtained from the instrument). The percentage  contents of  the  
different  secondary  structural components  (α-helix,  β-sheet  and  random  coil) 
were calculated using the software provided along with the instruments. 
We performed the fluorescence spectroscopy analysis to observe the conformational 
change of BLA, in FZnONP. For fluorescence spectroscopy measurement, 20 mM 
sodium phosphate buffer at pH 7.4 was used. The change in the fluorescence spectra 
was measured with a Fluorescence spectrometer at 25°C keeping the excitation 
wavelength at 290 nm.  
The Trp fluorescence emission spectrum of BLA was recorded in the range of 300 to 
500 nm. The excitation and emission slit widths were set at 10 nm. The samples were 
analyzed in quartz cuvettes (1cm x 1cm). Background corrections were made with 
buffer without protein in all cases. 
 
8.1.2.4 Stability analysis under varying conditions of temperature and pH: 
 
The stability analysis of FZnONP was performed using CD, Trp and ANS 
fluorescence spectroscopy with varying temperature and pH. While CD signal is an 
indicative of secondary structure contents, fluorescence spectroscopy provides 
conformation change around Trp and surface hydrophobicity.  
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The thermal stability analysis of FZnONP across a temperature range of 20-80 0C 
was performed in a CD spectrometer. The thermal stress may cause the change in the 
conformation of the protein layer over ZnONP in FZnONP. Both Trp and ANS 
fluorescence of FZnONP was measured in a temperature range of 20-80 0C. Rest of 
the procedure for performing the CD, Trp and ANS fluorescence spectroscopy was 
as mentioned in section 8.5.3. 
Hence, to study secondary structural change in the protein layer over ZnONP due to 
increased thermal stress, CD and fluorescence spectroscopy was performed. To assess 
the pH dependent stability of FZnONP the CD spectrum was also recorded by varying 
the pH of the buffer in the pH range of 3-10. The Trp fluorescence was measured in a 
pH range of 3.0 to 10 for FZnONP. Rest of the procedure for performing the CD, Trp 
and ANS fluorescence spectroscopy remains same as mentioned in section 8.5.3. 
 
8.2 RESULTS AND DISCUSSION: 
 
8.2.1 Preparation and Characterization of ZnO nanoparticles (ZnONP) and 
FZnONP: 
The FESEM images of the synthesized ZnONP showed a particle size in the range of 
100- 250 nm (see Fig.8.1A). The AFM image of ZnONP also showed the particle size 
in the range of 100-200 nm(see Fig.8.2).FZnONP prepared by the crosslinking of 
BLA with ZnONP (100-250nm) and the size was found to be 500 nm (see Fig.8.1B).  
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(A) (B)
 
Figure 8.1 Characterization of size and shape using FESEM images of (A) ZnONP, 
(B) FZnONP conjugates 
 
Figure 8.2AFM image of ZnONP, inset shows the 3D morphology of ZnONP. 
 
8.2.2 DLS particle size and Zeta potential analysis 
 The DLS particle size analysis of ZnONP and FZnONP as shown in Fig.8.3 (A) and 
(B) showed the average hydrodynamic size as 295 and 460 nm respectively. The DLS 
results also supports the FESEM- based size distribution. To understand the stability 
zeta potential was also measured. The zeta potential value of ZnO and FZnONP was 
estimated to be -48 and -25mV respectively. 
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Figure 8.3 DLS particle size analysis of various samples in suspension (A) ZnONP 
and (B) FZnONP. 
8.2.3 FTIR analysis: 
Fig 8.4 shows the FTIR spectrum of native BLA, FZnONP and ZnONP showed the 
characteristic peaks of Amide I and Amide II that normally exist in proteins. 
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Figure 8.4 FTIR spectrum of Native BLA, FZnONP and ZnONP. Inset shows the 
spectra between 1400 – 1800 cm-1 highlighting the Amide I and Amide II peaks. 
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These peaks are due to the amide bonds that act as a link between the amino acids. 
The Amide I signal develops due to the stretching vibrations of the C=O bond and C-
N bond while Amide II bondgenerates due to the bending vibrations of the N—H 
bond and minimal contributions to the peak also come from C-N and C-C  stretching 
vibrations. The presence of prominent Amide-I and Amide-II peaks in the FZnONP 
sample confirmed the presence of cross-linked protein.  
8.2.4 Circular Dichroism (CD), Trp fluorescence and ANS fluorescence 
measurement: 
CD spectra of both nmBLA (0.2 mg/ml) and FZnONP were recorded based on the 
protocol mentioned in the ‘Materials and Methods’ section. The CD spectral analysis 
provides information about the secondary structural contents of the protein.  
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Figure 8.5 Characterization of nmBLA and FZnONP with respect to its 
conformational state analyzed by the CD spectra of nmBLA and FZnONP. Significant 
change in the secondary structure was observed for FZnONP. All data were expressed 
as the mean of three readouts generated from the instrument. 
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The percentage of secondary structural components such as α-helix, ß-sheet of the 
protein and its various conjugated states was estimated by the software provided along 
with the instrument. From (Fig.8.5) it was found that FZnONP contains reduced 
amount of α-helix and an increased amount ofβ-sheet and turns(see Fig.8.5).The 
increase of ß- sheet here has a lot of importance. It indicates higher stability in the 
FZnONP. 
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Figure 8.6 Trp fluorescence spectra of BLA and FZnONP. The drop in fluorescence 
intensity of FZnONP was due to translocation of Trp residues from the surface of the 
protein to the core of the protein or to a more hydrophobic region. All data were 
expressed as the mean of three readouts generated from the instrument. 
 
Such, a change in the secondary structural components is bound to induce a change in 
Trp fluorescence intensity. The Trp fluorescence measurement of nmBLA and 
FZnONP was shown in Fig.8.6, which clearly showed a huge drop in the fluorescence 
intensity of BLA in FZnONP indicating that the Trp residues were moved to the 
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surface of the protein and in proximity of solvent molecules. Alternatively, they might 
have moved to some location of  higher polar groups and  hence fluorescence was 
quenched. Moreover, it might be possible that the presence of ZnONP could have 
quenched the fluorescence of Trp residues of BLA in FZnONP. 
Based on the results of the Trp fluorescence measurements of native BLA and 
FZnONP, we performed ANS fluorescence measurements to observe the suface 
hydrophobic character of FZnONP. 
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Figure 8.7 ANS fluorescence spectra of nmBLA and FZnONP. The surface 
hydrophobicity of FZnONP was reduced compared to nmBLA indicated a structural 
change at the surface. All data were expressed as the mean of three readouts generated 
from the instrument. 
 
The ANS fluorescence measurements also demonstrated a drop in fluorescence 
intensity of ANS in FZnONP compared to native BLA as shown in Fig.8.7.The result 
clearly indicates a drop in surface hydrophobiciity compared to native BLA. This 
result also supported our claim that the specfic structural change occured in the 
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surface coated BLA which has resulted in the drop in surface hydrophobicity. It also 
supports our previous hypothesis that Trp residues in FZnONP moved to a location of 
highly hydrophobic in character. 
8.2.5 Stability Analysis due to varying temperature and pH 
8.2.5.1 Thermal Stability 
The CD signal remained stable for FZnONPcompared to nmBLA  in a temperature 
range of 20-80 0C indicating increased stability for FZnONP compared to their native 
forms where we observed a clear variation in the CD signal indicating instability (Fig. 
8.8 A, B and C).  
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Figure 8.8 Thermal stability analysis by CD spectroscopy of (A) native bovine α-
lactalbumin (nmBLA), (B) Functionalized Zinc oxide nanoparticle (FZnONP) and (C) 
170 
 
Comparison of the change in molar ellipticity of nmBLA and FZnONP at 222nm (α-
helix). All data were expressed as the mean of three readouts generated from the 
instrument. 
 
However, beyond a certain level of thermal stress the protein suddenly deviates from 
the natural CD signal as observed in nmBLA (see Fig.8.8 A and C).The overall 
change in the CD signal at 222 nm is shown in Fig. 8.8C. We have choosen the CD 
signal at 222 nm for comparison between nmBLA and FZnONP since, it represents 
the signal from the α- helix region . Moreover, the region around the α- helix shows 
visible change in signal intensity which can be extrapolated to obtain a line graph 
between Temperature and CD signal. 
In order to assess the thermal stability of snBLA and FZnONP we also measured the 
Trp fluorescence at varying temperature conditions. We found a drop in Trp 
fluorescence for nmBLA and FZnONP (Fig.8.9 A, B and C).  
The increased drop in fluorescence of the nmBLA and FZnONP due to increase in 
temperature suggests that the Trp residues present on the surface moved from the 
surface of the protein to the core of the protein structure or the Trp residues moved to 
region surrounded by hydrophobic residues. 
Since, the Trp residues directly contribute to the Trp fluorescence, any decrease in the 
number of Trp residues on the surface of the of the protein would cause a decrease in 
the overall fluorescence intensity. Such a change in Trp fluorescence is also an 
indicative of structural change and the environment around the Trp residues present 
on the surface of the protein.  
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Figure 8.9 Thermal stability analysis by measurement of Trp fluorescence 
spectroscopy of (A) native bovine α-lactalbumin (nmBLA), (B) Functionalized Zinc 
oxide nanoparticle (FZnONP) and (C) Comparison of the change in Trp fluorescence 
of nmBLA and FZnONP. All data were expressed as the mean of three readouts 
generated from the instrument. 
 
ANS is a surface hydrophocity marker for proteins and usually used for the indirect 
measurement of the surface hydrophobicity on the surface of the protein. The increase 
in protein bound ANS fluorescence is an indicator of increase in surface 
hydrophobicity of the protein.  
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The protein bound ANS fluorescence for nmBLA showed that with increase in 
temperature the surface hydrophobicity of native protein deccreased indicating 
deccreased in surface hydrophobicity (see Fig 8.10 A and C). 
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Figure 8.10 Thermal stability analysis by measurement of ANS fluorescence 
spectroscopy of (A) native bovine α-lactalbumin (nmBLA), (B) Functionalized Zinc 
oxide nanoparticle (FZnONP) and (C) Comparison of the change in Trp fluorescence 
of nmBLA and FZnONP. All data were expressed as the mean of three readouts 
generated from the instrument. 
 
The results indicate that with the increase in temperature structural changes occured 
on the surface, of the native protein. Such a change on the surface of the protein may 
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be due to the weakening of the hydrogen bonds present in the protein. The increase in 
surface hydrophobicity is also a protective mechanism that protects the protein against 
thermal stress (Gromiha et al., 2013).  
However, a decrease in the surface hydrophobicity with increase in temperature is an 
indication of decrease in stability as observed in nmBLA(see Fig.8.10 A and C). 
FZnONP demonstrated a stable ANS fluorescence intensity till 800C (see Fig 8.10 B 
and C) indicating that there was no change in the surface hydrophobicity and 
remained stable.  
8.2.5.2 Stability against varying pH 
The CD signal remained stable for FZnONP compared to nmBLA (Fig. 8.11 A, B and 
C) in a pH range of 3-10. This indicates increased stability for FZnONP compared to 
the nmBLA where we observed a clear variation in the CD signal indicating 
instability.  
The native proteins change their structure in response to pH stress so that they can 
maintain their stability, however beyond a certain level of pH related stress the protein 
looses its native conformational state (see Fig.8.11 A and C). 
The overall change in the CD signal at 222 nm is shown in Fig. 8.11C. We have 
chosen the CD signal at 222 nm for comparison between nmBLA and FZnONP since, 
it represents the signal from the α- helix region . Moreover, the region around the α 
helix shows visible change in signal intensity which can be extrapolated to obtain a 
line graph between pH and CD signal. 
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Figure 8.11 pH stability analysis by CD spectroscopy of (A) native bovine α-
lactalbumin (nmBLA), (B) Functionalized Zinc oxide nanoparticle (FZnONP) and (C) 
Comparison of the change in molar ellipticity of nmBLA and FZnONP at 222nm (α-
helix). All data were expressed as the mean of three readouts generated from the 
instrument. 
 
The Trp fluorescence intensity of nmBLA showed variable intensity with increase in 
pH, however, the Trp fluorescence intensity of FZnONP had subtle variations but was 
observed fairly constant (Fig. 8.12 A, B and C). Such changes in nmBLA was due 
change in the ionization state of the charged amino acids, which caused the spectral 
differences, (Kwaambwa and Maikokera, 2008).  
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Figure 8.12 pH stability analysis by measurement of Trp fluorescence spectroscopy 
of (A) native bovine α-lactalbumin (nmBLA), (B) Functionalized Zinc oxide 
nanoparticle (FZnONP) and (C) Comparison of the change in Trp fluorescence of 
nmBLA and FZnONP. All data were expressed as the mean of three readouts 
generated from the instrument. 
 
The protein bound ANS fluorescence for native BLA clearly show that the surface 
hydrophobicity of native BLA decreased rapidly with increase in pH (see Fig. 8.13 A, 
B and C) indicating instability, whereas FZnONP showed no change in its FZnONP 
bound ANS fluorescence intensity indicating increased stability.  
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Figure 8.13 pH stability analysis by measurement of ANS fluorescence spectroscopy 
of (A) native bovine α-lactalbumin (nmBLA), (B) Functionalized Zinc oxide 
nanoparticle (FZnONP) and (C) Comparison of the change in Trp fluorescence of 
nmBLA and FZnONP. All data were expressed as the mean of three readouts 
generated from the instrument. 
 
The results clearly indicate that the surface hydrophobic character of nmBLA 
decreases rapidly and for FZnONP remains intact with an increase in pH. The protein 
bound ANS fluorescence for FZnONP and nmBLA clearly show that the surface 
hydrophobicity of nmBLA decreased rapidly with increase in pH (see Fig. 8.13 A, B 
and C) indicating instability, whereas FZnONP showed no change in its FZnONP 
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bound ANS fluorescence intensity indicating increased stability. The results clearly 
indicate that the surface hydrophobic character of nmBLA decreases rapidly and for 
FZnONP remains intact with an increase in pH.  
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Chapter 9   
Biocompatibility and Cell Viability Assays of            
Graphene oxide nanosheets (GOns) and Zinc oxide 
nanoparticle (ZnONP) 
9.1 Materials and Methods 
 
9.1.1 Materials 
Triton-X and Sodium Chloride were purchased from Sigma-Aldrich, India. MTT 
assay kit, Ethanol, DMEM, Fetal bovine serum (FBS), antibiotics, disodium EDTA 
,DAPI, Fluorescein diacetate, HiMedia India Pvt. Ltd. Milli-Q water was used in all 
the experiments. T-25 flasks, 96 well plates and all other plasticwares were purchased 
from Tarsons Pvt. Ltd. MCF-7, MDAMB-231 (Breast cancer cell line), HaCaT, 3T3 
cells were procured from NCCS, Pune, India. All the glasswares used in the study 
were purchased from Borosil, India. All other reagents were of analytical grade. 
 
9.1.2 Methods 
 
9.1.2.1 Hemolysis assay 
A volume of 5ml of  B +ve human blood was collected by an expert medical 
practitioner.Blood was collected in a centrifuge tube containing 2 mg of disodium 
EDTA (anti-coagulant). The contents were gently resuspended and centrifuged at 
1000 g for 10 min. The supernatant was removed and the erythrocyte collected at the 
bottom was washed three times by gentle resuspension with 10 times the volume of 
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pyrogen-free saline (0.9% NaCl). The solution was further centrifuged at 1000 g for 
10 min at room temperature.  
The erythrocyte pellet was gently resuspended in normal saline and was diluted to 
0.8% (v/v). The suspended erythrocyte solution (3 ml) was placed in sterile glass 
vials, and various test samples were administered to evaluate their hemolytic 
potential. Triton-X (1%) was used as a positive control and erythrocyte suspension 
treated with none were used as a negative control.  
The absorbance of the hemoglobin released was measured at 405 nm. The percentage 
hemolysis was calculated from the absorbance values with respect to Triton X-1% 
(Positive control) at 1 h. FESEM and phase-contrast microscopic images of human 
erythrocytes treated with GOns and FGOns were also captured for analysis. For 
ZnONP and FZnONP, FESEM images were also analyzed for observing the extent of 
erythrocyte damage or percentage hemolysis. 
9.1.2.2  Cellular uptake of GOns and FGOns 
Both GOns and FGOns-acridine orange conjugates were administered to the MCF-7 
cells and the cellular uptake of GOns and FGOns was observed at the end of 12 h post 
administration. At the end of 12 h DAPI (blue fluorescence) and ﬂuorescein diacetate 
(green ﬂuorescence for the cytoskeletal component) was added to the sample cells to 
visualize the cells. The samples were analysed using fluorescence and confocal 
microscopy. 
9.1.2.3 Cytotoxicity study 
The cytotoxicity of GOns and FGOnswere assessed against two human Breast cancer 
cell lines (MCF-7 and MDAMB-231) and two normal cell lines, HaCaT (human 
keratinocyte cell line) and 3T3 (murine fibroblast cells) using MTT assay.For 
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ZnONP and FZnONP the cytotoxicity as well as cytocompatibility assay was 
performed in MDAMB-231 cells and HaCaT cells.All the cells were cultured in 
DMEM (Dulbecco’s Minimum Essential Medium) containing 10% foetal bovine 
serum. Cells were grown in T-25 flasks that were incubated at 370C in a humidified 
5% CO2 incubator. The cells were grown to 80% confluence, trypsinized followed by 
seeding at a density of 1x104 cells/ml.  
The cells were seeded in a 96 well plate containing 100 µl of DMEM in each well 
and allowed to proliferate for 24 h. GOns, FGOns, ZnONP and FZnONPwere 
administered to the cells and cytotoxicity was evaluated by MTT assay at the end of 
next 24 h. MTT (10 µl of 5 mg/ml stock) was added 6 h before the end point.  
In the end, media was removed, and 100 µl of DMSO was added to dissolve the 
formazan formed and the absorbance was measured at 595 nm. The absorbance 
values were recorded, and percentage cell viability of the cells was calculated from 
the absorbance values and the result was plotted. Reactive oxygen species (ROS) 
inhibitor, N-acetylcysteine (NAC) with 2mM final concentration was also 
administered to confirm ROS-based cell death.  
9.2 Results and Discussion 
 
9.2.1 Hemolysis assay for GOns, FGOns, ZnONP and FZnONP 
We performed the hemolysis assay of GOns as well as FGOns for evaluating their 
effect on human erythrocytes. We used human erythrocytes with normal saline as the 
negative control and 1% Triton-X as a positive control. Fig. 9.1A and B showed the 
hemolytic propensity of GOns and FGOns.  
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Figure 9.1 Hemolysis assay of (A) GOns and (B) FGOns. FGOns demonstrates 
excellent hemocompatibility compared to GOns. All data were expressed as Mean ± 
S.E.M, n = 3. 
The results clearly revealed a high hemolytic activity of GOns beyond 10 µg/ml 
concentration (Fig. 9.1A) while FGOns exhibited negligible hemolytic potential (Fig. 
9.1 B) at the same concentration and less than 5% hemolysis was observed at 333 
µg/ml of GOns concentration in FGOns. 
Moreover, noticeable damage of erythrocytes was observed in FESEM images of 
GOns treated erythrocytes sample (see Fig. 9.2 B) while FGOns treated sample (see 
Fig.9.2 C-F) showed intact erythrocytes. The image of normal erythrocyte was 
shown in Fig. 9.2 A as control. 
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Figure 9.2 FESEM images of erythrocytes treated with various samples. (A) 
Control; erythrocytes administered with none. Administered with (B) 15µg/ml of 
GOns (C) administered with 15µg/ml of FGOns (GOns and BLA was 1:1 w/w). 
(D) 66 µg/ml FGOns, (E) 133 µg/ml FGOns and (F) 333 µg/ml FGOns. FGOns 
demonstrates excellent hemocompatibility compared to GOns. 
 
When erythrocytes were treated with 15 µg/ml of GOns at different periods such as 
15, 30 and 60 min, the microscopic images (Fig.9.3) showed the initiation of 
erythrocyte damage after 15 min of GOns administration. Cell shrinkage was also 
found associated with the initiation of erythrocyte damage followed by the gradual 
disintegration of cells. 
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Figure 9.3 Microscope images of human erythrocytes exposed to GOns (15 µg/ml) at 
different time points. (A) Control at 0 min, (B) 15min, (C) 30 min and (D) 60 min. 
Magnification is (800X). GOns induces visible damage to human erythrocytes. 
 
Here, we demonstrated the GOns-mediated hemolysis of erythrocytes. Although 
numerous reports demonstrated the evidence of GOns-based hemolysis, no specific 
reason was clearly mentioned or explained behind hemotoxicity. However, ROS-based 
damage of erythrocytes may be one of the causes. Moreover, studies of GO-based 
treatment on few bacteria also reported the cell death due to sharp edges of GOns 
(Akhavan and Ghaderi, 2010). Our experimental results clearly demonstrated that the 
protein-coated GOns (FGOns) prevented the hemolysis of human erythrocytes.  
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Based on our results, we proposed a model how GOns and its functionalized form 
caused damage to human erythrocytes (Fig 9.4). 
 
Figure 9.4 Schematic representation of the interaction of GOns and FGOns with 
human erythrocytes: Step (1) GOns come in contact with erythrocytes. Step (2) 
GOns attach on the surface of erythrocytes and cause haemolysis if the 
concentration of GOns is greater than 30 µg/ml. Step (3) GOns attach on the 
surface of erythrocytes and do not cause haemolysis if the concentration of GOns 
is less than 30µg/ml. Step (4) FGOns nanosheets do not interact with RBC’s 
hence, insignificant haemolysis. 
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We also performed the hemolysis assay for ZnONP and FZnONP for assessing the 
hemocompatibility in human erythrocytes.  
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Figure 9.5 Hemolysis assay of (A) ZnONP, (B) FZnONP. FZnONP shows enhanced 
hemocompatibility compared to ZnONP alone. All data were expressed as Mean ± 
S.E.M, n = 3. 
 
The results of the hemolysis assay for ZnONP and FZnONP (see Fig.9.5 A and B) 
clearly revealed that ZnONP at concentrations of 300 µg/ml and 600 µg/ml, caused 
7.7 % and 75.3 % haemolysis of human erythrocytes respectively. However, the BLA-
187 
 
ZnONP exhibited no hemolysis till 600 µg/ml. The results clearly established the 
hemocompatibility of ZnONP till 160 µg/ml and BLA-ZnONP till 600 µg/ml.  
9.2.2 Cellular Uptake of GOns and FGOns 
 
To observe the cellular uptake of GO samples, we performed the ﬂuorescence 
imaging of MCF-7 cancer cells. Fluorescent dyes such as DAPI (blue ﬂuorescence for 
the nucleus), ﬂuorescein diacetate (green ﬂuorescence for the cytoskeletal component) 
and acridine orange (FGOns) were used for ﬂuorescence imaging. At the end of 12 h 
post-administration of FGOns-conjugated acridine orange, we observed the 
appearance of FGOns particles exhibiting orange ﬂuorescence inside the cytoplasm of 
MCF-7 breast cancer cells (see Fig. 9.6A–E).  
When the image of the same sample was analyzed by confocal laser scanning 
microscopy it showed the cytoplasm containing granular particles exhibit orange 
ﬂuorescence (see Fig. 9.6H and I). Therefore, the results conﬁrm the cellular 
internalization of FGOns in MCF-7 cancer cells.  
When we performed the experiments with GOns, we observed ﬂuorescence image 
exhibiting orange ﬂuorescence inside the cytoplasm (see Fig. 9.6G). However, such 
cells were found damaged (Fig. 9.6F) and the amount of fluorescence from the cells 
was quite low compared to FGOns in MCF-7 cells. Thus, we hypothesized that GOns 
perhaps was not uptaken by the intact cells, however, it ﬁrst damaged the cell 
membrane due to its surface geometry (sharp edges) using strong shear forces that 
subsequently induced intracellular ROS generation via mitochondria and cause cell 
death.  
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Figure 9.6 Imaging of MCF-7 cells at 12 h post administration of FGOns. (A) Phase 
contrast image (B) Cells stained with ﬂuorescein di-acetate (green ﬂuorescence) 
highlighting cytoplasmic boundary (C) Cells stained with DAPI (blue ﬂuorescence) 
highlighting the intact nucleus (D) Acridine orange cross-linked FGOns (E) Merged 
images of A–D. Confocal microscopy images of cellular uptake (12h post 
administration) of GOns and FGOns cross-linked with acridine orange (F) Merged 
Phase contrast image showing the degraded cytoplasmic regions treated with 
GOns.(G)The image highlighting the cellular uptake of GOns (H) merged phase 
contrast image showing a comparatively intact cytoplasmic boundary of the MCF-7 
cells treated with FGOns.(I) The image shows the cellular uptake of FGOns. 
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Earlier in the hemolysis section, we also demonstrated a similar kind of mechanism of 
action for GOns damaged erythrocytes (Fig. 9.2B) and such mechanism also supports 
our current hypothesis of cellular damages of induced by GOns in cancer cells. The 
overall results also revealed that the cellular internalization of any molecule is not 
only size dependent, but also shape and surface geometry dependent. 
The cellular uptake study also revealed that the cellular damage induced by GOns was 
faster than FGOns. However, as we observed the mechanism of action by which both 
GOns and FGOns generated their toxicity in cancer cells were different. It also 
signiﬁes the fact that the preparation of a stable protein functionalized GOns (FGOns) 
assist the successful uptake of FGOns by cancer cells towards ROS generation that 
consequently cause cell death.  
9.2.3 Cytotoxicity study of GOns, FGOns, ZnONP and FZnONP 
We already observed the high hemolytic potential of GOns, however excellent 
hemocompatibility was noticed for FGOns. Such a fact can allow us to use a high 
concentration of GOns in FGOns in various biomedical applications. Hence, we 
performed their cytotoxicity study on human Breast cancer cell lines MCF-7 and 
MDAMB-231.  
We found that GOns induced more than 85 % cytotoxicity to the cells within 24 h, 
however, the toxicity was reduced to 21% in the presence of NAC (2 mM) a ROS 
inhibitor (see Fig.9.7 A and C). 
Therefore, this ~64 % reduction in toxicity was due to the ROS-mediated cell death, 
which also proves that rest 21% cytotoxic effect is due to some other mechanism, 
which we assumed to be the shear stress-mediated membrane damage induced to 
cancer cells by sharp edges of GOns. 
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Figure 9.7 Relative cytotoxicity of GOns and FGOns in various cancer. (A) and (B) 
MCF-7 cells; (C) and (D) MDAMB-231 cells. The cell cytotoxicity was presented as 
the percentage of mean value. Statistically significant vs. control group, *** p < 0. 
001 by One way ANOVA and post Tukey test. All the data were expressed as Mean ± 
S.E.M, n = 3. 
 
When FGOns was administered to cancer cells, it showed a maximum cytotoxicity of 
~90% which decreased to 8% due to the presence of 2mM NAC (see Fig.9.7B and D). 
This reduction in cytotoxicity of 82% was solely due to the ROS inhibitor NAC.  
Similar results were also found in the caseof MDAMB-231 cells treated with GOns. It 
showed a maximum cytotoxicity of 88% at 12 µg/ml. However, in the presence of 
NAC, the cytotoxicity was reduced to 19%, revealed a ROS-based death (see 
Fig.9.7A). Rest 19% cell death perhaps occurred due to shear stress that induced 
membrane damage mediated by the sharp edges of GOns. Similar result was also 
observed in MDAMB-231 cells (Fig.9.7C).  
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The effect of GOns and FGOns in normal human cells like HaCaT (human 
keratinocyte cells) and murine fibroblast cells 3T3 was also assessed. The MTT assay 
of GOns revealed dose-dependent increase of cytotoxicity with more than 50% and 
45% cell killing at a GOns concentration of 30 µg/ml in HaCaT and 3T3 cells, 
respectively. The administration of NAC in cell culture medium resulted in the 
inhibition of HaCaT and 3T3 cell death significantly (Fig. 9.8A and C) indicating a 
ROS-mediated cytotoxicity induced by GOns.  
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Figure 9.8 Relative cytotoxicity of GOns and FGOns in various cancer and normal 
cells. (A) and (B) HaCaT cells (C) and (D) 3T3 cells. The cell cytotoxicity was 
presented as the percentage of mean value. Statistically significant vs. control group, 
*** p < 0.001 by One way ANOVA and post Tukey test. All the data were expressed 
as Mean ± S.E.M, n = 3. 
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However, after the addition of NAC, low cell death in HaCaT and 3T3 cells was 
observed, which revealed the existence of a second mechanism of cell death and we 
anticipated that to be the shear force induced by sharp edges of GOns.  
In our second set of experiments, we evaluated the cytotoxicity of FGOns in normal 
cells like HaCaT and 3T3 cells (see Fig. 9.8 B and D). FGOns demonstrated a 
maximum cytotoxicity of 17 % and 13.4% at a concentration of 30 µg/ml in HaCaT 
and 3T3 cells respectively, which is almost 35.4 % and 31.99 % less cytotoxic 
compared to GOns at a similar dose. Although, 30µg/ml FGOns (GOns/BLA is 1:1 
w/w %) contains an equal amount of GOns and BLA, the cytotoxicity induced by 
FGOns reduced significantly. Such a decrease in cytotoxicity was perhaps due to the 
surface coating of GOns using BLA molecules.  
Therefore, we assumed that the surface character of GOns and its sharp edges were 
probably responsible for causing such toxicity to HaCaT and 3T3 cells that were 
significantly suppressed when GOns was functionalized by BLA. 
In both the cases of MCF-7 and MDAMB-231 cells, the surface of GOns was coated 
with protein, hence, the only source of ROS generation was due to the specific folded 
state of BLA. The specific conformational variant of BLA in FGOns perhaps 
generated sufficient ROS for killing the cancerous cells.  
This may be due to the fact that the cancerous cells were already in a stressed state 
utilizing all the superoxide dismutase (SOD) and glutathione-s-transferase (GST) for 
protecting the cell. The cancerous cells were not able to withstand the extra burden of 
ROS generated due to the specific folding variant of BLA in FGOns. 
From the cytotoxicity study, we concluded that ROS generation was the reason behind 
the cytotoxicity of GOns against normal cells and cancer cells apart from the cell death 
resulting from the sharp edges of GOns.  
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We also examined the anti-proliferative activity of ZnONP in both MDAMB-231 
and MCF-7 cancer cell lines. ZnONP clearly demonstrated dose-dependent 
cytotoxicity in MDAMB-231 and MCF-7 breast cancer cells with 83 and 87.7% 
cytotoxicity at a dose of 100 µg/ml. In the presence of NAC, MDAMB-231 and 
MCF-7 breast cancer cells demonstrated 38.61 and 21.22% cytotoxicity at 100 µg/ml 
respectively.  
The presence of NAC could reverse the cytotoxicity by 61.39and 78.78% 
respectively (Fig.9.9A). The result clearly indicates that the cytotoxicity induced by 
ZnONP in MDAMB-231 and MCF-7 cells is mediated primarily through ROS 
generation.  
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Figure 9.9 MTT assay of ZnONP in breast cancer cells, both in the presence and 
absence of NAC, (A) MDAMB-231 cells and (B) MCF-7 cells. ZnONP shows a dose 
dependent increase in cytotoxicity and acts by a ROS dependent mechanism. All the 
data were expressed as Mean ± S.E.M, n = 3. 
FZnONP clearly demonstrated dose-dependent cytotoxicity in MDAMB-231 and 
MCF-7 breast cancer cells with 89.74 and 97.24 % cytotoxicity at 100 µg/ml. 
However, in the presence of NAC, MDAMB-231 and MCF-7 breast cancer cells 
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demonstrated 37.27 and 12.75% cytotoxicity at 100 µg/ml respectively (Fig.9.10A 
and B).  
The result indicates that FZnONP generates cytotoxicity in MDAMB-231 and MCF-
7 cells mainly through ROS due to the fact that the amount of ROS generated by 
FZnONP was nullified by the presence of NAC by 62.73 (partially) and 87.25% 
(primarily) respectively (Fig.9.10A and B).  
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Figure 9.10 MTT assay of FZnONP in breast cancer cells, both in the presence and 
absence of NAC, (A) MDAMB-231 cells and (B) MCF-7 cells. ZnONP shows a dose 
dependent increase in cytotoxicity and acts by a ROS dependent mechanism. All the 
data were expressed as Mean ± S.E.M, n = 3. 
 
We also evaluated the effect of ZnONP and FZnONP in normal cells such as HaCaT 
in order observe the cytocompatibility of ZnONP and FZnONP. ZnONP showed a 
dose dependent cytotoxicity in HaCaT cells, however, in the presence of NAC the 
cytotoxic effect was reduced significantly (see Fig.9.11). The cytotoxicity of ZnONP 
in HaCaT cells was due to ROS generation since; the treatment of NAC (ROS 
inhibitor) reduced the cytotoxicity significantly (see Fig.9.11). The administration of 
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ZnONP in HaCaT cells generated sufficient ROS which was responsible for the 
HaCaT cell death. 
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Figure 9.11 MTT assay of ZnONP in HaCaT cells, both in the presence and absence 
of NAC. ZnONP shows a dose dependent increase in cytotoxicity and acts by a ROS 
dependent mechanism. All the data were expressed as Mean ± S.E.M, n = 3. 
 
The treatment of HaCaT cells with FZnONP did not result in any cytotoxicity till a 
dose of 100 µg/ml both in the presence and absence of NAC (see Fig.9.12). 
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Figure 9.12 MTT assay of FZnONP in HaCaT cells, both in the presence and absence 
of NAC. FZnONP did not show any cytotoxicity in HaCaT cells. All the data were 
expressed as Mean ± S.E.M, n = 3. 
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The result clearly indicates that the layer of BLA over ZnONP reduced the 
cytotoxicity of ZnONP in HaCaT cells.  
The cancer cells are already in a stressed state and the ROS inhibitory mechanism is 
already overloaded. Hence, the specific structural state of the BLA coat was 
responsible for the toxicity generated in MDAMB231 cells. The additional ROS 
generated by the BLA coat over ZnONP proved fatal for the MDAMB231 cells as 
the internal ROS inhibitory mechanism failed to with stand the additional ROS load. 
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Chapter 10 
Conclusion 
 
Overall, in our present study we have developed small protein based therapeutic 
strategies for the therapy of breast cancer, where self-assembled structure of two 
small globular proteins demonstrated strong cytotoxicity in two human breast cancer 
cells, without causing any toxicity in normal cells. Moreover, both protein 
nanoassemblies demonstrated to act as excellent drug delivery system in cancer. 
Furthermore, they proved to be a far better therapeutic option than Zinc oxide 
nanoparticles (ZnONP) or Graphene oxide nanosheet (GOns) based therapeutic 
approach. 
Based on the whole experimental study, the following are the specific conclusions are 
derived: 
1. The self-assembled nanostructured hen egg white lysozyme (snLYZ) and 
bovine α-lactalbumin (snBLA) were synthesized using a simple desolvation 
technique through chemical crosslinking using 0.1% glutaraldehyde for 8 h. 
Both the nanoassembly were of 300 nm average size with spherical shape and 
were highly stable in a wide range of pH, temperature and proteinase K 
environment. Moreover, we concluded that substantial change in conformation 
change as well as surface hydrophobicity of the proteins took place in the 
proteins in their nanoassembly state compared to their respective native state. 
 
2. Both the protein nanoassembly caused rapid cell death in breast cancer cells 
MCF-7 and MDAMB-231 through cellular uptake and reactive oxygen species 
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(ROS) generation however, were found highly biocompatible as reflected from 
their excellent hemocompatibility as well as their cytocompatibility in normal 
human and murine cell lines. 
 
3. Both the protein nanoassemblies (snLYZ and snBLA) were rapidly taken up in 
breast cancer cells resulted in cellular size and nucleus followed by 
cytoplasmic degradation resulting in cellular death. Cellular necrosis was the 
mechanism behind such morphological changes in breast cancer cells.  
 
4. Both snLYZ and snBLA demonstrated increased cytotoxicity when conjugated 
with folic acid (FA) compared to their unconjugated forms. The folic acid 
conjugation was found to be an interesting approach as it enhances the uptake 
of snLYZ-FA and snBLA-FA in cancer cells expressing folate receptors (FR). 
Thus, we can easily target cancer cells that express folate receptors and induce 
higher levels of cytotoxicity. 
 
5. The protein nanoassembly of snBLA was compared with an anti-cancer agent, 
a lipid-conjugated protein popularly known as BAMLET (Bovine α-
lactalbumin made lethal to tumor cells). However, our synthesized snBLA 
demonstrated increased toxicity and proved to be a clear winner compared to 
BAMLET in four different cell lines such as MDAMB-231 and MCF-7 
(Breast cancer), HeLa (Cervical Cancer) and A549 (Lung cancer). While 
BAMLET followed the apoptotic pathway involving Caspase-3, snBLA 
induced necrosis in cancer cells and did not cause Caspase-3 mediated 
apoptosis as evidenced from Caspase-3 expression. 
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6. Both the nanoassembly demonstrated high Tamoxifen loading (124%) through 
chemical crosslinking process and release of drug efficiently in a pH-
responsive manner. Furthermore the drug release process was completely 
regulated by conformational change of the protein in nanoassembly. 
 
7. Although drug-loaded, both the protein nanoassembly showed predominantly 
only drug-mediated anti-proliferative activity, the post-drug release state of 
nanoassembly, however, demonstrated the complete recovery of its inherent 
anti-proliferative activity due to conformational reconstitution. 
 
8. Multilayer Graphene oxide nanosheet (GOns) with a size in the range of 100-
200 nm and an average height of 5.0 nm and ZnO nanoparticles (ZnONP) with 
the size in the range of 100- 250 nm were synthesized. Both GOns and 
ZnONP caused strong cytotoxicity in breast cancer cells and exhibited fair 
level of toxicity against normal cells such as HaCaT and 3T3. However, BLA-
functionalized GOns (FGOns) and ZnONP (FZnONP) exhibited enhanced 
cytotoxicity against MCF-7 and MDAMB-231 cells, compared to their non-
functionalized form (GOns and ZnONP) in a ROS dependent manner, with 
negligible cytotoxicity against normal cells under the same condition.  
 
9. Both GOns and FGOns were internalised by the cancer cells. FGOns was 
found to internalize more efficiently than GOns that entered the cells by 
damaging the cell membrane through its sharp edges. The cytoplasmic damage 
due to internalization was clearly visible in both the cases. 
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10. GOns exhibited hemotoxicity beyond a concentration of 10µg/ml whereas the 
functionalized GOns (FGOns) was observed to be hemocompatible till 
333.33µg/ml. However, ZnONP was found hemolytic beyond the 
concentration of 160 µg/ml, however when functionalized with BLA no 
hemolysis was observed till 600 µg/ml. Such enhanced compatibility was due 
to the protein functionalized form of GOns and ZnONP. 
 
11. ZnONP was found equally toxic in breast cancer cells (MDAMB-231 and 
MCF-7) as well as normal cells (HaCaT). When functionalized with bovine α-
lactalbumin (FZnONP), induced specific toxicity in breast cancer cells without 
affecting the normal cells. The toxicity of FZnONP was found to be mediated 
through ROS generation by the protein layer over ZnONP.  
 
On the whole the present study clearly established that the self-assembled 
nanostructured lysozyme (snLYZ) and bovine α-lactalbumin (snBLA) proved 
to be better therapeutic agents in breast cancer cells with excellent 
biocompatibility.  
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Chapter 11 
Future Work 
The following studies are hereby proposed as future work. 
1. Detailed in-vivo studies in various animal models followed by 
histopathological studies for observing biodistribution. Such study will 
help to validate our in-vitro findings. 
2. In-vitro experiments may be performed in cell lines from different 
types of cancers to observe the applicability of our protein 
nanoassembly in other cancers other than breast cancers. 
3. Detailed study may be performed on the use of protein nanoassembly 
with various promising anti-cancer drugs. 
4. Exploration of protein nanoassembly may be performed in other areas 
such as biomaterials, tissue engineering and regenerative medicine etc. 
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Appendix: Supplementary figures 
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Figure S1.Optimization of glutaraldehyde concentration used in the preparation of 
nanostructured LYZ. Lytic activity of LYZ in snLYZ prepared with various 
concentrations of GTD. All data are expressed as Mean ± S.E.M, n = 3. 
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Figure S2. (A)Trp fluorescence spectra of 2 µM of nmLYZ with increasing 
concentration of GTD. nmLYZ solution was incubated with varying concentration of 
GTD for 1hr followed by fluorescence spectra measurement. (B) CD spectra of 
nmLYZ treated with increasing concentration of GTD and snLYZ prepared using 
increasing concentration of GTD. All data are expressed as mean of three readouts 
generated from the instrument. 
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Figure S3 FESEM images of snLYZ prepared using various concentrations of the 
cross-linker Glutaraldehyde(GTD) (A) snLYZ prepared using 0.3% GTD. (B) snLYZ 
prepared using 1 % GTD. (C) snLYZ prepared using 3 % GTD. 
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Figure S4 Optimization of the amount of starting protein material for preparation of 
protein nanoparticles. (A) BLA 1mg (B) BLA 3mg (C) BLA 5mg (D) BLA 10mg (E) 
BLA 20mg. 
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Figure S5 Optimization of the amount of glutaraldehyde concentration for the 
preparation of protein nanoparticles using dynamic particle size analysis. (A) 0.1% 
glutaraldehyde (B) 0.3 % glutaraldehyde (C) 1 % glutaraldehyde (D) 3 % 
glutaraldehyde (E) 8% glutaraldehyde. 
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Figure.S6. Optimization of the amount of glutaraldehyde concentration for the preparation of 
protein nanoparticles using dynamic particle size analysis. Zeta potential of protein 
nanoparticles prepared using (A) 0.1 % glutaraldehyde (B) 0.3 % glutaraldehyde (C) 1 % 
glutaraldehyde (D) 3 % glutaraldehyde (E) 8% glutaraldehyde. 
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Figure S7 Optimization of the duration of glutaraldehyde crosslinking process for the 
preparation of protein nanoparticles (A) 1h (B) 3h (C) 5h (D) 8h. 
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Figure S8 Characterization of prepared BAMLET by CD spectroscopy 
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Fig.S9 Haemolysis assay of various samples (A) snBLA: TAM (1:1), (B) snBLA: 
TAM (4:1), (C) snBLA: TAM (10:1), (D) snBLA: TAM (1:1 reconstituted), (E) 
snBLA: TAM (4:1 reconstituted) and (F) snBLA: TAM (10:1 reconstituted). 
 
 
Figure S11. AFM image of sLYZ-TAM conjugate clearly showing the drug layer over 
the protein nanostructure snLYZ. 
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Figure S12. FESEM image of snBSA (self-assembled nanostructured bovine serum 
albumin) prepared using the same protocol as of snLYZ. 
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Figure S13. Cytotoxicity study of snBSA (self-assembled nanostructured BSA) by 
MTT assay (A) MCF-7 breast cancer cells and (B) murine fibroblast cells 3T3. 
Glutaraldehyde 0.1% and 0.2% was used as control. All data are expressed as Mean ± 
S.E.M, n =3. 
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Brief synopsis of Research: 
Chemotherapy has been used as widely practiced therapy for the treatment of 
Breast cancer. However, it exposes the patient to various side effects. To avoid 
side effects and achieve a cheap and biocompatible therapeutics, the focus has 
been gradually shifting towards biomolecule-based therapeutics like peptide 
and proteins. In our present investigation, we have developed protein-based 
therapeutic approaches in Breast cancer using two proteins, bovine α-
lactalbumin (BLA) and hen egg white lysozyme (LYZ).  
Here, self-assembled nanostructures of both the proteins were prepared using 
simple desolvation process and evaluated its anti-proliferative activity in 
Breast cancer cells. The nanostructures were characterized using microscopy 
and dynamic light scattering analysis for shape and size; FTIR, Circular 
dichroism and Fluorescence spectroscopy for conformational change. We 
found the nanostructures were spherical in shape with 300 nm average size 
and highly  
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stable. Moreover, they demonstrated excellent haemocompatibility as well as 
cytocompatibility against normal human and mouse cells. When applied to 
Breast cancer cells such as MCF-7 and MDA-MB231, they demonstrated more 
than 90% cell death at 24 h and nearly complete cell death after 48 h, which 
was caused by the internalization of nanostructures in cells and through 
reactive oxygen species (ROS) generation. Moreover, they showed efficient 
loading of Tamoxifen (TAM) and pH-responsive drug release in vitro.  
We also developed a therapeutic approach based on ZnO nanoparticle 
(ZnONP) and graphene oxide (GO) nanosheets by surface functionalization 
with BLA to improve their biocompatibility. Although they demonstrated 
high anti-proliferative activity in cancer cells via ROS-based cell death, we 
found some limitations of ZnONP and GO nanosheets based therapeutic 
approach compared to protein nanostructure–based therapeutics. Therefore, 
our developed stable self-assembled nanostructured lysozyme and α-
lactalbumin can be used as a rational therapeutic approach in Breast cancer. 
 
Academic Qualifications: 
 
 Pursuing PhD on the topic “An investigation of self-assembled 
nanostructured protein-based therapeutic approaches in Breast 
cancer” under the supervision of Prof. Subhankar Paul, at Department 
of Biotechnology and Medical Engineering, N.I.T, Rourkela-769008, 
Odisha. (Thesis submitted) 
 
 Masters in Pharmaceutical Sciences (Pharmacology) with C.G.P.A of 
9.03 from Kanak Manjari Institute of Pharmaceutical Sciences, Rourkela 
affiliated to Biju Pattnaik University of Technology (BPUT), Rourkela, 
Orissa, 2008. 
 
 Bachelor Degree in Pharmaceutical Sciences from North Orissa 
University affiliated to BPUT with 72.09% in 2006. 
 
 
253 
 
 
 
List of Publications: 
 
1) S. Mahanta, S. Paul. Stable self-assembly of bovine α-lactalbumin 
exhibits target specific anti-proliferative activity in multiple cancer 
cells. ACS Applied Materials & Interfaces, 2015, DOI: 
10.1021/acsami.5b06076. 
 
2) S. Mahanta, S. Paul. Bovine α-lactalbumin functionalized graphene 
oxide nano-sheet exhibits enhanced biocompatibility: A rational 
strategy for graphene-based targeted cancer therapy. Colloids and 
Surfaces B: Biointerfaces 2015, (134), 178-187. 
 
3) S. Mahanta, S. Paul, A. Srivastava, A. Pastor, B. Kundu, T.K. 
Chaudhuri, Stable self-assembled nanostructured hen egg white 
lysozyme exhibits strong anti-proliferative activity against Breast 
cancer cells, Colloids and Surfaces B: Biointerfaces 2015, (130), 237-
245. 
 
4) Tripathy, R. K.; Mahanta, S.; Paul, S., Artificial intelligence-based 
classification of Breast cancer using cellular images. RSC Advances 
2014, 4, (18), 9349-9355. 
 
5) Paul, S.; Mahanta, S., Association of heat-shock proteins in various 
neurodegenerative disorders: is it a master key to open the therapeutic 
door? Mol Cell Biochem 2014, 386, (1-2), 45-61. 
 
6) Gupta, U. K.; Mahanta, S.; Paul, S., In silico design of small peptide-
based Hsp90 inhibitor: a novel anticancer agent. Med Hypotheses 
2013, 81, (5), 853-61. 
 
254 
 
7) Mahanta, S.; Pilla, S.; Paul, S., Design of novel Geldanamycin analogue 
hsp90 alpha-inhibitor in silico for Breast cancer therapy. Med 
Hypotheses 2013, 81, (3), 463-9. 
 
Conference Papers: 
 S Paul and S Mahanta, "Preparation and Characterization of Self-
Assembled Graphene Oxide Supramolecular Structures," Journal of 
Medical and Bioengineering 2015, (4), 480-483. 
 
 Abstract  Publication  on  the  topic  “Study  of  Anti-inflammatory  
activity  of Sphaeranthus indicus” in Souvenir and Scientific Abstracts 
2008, Orissa Journal of Pharmacology. 
 
 
Industrial Experience: 
 1.8 year experience (1st December 2008 – 9th July 2010) as Research 
Associate at Biological Research Division, Glenmark Pharmaceuticals, 
Navi-Mumbai, Maharashtra. 
 
 The work profile involved routine in-vivo and in-vitro experiments 
involving Neuropathic Pain, Inflammatory Pain and Safety Studies in 
both male and female S.D.rats and mice (BABL6J).  
Various experiments with animal models of Schizophrenia and 
Experimental Autoimmune Encephalomyelitis (EAE) were also 
involved.Routine dosing, blood collection for PD-PK correlation, 
Cerebrospinal fluid collection, Dissection of Brain, Spinal cord and 
dorsal root ganglion were also performed. 
 
 
 
Academic Experience: 
Four months of teaching experience (16th July 2008 - 30th November 
2008) as Lecturer in Pharmacology at Saraswati Vidya Bhawan’s 
College of Pharmacy, Dombivili, Maharashtra, India. 
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Molecular Docking methods and Software skills: 
 Discovery Studio 2.5 
 Autodock 4.0 
 Hex 6.3 
 Chembiodraw Ultra13.0 
 Graphpad Prism 5.0 
 Origin Pro 8.0 
 
Languages known: 
English, Hindi, Oriya and Bengali 
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